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Within the past decades, extensive research has been focusing on developing 
electroluminescent technologies (OLED and LEC). Especially, a lot of effort has been 
dedicated to the search of efficient phosphorescent materials with highly tuneable emission 
maxima bearing late transition metal atoms. Emitters such as cyclometalated idirium 
complexes have been proven to be very successful in this regard, exhibiting colours from blue 
to red and being successfully applied in electroluminescent technologies. However, in order to 
decrease the manufacturing cost of these technologies, a single-centre white emitting material 
is highly desirable. In this context, this work investigates a new family of complexes bearing 
three different bidentate ligands known as tris-heteroleptic complexes to develop an emitter 
with a broad emission profile that would result in a white colour. Eighteen new tris-
heteroleptic complexes with unprecedented ligand configurations have been synthesised by 
mixing different kind of ligands such as phenylpyridines (ppy), phenylpyrazoles (ppz) and 
phenylimidazoles (pim). This resulted in significant emission broadening with FWHM values 
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1.1 General introduction 
Since the industrial revolution, mankind never stopped increasing its consumption of artificial 
light and invented many technologies to answer this demand. The twentieth century saw the 
progressive marginalisation of gas for the production of artificial light to the profit of 
electricity.
1
 Nowadays, electricity plays a very important role as an energy carrier and the 
technologies relying on it are uncountable. In 2010, the production of artificial light was 
estimated to represent 6.5 % of the world’s primary energy.
2
 It has been identified as one of 
the main energy consumption sources in buildings, both commercial and residential.
3
 In 
Japan, the part of electricity used to produce artificial light represented nearly 14 % of the 
total electricity consumption in 2009
4
 and the world energy council estimated this percentage 
to be 19 % for developed countries in its 2013 report.
5
 As the world energy and electricity 
demand never stopped increasing, and is still projected to increase during the next decades,
6
 
tremendous efforts have been achieved in order to provide the world with more efficient 
electrical devices, use the available resources in the best possible way and meet with the 
challenges of the future energy consumption. In this regard, artificial lighting technologies are 
a perfect example. Incredible progress has been realised since first very unefficient 
incandescent light bulbs, with the development of technologies such as fluorescent tubes. In 
the last decades, devices such as LEDs have also become very efficient and popular, opening 
a new chapter in the artificial lighting history.
7
 However, all light sources have drawbacks 
such as heat generation, incorporation of toxic gas or metals, bad extraction of produced light, 
short life spans or high costs. Therefore, the need for new, more efficient and cheaper light 





1.2 Electroluminescent technologies 
As part of an answer to the world energy challenge, more efficient lighting sources are 
required. A solution could be to use electroluminescent devices along with, or instead of 
current lighting technologies. These electroluminescent devices are organic light emitting-
diodes (OLED) and light-emitting electrochemical cells (LEC or LEEC). 
As this work focuses on light-emitting molecules that can be applied to these technologies, the 
basics of their working principle and architectures are briefly discussed below. However, this 
work does not focus on OLED and LEC technologies per say, as almost every aspect of their 
architecture is a specific field of research. 
These technologies both work on the same principle of electro-excitation. A thin layer of 
photoactive molecules is placed between two electrodes and an electrical current is applied. 
Electrons and holes are injected in the system and recombine at the emitter level, leaving the 
molecules in an electronic excited state. The emitting molecules then release the electrical 
energy under the form of photons when they go relax to their electronic ground state. 
Both technologies are cold light sources that can be used for surface lighting and/or in flexible 
devices
8,9
 and can be made by relatively easy printing methods. The main difference between 
the two is that LECs use charged electroluminescent materials when OLEDs use neutral 
ones.
10
 Since OLED technology is also older and more developed, it occupies a larger market 








Figure 1.1: Schematic representation of an OLED device (left). Schematic representation of charge 
movement and light emission in an OLED device (right). 
In an OLED, the emitting material is not only sandwiched between the electrodes but also 
between charge injection and transport layers in order to increase the device efficiency. The 
schematic OLED drawing (Figure 1.1, left) shows a situation where the emitting layer (EML) 
is surrounded by an electron transport layer (ETL) and a hole transport layer (HTL). These 
additional layers insure the efficient carrying of the charges from the electrodes to the 
emitting layer and prevent unwanted phenomena such as exciton quenching close to the 
electrodes.
12
 The scheme presented above (Figure 1.1, right) shows the working principle of a 
simple OLED. Under the application of an electric potential, charges are injected from the 
electrodes to the adjacent layer (electrons at the cathode and holes at the anode). Electrons 
and holes then migrate through the ETL and HTL and are injected in the LUMO (electrons) 
and HOMO (holes) of the emitting material (inside the emitting layer), leaving it in an excited 
state (exciton). The high energy contained in this excited state is released under the form of 





All the materials involved have to fulfil specific conditions. Cathodes and anodes are chosen 
respectively according to their low and high work functions respectively, usually from metals 
(such as Ca or Mg for the cathode) or metal oxides (indium tin oxide, ITO, mixture of SnO2 
and In2O3 for the anode). ETL and HTL materials have to be adapted to the emitter material 
and show adapted HOMO and LUMO energy levels as well as good holes and electrons 
conductivities (examples of such materials are shown in Figure 1.2). Additional layers such as 
electrons/hole blocking and injecting layers can be added to the device to facilitate the 
injection of charges from the electrodes to the transport layer and to prevent the charges to 
pass the EML. In addition, the emitting material has to be doped into a host material in order 
to avoid concentration quenching. Therefore, this material must also fulfil conditions such as 
high triplet energy (compared to the emitter). 
By contrast, LEC architecture is simpler as the electron and hole transport layers are not 
required. Because of the ionic nature of the materials used, the charge repartition adapts itself 
in the emissive layer and produces efficient charge transport.
13
 Therefore, these systems are 









Figure 1.2: Examples of materials used in OLED technology: N,N′-Bis(3-methylphenyl)-N,N′-
diphenylbenzidine (TPD) as a hole transporter, bathocuproine (BCP) and tris(8-
hydroxyquinolinato)aluminium (Alq3) as electron transporter and 4,4′-bis(N-carbazolyl)biphenyl 
(CBP) as a host material for green emitters. 
As for OLED, the emitting molecule is doped into a host that can be a polymer
16,17
 or a small 
organic molecule.
15
 They can also be used alone while relying on bulky groups to reduce self-
quenching processes.
18,19
 For charged complexes, the solubility in organic solvent is 
influenced by the counter-anion and can therefore be increased by changing this parameter 
making charged iridium complexes easy to use in liquid printing device fabrication. 
Even though OLED technology is now more developed and shows good results in a wide 
range of applications such as screens and displays, its high manufacturing cost limits its use 
for wider low-cost applications. In this regard, LEC technology provides cheaper and easier to 
make devices to fill this gap. In the context of the present research, both neutral and charged 
complexes can be considered as the photophysical properties of the studied complexes are not 





1.3 Photophysical principles of light emission 
If a molecule absorbs a sufficient amount of energy, one of its electrons can be promoted from 
the HOMO to the LUMO. The molecule, previously lying in an energy state defined as the 
ground state (S0), finds itself in an excited state of higher energy characterised by the new 
electronic configuration. The new electron distribution around the nuclei induces a geometry 
change in the molecule. A part of the energy absorbed then dissipates as heat with the 
molecule vibrating down to the minimal energy of the excited state. This process is known as 
internal conversion. If the LUMO electron has kept its spin and still opposes the spin of the 
HOMO electron, the excited state is a singlet (S1, S2, ... , Sn). If a spin flip occurs and the two 
electrons have the same spin, the excited state is a triplet (e.g. T1). As the molecule finds itself 
in the most stable excited state conformation, it can release the remaining energy by 
“jumping” back to the ground state (S0). The excited electron goes back to the HOMO and a 
photon is emitted which energy corresponds to the energy difference between the excited state 
and S0.  
However, excited states also can relax back to S0 via non radiative pathways and the 
efficiency of the light emission process is modulated by its rate of occurrence in relation to 
the rate of all the non radiative processes possible. In order to obtain visible light emission, a 
molecule must satisfy two major criteria. 1) The energy difference between its emissive 
excited state and S0 must be in the energy range of visible light. 2) The rate of its light 






Figure 1.3: Simplified Jablonski diagram showing the possible energy pathway happening in a 
molecule. The thick black lines represent the lowest energy conformation of a state. The thin black 
lines represent the vibrational sub states. S0 is the singlet ground state and S1 and S2 the two first 
singlet excited states. T1 is the most stable triplet excited state. Blue arrows represent light absorption 
transitions. The green and red are fluorescence and phosphorescence respectively. The orange arrows 
show internal conversion and non radiative deactivation processes in general. 
For a purely organic molecule, the spin flip of one electron to create a triplet state (T1) known 
as intersystem crossing (ISC, purple arrow) is forbidden. The light emission therefore only 
happens from S1. Light emission generated by a singlet to singlet (S1  S0) transition is 
designated as fluorescence (green arrow). The influence of a large atom is required to 
introduce spin-orbit coupling (SOC) that makes the ISC process efficient enough to allow a 








1.4 Why Iridium 
The major reason for using transition metal complexes for electroluminescent devices is that 
electric generation of excited state gives rise to 75% of triplet states.
22–24
 As purely organic 
fluorescent molecules do not benefit from the spin-orbit coupling provided by heavy 
transition metal atoms, light emission from these states is extremely slow and the molecules 
relax their energy via non radiative pathways.
25
 These triplet excited states are then lost which 
means that the maximum electroluminescent quantum yield of a purely fluorescent molecule 
is 25% since only the singlet states are emissive. 
Heavy atoms such as iridium are known to reduce the radiative lifetime of triplet excited 
states
26
 allowing efficient light emission via phosphorescence pathways. Intersystem crossing 
(ISC, which describes the spin flip of the excited electron to create a triplet excited state S1  
T1)
20
 is also accelerated in presence of a heavy atom and increases the probability to observe 
phosphorescence. In other words, electro-excitation of a luminescent iridium complex can 




Iridium being a third row transition metal, it provides a large splitting of d orbitals (Δ0) further 
increased by the 3+ oxidation of the iridium ion in complexes. In addition the cyclometalation 
to high field ligands such as phenylpyridines further increase Δ0.
21,28
 A large Δ0 reduces the 
chance of generating d-d
*
 states leading to quenching of light emission and higher complex 
degradation rate under excitation. It also leaves a larger energy gap to tune the π and π
*
 






1.5 Structure of iridium complexes 
Iridium complexes for electroluminescence applications are generally formed of three 
bidentate cyclometalated ligands arranged around the metal centre in an octahedral geometry. 
These complexes are divided into three major families. One with three same ligands (L^L), 
giving a formula Ir(L^L)3 referred to as tris-homoleptic complexes. One with two L^L ligands 
and a different ligand (X^X), referred to as bis-heteroleptic complexes of general formula 
Ir(L^L)2(X^X). For these complexes, the L^L ligands are called the main ligands while X^X 
is called the ancillary ligand. These two families of complexes represent the vast majority of 
luminescent iridium complexes present in the literature. However, there is a third family of 
complexes where the three ligands are different. These complexes are called tris-heteroleptic 
and have the general formula Ir(L1^L1)(L2^L2)(X^X). In most cases L^L represents a 





 generally abbreviated C^N). The ancillary 







 and are therefore abbreviated by their coordinating atoms (O^O, N^N or 
N^O). 
1.5.1 Chirality and structural isomerism 
If we consider tris-cyclometalated homoleptic complexes of general formula Ir(C^N)3, the 
octahedral geometry generates a Λ/Δ chirality. Furthermore, since a C^N type ligand is 
asymmetric, facial (fac) and meridional (mer) diastereomers can be created for each Λ and Δ 
complex.
35,36
 The Λ/Δ chirality does not play an important role in the physical properties of 
these complexes in solution as their symmetry, polarity and magnetism remain the same. 
Therefore, it does not impact the photophysical properties. This chirality is however useful 
when one considers using these complexes as catalysts.
37





complexes only present one enantiomer for clarity, but racemic mixtures are assumed unless 
stated otherwise. 
The mer/fac isomerism has much more influence on the properties of such complexes, as they 
drastically change local chemical environments and the overall symmetry. Mer and fac 
isomers are therefore easily differentiable by 
1
H-NMR and separable by standard 
chromatography techniques (at least in theory). Moreover, they display different stabilities in 
solution and also differ in their photophysical properties. 
 
Figure 1.4: Meridional (mer) and facial (fac) representations of homoleptic tris-cyclometalated 
iridium complexes with C^N type ligands. 
Bis-heteroleptic complexes are similar to homoleptic mer homoleptic complexes. If we 
consider that X^X is a non symmetrical ligand N^O (e.g. pic), the general formula becomes 
Ir(C^N)2(N^O) and the orientation of the N^O ligand allows to differentiate the two main 
ligands (Figure 1.5). 
Keeping the C^N ligands in a pseudo facial position and changing the orientation of the N^O 
ligand allows to draw two pairs of enantiomers (Λ1/Δ1 and Λ2/Δ2). As for the homoleptic 
complexes, enantiomers of the same complex present almost identical properties and are 
impossible to differentiate by NMR or to separate by simple chromatography methods. 
Differences are observable when comparing the ones and the twos as the magnetic properties 





same as C2^N2, there is no distinction between the two rows of pseudo fac complexes shown 
below (Λ1/Δ2 = Λ3/Δ3 and Λ2/Δ2 = Λ4/Δ4). 
Pseudo mer complexes display only two times two possibilities obtained by switching the 
orientation of one or both of the C^N ligands to obtain a trans N-Ir-N or trans C-Ir-C 
configuration. As the two C^N ligands are oriented the same way around the iridium, the 
orientation of the N^O ligand does not matter (Λ5/Δ5 = Λ6/Δ6 and Λ7/Δ7 = Λ8/Δ8). However, 
due to the asymmetry of N^O, the two C^N ligands are not magnetically equivalent (in a 
particular complex) and display separate NMR signals. 
Tris-heteroleptic complexes display even more possible configurations with Λ1/Δ1 ≠ Λ3/Δ3, 






Figure 1.5: Representations of bis and tris-heteroleptic complexes with C^N type main ligands and 
asymmetric N^O type ancillary ligands. These ligands organisations are shown for the sake of the 
example do not all represent current products of iridium complexes syntheses. The pseudo mer and 
pseudo fac notation is based on the orientation of the C^N ligands only and refer to their orientation 
in a tris-homoleptic complex. 
In practice, not all configurations presented above are formed during the synthesis of iridium 
complexes. With homoleptic complexes, the meridional configuration tends to be kinetically 
favoured while the facial configuration is the thermodynamically favoured product. Mer to fac 








Bis-heteroleptic and tris-heteroleptic complexes are synthesised in a way that strongly favours 
the N-Ir-N pseudo mer configuration (Λ5/Δ5 and Λ6/Δ6), but a complex with a flipped C^N 
ligand is a possible degradation product.
38
 Pseudo mer configurations with trans-
cyclometalated carbons (C-Ir-C) are never observed and are only depicted in Figure 1.5 for 
the sake of the argument. (However, in a situation where the ancillary ligand is also 
cyclometalated (Ir(C1^N1)(C2^N2)(C3^N3)), it is possible that facial and meridional 
configurations would coexist, allowing most of these configurations to be observed.) 
This brings the number of different complexes actually encountered back to respectively one 
and two enantiomer couples for bis- and tris-heteroleptic complexes. Furthermore, replacing 
an asymmetric N^O ancillary ligand by a symmetric N^N or O^O ligand allows only one tris-
heteroleptic enantiomer couple complexes as the difference between Λ5/Δ5 and Λ6/Δ6 is 
suppressed. 
In this context, the syntheses of bis-heteroleptic complexes with symmetrical or asymmetrical 
ancillary ligands are equivalent while the introduction of a non-symmetrical ancillary ligand 






1.5.2 Bonding and electronic structure 
Iridium(III) complexes of the type Ir(C^N)3 can be described from a crystal field theory 
perspective.
28
 They are formed of a triply charged 5d
6
 iridium cation counterbalanced by three 
(
–
C^N) anions. Each ligand contributes to the filling of the valence shell with four electrons 
(two from the coordinating nitrogen and two from the cyclometalated carbon) which makes a 
total of 18 valence electrons. 
The d orbital splitting is large, due to the combined influence of the third row metal and a 
strong ligand field provided by the cyclometalated ligands. The six remaining d electrons are 
therefore in a “low spin” configuration and the complex is diamagnetic.
21
 
For bis-heteroleptic complexes, the third ligand often provides a third negative charge  (e.g. 
O
-
) but if it is not the case, the complex carries a positive charge counterbalanced by a 





From a ligand field perspective, σ bonds are made from the interaction between the 5d, 6s and 
6p metal orbitals with the sp
2
 ligand orbitals from the aromatic nitrogens and cyclometalated 
carbons.
28,39,40
 Therefore, they are not degenerate as depicted in Figure 1.6 and are only 
depicted as such to simplify the picture. The shared electrons are coming from the nitrogen 
lone pairs (3x2 electrons), d orbitals of the metal (3 electrons) and C-H bond broken during 






Figure 1.6: Simplified molecular orbital diagram for an octahedral iridium complex. 
The creation of the six σ bonding orbitals is associated with six σ
*
 anti-bonding orbitals much 
higher in energy. 
The six σ bonding orbitals being closer in energy to the ligand sp
2
 orbitals than to the metal s, 
p, or d orbitals, they contain an increased “ligand character” while the corresponding anti-
bonding σ
*
 are more metal based and contain an increased “metal character”. 
The energies of the σ and σ
*
 orbitals depend on their amount of s, p, d character (on the metal 
part) and of the nature the ligands used. The precise determination of these energies is not 
useful for electroluminescent applications as they lay way below the HOMO (bonding) and 
way above the LUMO (antibonding) energies. One notable exception is the two first σ
*
 orbital 









In this model, three degenerate d orbitals of the metal core remain filled with six non-bonding 
d electrons, leaving the complex in a low spin configuration. 
1.5.3 Excited states of iridium complexes 
As photo excitation goes, an electron is promoted from the HOMOs located on the metal 5d 
non-bonding orbitals and on the π orbitals of the ligand (phenyl ring for a ppy ligand) to the 
LUMO, located on the π
*
orbital of the ligand (on the pyridine part). The transition is said to 
be of mixed metal-to-ligand-charge-transfer (MLCT, 5dIr to π
*






To achieve a precise analysis of the possible molecular excited states, the simplistic HOMO-
LUMO transition model must be extended as HOMO-1, -2 and LUMO+1, +2 (for example, 
but not only those) are also involved in electronic excitation. As these molecular orbitals are 
close in energy, there is a certain degree of quantum chemical mixing between them that 
influences the photophysical properties. As an example, the mixing of the metal 5d orbitals 




In depth analysis of all the states generated by the transitions allowed will not be attempted 
here. It can be achieved by DFT calculation methods, which can predict the absorption and 
emission spectra shapes and give insights on other photophysical properties such as quantum 
yields or radiative lifetimes.
25
 










MLCT), the strong SOC induced by the large iridium atom allows an 







relative amounts of these states roughly determines the shape of the emission spectrum as LC 
emission is expected to be more defined with apparent vibrational peaks or shoulders. MLCT 
shaped emission is expected to be less defined and broader as well as shifted to a lower 
energy region of the emission spectrum. 
In the process, metal centred states (MC) resulting from a d-σ
*
 transition can also be 
generated. Since the σ
*
 orbitals have a strong metal character, the transition is essentially 





In the case of the iridium complexes of interest, these states are generated mostly if they are 
thermally accessible from a close MLCT or LC state. In other words, if the π
*
 orbitals of the 
ligands and the d
*
 orbitals of the metal are close in energy. 
As these orbitals are antibonding, their population produces an elongation of one metal-ligand 
bond that can result in breaking a metal nitrogen bond.
45,46
 This represents an efficient 
quenching of the excited state as well as degradation factor for electroluminescent materials. 











1.5.4 Tris-homoleptic & Bis-heteroleptic Complexes 
 
Figure 1.7: An example of tris-homoleptic complex, [Ir(ppy)3] (left), of bis-heteroleptic complex 
[Ir(ppy)2(acac)] (centre) and of tris-heteroleptic complex, [Ir(ppy)(diFppy)(dtb-bpy)][PF6] (right). 
Many transition metal complexes have been studied over the years for lighting applications in 






, but none 
of them provides the same tunability as iridium, with stable complexes emitting among the 
entire visible spectrum. 
Iridium complexes can be divided into three major groups; the tris-homoleptic complexes
54
 ( 
like [Ir(ppy)3], Figure 1.7 left, ppy: 2-phenylpyridine) having three identical ligands, the bis-
heteroleptic complexes
55
 (like [Ir(ppy)2(acac)], Figure 1.7 centre, acac: acetylacetonate) 
having two identical main ligands, and a third ancillary ligand, and the tris-heteroleptic 
complexes where the three ligands are different
56
 (like [Ir(ppy)(diFppy)(dtb-bpy)][PF6], 
Figure 1.7 right, diFppy: 2-(2,4-difluorophenyl)pyridine, dtb-bpy: 4,4'-di-tert-butyl-2,2'-
bipyridine). Homoleptic and bis-heteroleptic have been largely studied over the years, giving 
rise to a large number of compounds used for device application. Tris-heteroleptic complexes 
are very new and only a few of them have been studied until now (see below) 
To offer a good approximation, the electronic transition involved in light emission can be 
considered as a HOMO-LUMO transition. Tuning the emission wavelength can then be 







 This is made possible because these orbitals are located on distinct parts of the 
complex. Therefore, it is possible to alter the energy of one of them without drastically 
influencing the other. 
From a practical point of view, donor or acceptor groups can be added on key locations of the 
complex to destabilise or stabilise either the HOMO or the LUMO. With a homoleptic 
complex like [Ir(ppy)3], the HOMO is delocalised between the metal core and the phenyl ring 
while the LUMO is located on the pyridine ring (as presented in Figure 1.8). A blue shift can 
then be obtained by adding an electron withdrawing group (or two) on the phenyl ring or by 
adding an electron donating group on the pyridine (or by doing both at the same time). 
 
Figure 1.8: Kohn-Sham HOMO (left) and LUMO (right) of the fac tris-homoleptic compound 
[Ir(ppy)3]. A courtesy of Basile Curchod; as presented in literature.
57
 
With a bis-heteroleptic complex such as [Ir(ppy)2(acac)] (Figure 1.9, centre), the same 
technique can be used and the emission is blue shifted by the addition of fluorine on the 





is the perfect example of this effect, with an emission maximum 36 nm blue shifted compared 
to the non-fluorinated complex due to the stabilization of the HOMO. 
A chromophoric ancillary ligand can provide a more stable LUMO than the main ligands, 
resulting in a red shifted emission. This effect is obtained by replacing the acac ligand by a 
2,2’-bipyridine (bpy) type ligand (Figure 1.9, left). In this last case, the emission is blue 
shifted by destabilizing the LUMO with a donor group added on the ancillary ligand.
20
 
However, different non-chromophoric ligands can also influence the HOMO-LUMO energy 
gap as it is the case for picolinic acid. Its different coordination properties to the metal centre 





Figure 1.9: Emission maxima of complexes [Ir(ppy)2(bpy)][PF6],recorded in MeCN (left)
60
, 
[Ir(ppy)2(acac)], recorded in DCM (middle)
61








1.5.5 Blue-emitting complexes 
In the context of creating efficient electroluminescent devices using phosphorescent emitters, 
blue emitters represent a special challenge. Indeed, the large HOMO-LUMO gap needed to 
achieve high energy emission suffers some design limitations. As discussed above, the use of 
high LUMO ligands is limited by the thermal population of the 
3
MC state resulting from the 
filling of antibonding metal orbitals.
43,46
 To overcome this issue, the d orbital splitting is 
increased by introducing ancillary ligands with strong field effects that raise the energy 
difference without playing a direct role in the light emission process. However, the bonding d 
orbitals are also stabilised in the process. A strong stabilisation of these orbitals would reduce 
the MLCT character of the excited state, favouring the formation of pure LC excited states. 
This would induce a reduction of the SOC with a less efficient emission as a consequence.
25
 
Research overview and limitations of blue phosphors are well summarised in the literature.
62–
64
 A brief overview of the different approaches and possibilities is presented here. 
The first way of obtaining blue shifted emission is by substitution of the ligand. This effect 
(extensively discussed above) enables to obtain blue-shifted emission in tris-homoleptic 
iridium complexes by going from [Ir(ppy)3] (em. max. In solution at RT: 510 nm) to 
[Ir(dFppy)3] (em. max. 468 nm). It is also responsible for the room temperature emission 
obtained by substitution of the ppz ligand of [Ir(ppz)3] with -CF3 to form [Ir(tfmppz)3] (em. 
max 428 nm).
35
 Alternatively to tris-homoleptic complexes, bis-heteroleptic complexes can 
also be used, since the ancillary ligand properties can be used to tune the photophysical 
properties. 
In this regard, the largely studied complex FIrpic is the perfect example (Figure 1.10, 
left).
34,65,66





a pyrazolyl-borate (Figure 1.10, FIr6, , centre)
67,68
, (Figure 1.10, right) dFppz,
45





Figure 1.10: Blue emitters FIrpic (left), FIr6 (centre) and [Ir(dFppy)2(dFppz)] (right). 
Phosphine based ancillary ligands such as benzyldiphenylphosphine (P^C) or 5-
(diphenylphosphinomethyl)-3-(trifluoromethyl)pyrazol (P^N) were shown to efficiently 





Figure 1.11: Bis-heteroleptic blue emitter complexes bearing dFppy main ligands and P^C or P^N 





Several alternatives to the dFppy main ligand have also been studied both in tris-homoleptic 
and bis-heteroleptic complexes. Many of these ligands have also been used as main or 
ancillary ligands, as for example phenyltriazole ligands.
71,73
 
As an alternative to the use of dFppy, cyclometalated bipyridine ligands can be used as a way 
to obtain a more stabilised HOMO energy, by taking advantage of the withdrawing effect of 
the nitrogen atom and fluorine substituents.
74–76
 Another common ligand architecture that has 
been extensively investigated over the last years because of its high ligand field strength is N 
heterocycle carbene (NHC, C^C) ligands. These ligands allow deep blue emission by 
providing high LUMO energies while the reinforced Ir-Ccarbene bond (compared to Ir-N bonds) 
strongly destabilises the metal based d
*
 orbitals. In addition to the blue emission, they also 
provide a great colour tunability when substituted with various groups
77
 or mixed with various 
ancillary ligands.
78
 They have been studied as tris-homoleptic complexes (Figure 1.12, 
left),
79–84
 as well as main ligands (Figure 1.12, centre)
85,86
 or ancillary ligands (Figure 1.12, 
right)
77,87–90
 in bis-heteroleptic complexes They also have been used in tridentate bis-pincer 
ligands (not shown)
91




Figure 1.12: Complexes with carbene ligands; tris-homoleptic (left), with carbene main ligand 





1.5.6 Tris-heteroleptic complexes 
The first tris-heteroleptic iridium complex was reported in 2001 by Stinner et al. as a 
metallointercalator for DNA probing purposes.
94
 This tris-heteroleptic complex is different 
from all others as it is not cyclometalated but coordinated to six nitrogen atoms in three 
bidentate ligands; 2,2'-bipyridine (bpy), 1,10-phenanthroline (phen) and phenanthrene-9,10-
diimine (phi). Therefore, the complex bears three positive charges; [Ir(bpy)(phen)(phi)]
3+
. The 
synthesis pathway also differs from the standard methodology applied to the cyclometalated 
complexes, which consists in a simultaneous reaction of the two main ligands with an iridium 
starting material (Ir(III) salt or an (Ir(I) dimer) to form a chloro-bridged dimer as described 
below. Instead, the ligands are added stepwise to an [Ir(phen)Cl4]H starting material.
95
 The 
bpy ligand is reacted first to obtain a cis-bischloro complex [Ir(phen)(bpy)Cl2]Cl.
96
 The 
bischloro complex is then converted in a cis-bisammine complex by exchange of the chloride 
with ammonia to obtain [Ir(phen)(bpy)(NH3)2]OTf3 (using triflate, OTf, as counter anion). 




The first attempt to synthesise tris-heteroleptic complexes with cyclometalated ligands for 
electroluminescent application was published by Park et al.
98
 The authors adapted a standard 
methodology for the synthesis of tris-homoleptic complexes
99
 by making three different C^N 
ligands (dFppy, ppy and 1-(4-fluorophenyl)isoquinoline, piq-F) react simultaneously with 
Ir(acac)3. By doing so, they hoped to obtain a tris-heteroleptic complex with complementary 
light emission centres for an overall white emission. 
However, despites using different ligand ratio, the authors were confronted to a purification 





that only facial isomers are formed and ignoring the Λ/Δ enantiomerism.) and failed to obtain 




 complex synthesised by Stinner et al. (left, showed without the OTf 
counter anions). [Ir(dFppy)(ppy)(piq-F)] as attempted by Park et al. (right). 
Since 2001 and the study by Stinner et al. most tris-heteroleptic complexes published were 
synthesised following the standard two steps procedure (described in details below). First, the 
ligands are reacted with an iridium source to obtain a mixture of chloro-bridged dimers (of the 
type {Ir(C1^N1)(C2^N2)(µ-Cl)}2) followed by the insertion of an ancillary ligand and 
separation of the tris-heteroleptic complex from the side products.
56,61,100–103
 These complexes 
always involve ppy-type ligands often modified in order to improve a device efficiency.
100–102
 
These studies have shown the applicability of tris-heteroleptic complexes as neutral or 








Figure 1.14: Cationic complex with adamantine substituted ligands (left) as published by Felici et al. 
Acac complex with substituted ppy ligands as published by Edkins et al. (centre) and Xu et al. (right). 
Recently, Liao et al. explored a different approach for the synthesis of tris-heteroleptic 
complexes.
104
 During the first step, they replaced the second C^N ligand by a neutral N^N 
one (4,4'-di-tert-butyl-2,2'-bipyridine, dtbbpy). Due to the different charge repartition of the 
ligand, the chloro-bridged dimer is not formed. Instead, they obtain a bis-chloro compound of 
the type [Ir(C^N)(N^N)(Cl)2] (in this case [Ir(ppy)(dtbbpy)(Cl)2]). This product has the 
advantage of being different from side products and therefore easy to purify. Indeed, the side 
reaction implying only the C^N ligand forms chloro-bridged dimers while the one implying 
only the N^N ligand forms charged species of general formula [Ir(N^N)2(Cl)2][Cl].
105–107
 
The pure tris-heteroleptic precursor is then easily purified and can be reacted with dianionic 







Figure 1.15: Synthesis of tris-heteroleptic complex as published by Liao et al. 
Very recently, Aoki et al. successfully synthesised tris-heteroleptic complexes by two 
different methods. Firstly, they used a Zn
2+
-promoted degradation method to remove one 
ligand from a [Ir(C1^N1)2(C2^N2)] type complex to obtain the corresponding chloro-bridged 
dimers {Ir(C1^N1)2(-Cl)}2 and {Ir(C1^N1)(C2^N2)(-Cl)}2 which were reacted with acacNa in 
order to obtain the final product that had to be purified.
108
 This represents an interesting 
approach as only two acac complexes are formed instead of three. However, the number of 
steps required for the entire process is increased due to the synthesis of the starting complex. 
The other approach is to use the properties of ancillary ligands to selectively modify one of 








1.6 Project overviews and ambitions 
1.6.1 White electroluminescent devices, the need of white emitting materials 
White emitting electroluminescent devices are currently made by mixing two or more 
emitting materials of complementary colours. The way the emitters are organised in the 
device can follow different strategies
110
 but all of them will result in the same drawbacks. 
The first one is that it requires a quite complicated architecture (for OLEDs), as the different 
materials are distributed in different layers. The second drawback is the necessity to control 
precisely the amount of each material, in order to avoid unwanted energy transfers (e.g. red 
emitters absorbing blue light) and obtain a good quality of white light. Thirdly, all emitting 
materials have different stabilities and therefore, some degrade faster than others. This effect 
inevitably produces a colour change in the overall emission of the electroluminescent device. 
This problem is especially important for blue emitting iridium complexes. In order to increase 
the emitted energy, the HOMO-LUMO gap must be increased and the LUMO destabilised. 
By doing this, the energy gap between the LUMO and the anti-bonding d
*
 metal orbital 
decreases and MC states become thermally accessible. This results in a lower stability of blue 
emitters as the probability to break a metal-ligand bond is increased. 
Therefore, the use of a white emitting material could provide means to overcome these issues 
and decrease the manufacturing cost of the devices. 
1.6.2 White emitting materials and strategies 
To create a white emitting material, one first approach could be to attach emitting centres 
together to get one molecule with an overall white emission resulting from the complementary 
wavelengths (Figure 1.16, A). This strategy does not present a particular improvement as it 





al. where a triple centred Ir-Eu-Ir complex was used to emit white light, with the europium 




Figure 1.16: Schematic representation of different approaches for the generation of white-emitting 
single molecules. 
This startegy is similar to the mixture approach used so far for electroluminescent devices. As 
it is likely that one centre would be less stable than the others, a device made with a multi-
centred single emitter is also susceptible to encounter colour changes over time. 
Another method consists in designing an emitter which interacts with itself (e.g. via π 
stacking interactions) to produce a modified emission (Figure 1.16, B). By controlling the 
ratio of free/interacting emitters in solid state, one can produce a dual emitting device with 
one kind of molecule. The difficulty of this approach would be to control the free/interacting 





Some examples of white emitting systems following this approach exist with pure organic 




When in solution, the molecule shows a normal blue-green emission. In solid state, the blue-
green signal is still present but a second signal appears in the red region, due to formation of 
cross-like dimers between the molecules, which change the overall emitted colour. 
 
Figure 1.17: (3,5-dimethyl-2,6-bis(dimesitylboryl)dithieno[3,2-b:2’,3’-d]thiophene.) used by Mazzeo 
et al.  
The third approach consists in using a molecule that can produce two distinct excited states of 
different geometries and energies that would both be emissive. Such a molecule would be 
called a dual emitter (Figure 1.16, C). 
Lastly, one could design a molecule whose emission spectrum is broad enough to cover the 
whole visible spectrum (Figure 1.16, D). Unlike a dual emitter, this molecule emission would 
not arise from two distinct excited states. Therefore, the emission spectrum would stay the 
same no matter what amount of energy is applied to excite the molecule. 
A nice example of this method was highlighted by Hamada et al. back in 1996 with their work 







complex exhibited an especially broad emission profile, with full width at half maximum of 
157 nm, resulting in a greenish-white colour when measured in thin film both by photo and 
electro excitation. 
 
Figure 1.18: Representation of the emitter Zn(BTZ)2 as a monomer (left) and as [Zn(BTZ)2]2. 
This interesting result was only reported by Hamada et al. but not explained. Further 
investigations were conducted by Xu et al.
114
 in an attempt to understand the mechanism of 
this broad emission. It appeared from this study that the emissive species was not a monomer, 
as was believed by Hamada et al. but a dimer where two of the BTZ ligands are shared 
between the Zn centres and the two others are linked to only one Zn atom (Figure 1.18, right). 
The emission spectra recorded at 77 K pointed out a significant difference between the 
fluorescence and the phosphorescence processes, both in solution and thin film. Therefore, the 
broad emission was the result of a mixture between the two emission processes. 
1.6.3 Iridium complexes; towards tris–heteroleptic complexes 
As far as iridium complexes are concerned, one example of broad emitter has also been 
published. This complex, (acetylacetonato)bis(1-methyl-2-phenylimidazole)iridium(III) 
(N966, Figure 1.19, left),
115
 has shown an especially broad emission profile, both in solution 
and device (Figure 1.19, right), leading to an almost white emitted light (CIE coordinates: x = 






Figure 1.19: N966 (left) and its emission spectra (right) in solution (red line) and in a device (black 
line), compared with the emission spectrum of [Ir(ppy)3] (green line). 
In device, the efficiency was only 1 cd A
-1
 and the luminance more than 1000 cd m
-2
 but at a 
driving voltage of 9 V (10 times lower than [Zn(BTZ)2]2 at a similar voltage). Even if the 
performances were poor, this example shows that it is possible to develop a single centred 
white emitting complex using a broad emission profile. 
The first explanation to this broad emission was based on theoretical calculations showing a 
degeneracy of the first three LUMOs (LUMO, LUMO+1 and LUMO+2). Calculations 
showed that the LUMO is made of π* orbitals delocalised over the bis(1-methyl-2-
phenylimidazole) ligands (main ligand). Due to the donor properties of the main ligand, the 
LUMO+1 and LUMO+2 exhibit a mixing of π* orbitals from the main and acac ligands. As a 
result, the three orbitals are almost degenerate. In comparison, [Ir(ppy)2(acac)] LUMO and 
LUMO+1 orbitals are degenerate π* orbitals of the ppy ligands and are much more stabilised 
than the degenerate LUMO+2 and LUMO+3 localised on both ppy and acac ligands. The 
narrower emission profile of [Ir(ppy)2(acac)] is compared to that of N966 in Figure 1.19. The 
degeneracy of the first LUMOs localised over distinct parts of the complex where thought to 





In order to obtain degenerate LUMO orbitals, one can use tris-heteroleptic complexes and 
take advantage of three ligands with different controllable properties to increase the broadness 
of the emission profile. 
An attempt at doing this was published by Baranoff et al.
61
 The tris-heteroleptic studied was 
an acac complex with two ppy ligands with and without 2’,4’-difluorination. 
 
Figure 1.20: [Ir(diFppy)(ppy)(acac)](left) and its emission spectrum (green) together with the spectra 
of the two corresponding bis-heteroleptic complexes [Ir(ppy)2(acac)] (red) and [Ir(diFppy)2(acac)] 
(black). 
Despite a degeneracy of the first two LUMOs of the complex, located on the two main ligands 
(diFppy and ppy), the emission is not broad, as shown in Figure 1.20 (green line). Instead, the 
emission profile is similar in shape to the profiles of the corresponding bis-heteroleptic 
complexes, with an emission maximum close to their average. 
The calculations performed on this molecule show that despite a quasi degeneracy of the 
LUMOs and of the two most stable excited states, the geometry change induced by one or the 





words, the molecule is trapped in one or the other excited state geometry and the excited 
electron is not delocalised over the two ligands. 
The hypothesis derived from this study as far as broad emission is concerned is that 
degeneracy of the LUMOs is not enough to predict the broadness of the emission spectrum. 
One has to take into account the excited state energies as well as their geometries. 
Tris-heteroleptic complexes allow playing with three ligands at a time, each of which having 
their own properties. In order to achieve this, it is necessary to study how these ligands react 
with the iridium starting material and which properties each ligand brings to the overall 
complex. The tris-heteroleptic family has scarcely been studied and only a few of these 
molecules have been synthesised. 
The reason for this poor representation of tris-heteroleptic complexes in literature comes from 
the difficulty to synthesise them following the usual method starting with Ir(III)Cl3 and the 
difficulty to purify them, due to the mixture of complexes formed. A new method has been 
described recently
61
, using an Ir(I) starting material which allows a reaction yield  as high as 
40%. 
1.6.4 Synthesis of bis and tris-heteroleptic complexes 
Bis-heteroleptic cyclometalated iridium complexes are usually synthesised in two steps
31
, as 
presented in Figure 1.21. The main ligand is mixed with iridium trichloride (IrCl3) and heated 
to reflux in an ethoxyethanol/water mixture. This results in the formation of a chloro-bridged 
dimer. This dimer is then reacted with the desired ancillary ligand by heating to reflux in 
DCM overnight. Details of the synthesis can differ in the case of some ancillary ligands. For 





original chloride ion can be exchanged with hexafluorophosphate. If the ligand is an acid (e.g. 
picolinic acid) and needs to be activated by deprotonation, a base such as TBAOH is added. 
 
Figure 1.21: Standard procedure for the synthesis of cyclometalated bis-heteroleptic iridium 
complexes. 
This methodology appeared to be inefficient when transposed to the synthesis of the tris-
heteroleptic complex [Ir(dFppy)(ppy)(acac)].
61
 As stated before, the method was adapted, 
using an iridium(I) starting material that allowed to improve the total yield while decreasing 
the reaction time of the first step from 12-24 hours to 3 hours. As there are now two different 
main ligands mixed together and reacting with the iridium starting material (Figure 1.23), it 
results in a mixture of 7 different dimers (Figure 1.22, without the Δ/Λ configurations of their 
iridium centres). 
 
Figure 1.22: Schematic representation of the seven possible configurations of chloro-bridged iridium 
dimers with two different main ligands. The main ligands are symbolised by the blue and red discs. 
The black cross represent the Ir(µ-Cl)2Ir architecture. The ligand configuration around the iridium 
atoms is supposed to be trans-nitrogen (N-Ir-N) only. The differentiation between Λ and Δ centres is 
ignored. 
When reacted with a symmetrical ancillary ligand such as acac, these dimers will form 14 





Therefore, assuming the ligands show the same reactivity with the iridium all the time, the 
maximum tris-heteroleptic yield would be 6/14 ≈ 0.43. 
 
Figure 1.23: General methodology for the synthesis of cyclometalated tris-heteroleptic iridium 
complexes with an acetylacetonate ancillary ligand. 
After reaction with acac complexes, the difficulty is to separate the tris-heteroleptic complex 
from the two bis-heteroleptic by-products. This task is more difficult if the ligands have 
similar properties such as same heterocycles or same substituents as the polarity differences of 
such complexes are small. 
Once purified, the tris-heteroleptic acac complex can be turned back into a pure dimer by 
reacting with HCl. This pure dimer can finally be reacted with any ancillary ligand to 
potentially obtain any tris-heteroleptic complex desired (Figure 1.24). Alternatively, the acac 
ligand can be removed with BF3 in acetonitrile to form a positively charged bis-acetonitrile 
cation. The anion is then exchanged with a PF6 anion. The advantage of this approach is the 
increased solubility of the bis-acetonitrile complex over the dimer, making it easier to 






Figure 1.24: Methodologies for the ancillary ligand replacement from acac to a general L^L ligand. 
The conditions of the second step are ligand specific. 
The tris-heteroleptic complex obtained after reacting with the X^X ligand does not require a 
complicated purification anymore. Depending on the X^X ligand used, it can easily be 
removed by dissolution into water (while the complex precipitates) or a recrystallisation 
process. In the worst case, a short chromatography column can be required. 
The advantage of this synthesis is that it is easy to achieve with standard laboratory 
equipment. It also produces impurities that are easily removed (excluding the by-product 
complexes) allowing to obtain iridium complexes in very good purity. The major drawback is 
the formation of the bis-heteroleptic by-products and the tedious purification process that they 
imply. This process is made worse by the relative instability of acac complex on the acidic 
silica. Unfortunately, a more stable ancillary ligand than acac would also be more difficult to 
remove in order to obtain a pure tris-heteroleptic precursor (dimer or bis-MeCN), which 
represents a great advantage for ancillary ligand screening experiments. 
In the present context, the acac ligand presents the double advantage of being easy to remove 





generate two tris-heteroleptic isomers which would only add more complexity to the 
separation task. 
1.7 Conclusion 
This chapter focused on the context of electroluminescent light emitting devices and their 
working principles. It presented the basics of light emission processes and introduced the 
iridium complexes studied in the present work. The development of single-centre white 
emitting molecule for electroluminescent device application was presented as a potential 
alternative to overcome the limitation of the current approach. It would allow the creation of 
devices with simplified architectures while suppressing the drawback inherent to the use of 
several emitters of complementary colours. The use of tris-heteroleptic complexes was 
proposed as well as the synthetic strategy to reach the goal of creating a broad emitting 






2 TRIS-HETEROLEPTIC IRIDIUM COMPLEXES; 
SYNTHESIS AND PURIFIFCATION  
2.1 Introduction 
This chapter focuses on the synthesis of the four series of complexes presented below (Figure 
2.5, Figure 2.10 and Figure 2.13). The goals are to explain the methodology used for their 
synthesis and purification, to describe the challenges encountered and discuss the practical 
means of overcoming these challenges. The chapter also discusses the characterisation of 
these complexes, mainly by detailed NMR spectra analyses, but also by looking at the crystal 
structures. Electrochemical and photophysical studies of the complexes and their analyses are 
discussed in the next chapter. 
The complexes are hereby divided in three main series, taking into account a chronological 
order of design and synthesis. This is why the tendency will be to discuss the results one 
series of complexes at a time, even though some links between them will be made if they 
appear to be relevant. 
A fourth series, which involves the synthesis and purification of complexes with non 
symmetrical ancillary ligands, is also presented. Even though these products are an extension 
of the first series, their particular purification challenges justify the addition of a dedicated 
section. 
As part of this chapter, the design and results of a preliminary ancillary ligand screening 
experiment is also discussed, as it represents a perfect example of the research possibilities 






2.2 Synthesis of the ligands 
The synthesis of each type of ligands used during this research is reported and briefly 
discussed. The aim is to present the main results (yields) and the difficulties encountered 
without providing too many details on the characterisations. An interested reader may consult 
the experimental details chapter. 
2.2.1 Suzuki coupling reactions 
Suzuki coupling reactions have been used to synthesise all phenylpyridine type ligands 
(except 2-phenylpyridine itself which is commercially available). The model method 
described for the synthesis of 2-(2,4-difluorophenyl)pyridine (dFppy)
116
 was adapted for the 
syntheses of other ligands such as 2-(2,4-dimethoxyphenyl)pyridine (dMeOppy), 2-(2,4-
dimethoxyphenyl)-4-methylpyridine (dMeOMeppy) and 2-(2,4-dimethoxyphenyl)-4-
methoxypyridine (dMeOMeOppy). Commercially available 2-bromopyridines were chosen 
and reacted with commercially available phenylboronic acids. 
 
Figure 2.1: Suzuki coupling reaction equation and synthesised products (with the carbon atoms 





The boronic acids were added in excess to maximise the reaction and to facilitate the 
purification process. This is especially necessary for dFppy where 2-bromopyridine has very 
similar Rf than the product and is therefore difficult to remove on silica gel columns.  
For the synthesis of dimethoxylated ligands, the increased polarity of the product is lowering 
its Rf compared to the bromopyridines used.  
Table 2.1: Substituents and reaction yields for the ligands synthesised by a Suzuki coupling reaction. 
 
2.2.2 Synthesis of the phenylpyrazole ligands 
1-(2,4-difluorophenyl)pyrazole (dFppz) was synthesised
117–119
 by a condensation reaction of 
an hydrazine and 1,1,3,3-tetramethoxypropane. The reaction is achieved in good yield (62%) 
and a sligthly yellow oil is obtained after a few chromatography columns on silica gel. The 
presence of an impurity migrating close to the product can be problematic but this issue is 
resolved by evaporation of the solvent and drying of the crude under vacuum prior to base 
neutralisation. 
 
Figure 2.2: Reaction scheme for the synthesis of dFppz (with the carbon atoms numbered for NMR 
assignment purposes).  
  
Ligand R1 R2 Yield (%) 
dFppy -F -H 98 
dMeOppy -OMe -H 75 
dMeOMeppy -OMe -Me 73 





CF3ppz was synthesised in two steps (Figure 2.3).
120,121
. First, a vinamidinium salt is made 
from trifluoroacetic acid and (N,N-dimethylformamide) DMF in the presence of phosphorus 
oxychloride (POCl3). The product is harvested by precipitation in water under the form of a 
PF6 salt that is more stable and easier to precipitate than the chloride salt. 
 
Figure 2.3: Reaction scheme for the synthesis of CF3ppz (with the carbon atoms numbered for NMR 
assignment purposes). 
The vinamidinium salt was not purified further and reacted with hydrazine to obtain the 
corresponding phenylpyrazole ligand. The product was purified by column chromatography. 
This synthesis produces the ligand in average yield (51%). The major uncertainty affecting 
the yield is the purity of the vinamidinium salt as only one precipitation in water is performed. 
It is possible that some KPF6 or other phosphorus salts from the synthesis remained. To 
ensure better quality of the vinamidinium salt, recrystallisation from water/2-propanol can be 
achieved. Nevertheless, the purity of the final ligand is more important and the efforts to 






2.2.3 Synthesis of the phenyl imidazole ligand (mespim) 
The synthesis of mespim is made via a one pot mixture of four reactants.
122
 First, 
trimethylaniline is mixed with Glyoxal and stirred at RT. A yellow precipitate forms and 
ammonium chloride and benzaldehyde are added to the flask. After a short heating period, 
TFA is added and the reaction mixture is heated to reflux for an additional 8 hours. 
 
Figure 2.4: Reaction scheme for the synthesis of mespim (with the carbon atoms numbered for NMR 
assignment purposes, the 2’ and 9’’ carbons are not numbered for clarity). 
The crude mixture is not clean and needs extensive chromatography purification before a 
sufficiently pure product can be obtained. The unclean crude mixture, and low yield (11%) 







2.3 First series: complexes with ppy/ppz ligands 
2.3.1 Choice of the ligands 
In order to explore the new family of tris-heteroleptic complexes and study their 
photophysical properties, it is necessary control the changes induced by each ligand as much 
as possible. 
The goal is to understand the influence of changing one ligand on the photophysical 
properties. Therefore, one needs to select ligands that differ sufficiently to induce a change, 
but not too drastically, to limit the chances of reaction failure. 
The choice of acac brings a practical synthetic advantage, as the complexes generated are 
neutral and stable enough to be purified and characterised relatively easily. It also provides 
the opportunity to still replace the ancillary ligand later on if necessary. 
Since it is a known non chromophoric ligand, acac does not interfere in the light emission 
process. Therefore, it allows to study the influence of two C^N chromophoric ligands and the 
photophysical properties without the effect of a chromophoric ancillary ligand coming in the 
way. Again, once an interesting combination of C^N ligand is discovered, one can easily 
remove the acac and start exploring the huge library of ancillary ligands available. 
The drawback of this approach is that one has to carry a relatively unstable complex through 
all the purification process with a non negligible degradation due to acac decoordination. 
Previous studies on a tris-heteroleptic complex suggested that two ppy based ligands provide 
LUMOs with similar energies, leading to the trapped excited state problem.
61
 Therefore, it 
was decided to select a second C^N ligand that is bringing a higher LUMO to the system. The 






The hope was that a ligand with higher LUMO energy would provide an extended degree of 
excited state mixing and an increased delocalisation of the excited electron over the ligands 
that would result in a broad emission profile. Ppz ligands are known for their high LUMO 
energy (-2.24 eV for [Ir(ppz)2(acac)]
123
 evaluated with a similar method than used in this 
work where the LUMO of [Ir(ppy)2(acac)] is evaluated at -2.65 eV) and to form non emissive 
complexes at room temperature. In the present context they represent a convenient starting 
point, leaving a large margin to adapt the LUMO level of future ligands. 
The atomic positions on the complexes (Figure 2.5) are assigned according to the normal 
ligand numbering positions followed by a letter to differentiate the three ligands (a, b and c). 
Prime marks are added to phenyl positions to distinguish them from the heteroaromatic ones. 
The acac ligand is always noted “c” even for a bis-heteroleptic complex (to facilitate 
comparisons between products). Numbers of heteroatoms and non protonated carbons are 
often omitted on drawings for clarity. 
Complex 3 is the only already published tris-heteroleptic complex of the series. It represents a 
known model with which to compare the synthesis of the other products. 6 is the equivalent of 
3 with only ppz ligands. 1, 2, 4 and 5 are their corresponding bis-heteroleptic complexes. 
They are by-products of the tris-heteroleptic complexes syntheses. 
Complexes 7, 8, 9 and 10 are obtained by mixing ppy and ppz ligands, with and without any 






2.3.2 Synthetic details and purification 
All acac complexes 1 to 10 were synthesised following the general procedure shown above 
(Figure 1.23). First, the ligands are heated up in the presence of an iridium source to obtain a 
mixture of chloro-bridged dimers. The obtained mixture is then reacted with sodium 
acetylacetonate (acacNa) in DCM/MeOH solvent mixture overnight. This approach results in 
the combination of the target tris-heteroleptic acac complex together with the two 
corresponding bis-heteroleptic complexes, [Ir(ppy)2acac] (1), [Ir(dFppy)2acac] (2), 
[Ir(ppz)2acac] (4) and [Ir(dFppz)2acac] (5). 
As the relative amount of the target tris-heteroleptic complex compared to bis-heteroleptic 
complexes is embedded in the mixture of chloro-bridged iridium dimers, different reaction 
conditions were explored as a possible mean to improve the yield of tris-heteroleptic 
complexes. Three sets of conditions were tested, A, B and C, varying the iridium source, the 
temperature and the solvent. 
Conditions: 
A IrCl3 xH2O, ethoxyethanol/water (7/3), 130°C, 12h. 
B {Ir(COD)Cl}2, ethoxyethanol, 130°C, 3h. 






Figure 2.5: Complexes of the first series: [Ir(ppy)2(acac)] (1), [Ir(dFppy)2(acac)] (2), 
[Ir(dFppy)(ppy)(acac)] (3), [Ir(ppz)2(acac)] (4), [Ir(dFppz)2(acac)] (5), [Ir(dFppz)(ppz)(acac)] (6), 






Conditions A are standard conditions for the synthesis of chloro-bridged iridium dimers. 
Conditions B were previously used for the synthesis of the tris-heteroleptic complex 3 where 
the use of an Ir(I) starting material tremendously decreased the reaction time from 12h to 3h. 
Conditions C were chosen to explore the effect of changing the solvent on the reaction yields. 
As the reaction generates a mixture of seven possible dimers, all with a low solubility in most 
solvents, any purification attempt at this stage would have been unnecessarily tedious. The 
dimer mixtures were reacted directly with acacNa (which is a nearly quantitative reaction)
61
 to 
obtain the three corresponding acac complexes (much more soluble than the dimers). At this 
stage, a 
1
H-NMR spectrum of each crude mixture (A, B, C) was recorded to perform an NMR 
yield analysis. 
The complexes can be purified by standard chromatography techniques with silica gel. In 
order to limit the degradation induced by the acidic silica,
61
 a small amount of triethylamine is 
added. This limits the acidity of the silica but it also decreases the retention times and the 
separation effectiveness. A balance has to be found between, 1: limiting the degradation but 
making the separation less efficient. And 2: losing more of the product on the column but 
having a slightly better separation. It is not possible to get a perfect balance and the 
purification remains tedious (involving many columns) and costly in product. 
The eluent of choice is pure DCM as it provides a good solubility as well as acceptable Rf 
values (Figure 2.6). Attempts to slow down fast migrating mixtures by adding hexane to the 
eluent only make the column more difficult to prepare as the solubility of the complexes are 
decreased. More eluent is then required to solubilise the crude and the deposition band on the 





On the other hand, accelerating the migration of slow crudes by adding a small amount of 
MeOH or MeCN can be useful in some cases. But the risk is high that it also decreases the Rf 
differences between the complexes in the mixture. 
In the end, ratios between the isolated yields of the three reaction products are not guaranteed 
to be representative of the real reaction yields. Firstly, the complex with the lowest Rf stays 
longer on the silica than the others. One can assume that a larger percentage of this complex is 
degraded by the silica, especially if the Rf differences between the complexes are large. 
Secondly, there is no guarantee that all the complexes have the same sensitivity to the silica. 
Some complexes might exhibit a higher degradation rate than others. This is especially 
plausible when the two main ligands have different hetero-aromatic rings. 
 
Figure 2.6: Schematic view of measured TLC separation for the crudes of complexes 1 to 10, with 





All tris-heteroleptic complexes were not equally difficult to purify. Since they show an 
intermediate Rf compared to their corresponding bis-heteroleptic complexes, some tris-
heteroleptic complexes are easier to separate than others. The Rf of the bis-heteroleptic 
complexes can be expressed in increasing order as follow: 4 < 1 < 5 < 2. Therefore, the most 
difficult complex to purify is 7 because its Rf lies between the ones of 1 and 4 which are low. 
On the other hand, the easiest purification is for 9 because it lies between 2 and 4 which have 
the largest Rf difference among the series. This simple analysis also underlines how the 
purification difficulty can vary even between two complexes with similar structures and Rf, 
such as 9 and 10 (The position of the fluorinated phenyl ring placed on the ppy or on the ppz 
being the only structural difference). Because the bis-heteroleptic complexes involved have a 
much smaller Rf difference for 10, it will be significantly more difficult to purify than 9. 
2.3.3 Proton NMR characterisation 






F NMR and 2D NMR 
techniques (COSY NOESY, HSQC). 
In order to assign proton peaks, many complementary approaches are available. Firstly, it is 
relatively easy to determine which signal belongs to which ligand only by comparing the tris-
heteroleptic spectrum with the two correspondingspectra of the bis-heteroleptic complexes. 
The spectrum of the tris-heteroleptic complex will look like a superimposition of the two 
others and chemical shift differences due to an environment change (such as fluorinated vs 
non fluorinated ligands) appear very clearly. This is true even if the two ligands are similar as 
it was shown in previous studies for 3.
61
 To demonstrate this effect, a comparison of the 
spectra of 4, 5 and 6 is shown below (Figure 2.7). On these spectra, the shift induced by the 
fluorine atom on the 5 positions of the pyrazoles is manifest. It is also very easy to spot the 2’ 






Figure 2.7: Aromatic regions of the 
1
H-NMR spectra of 6, 5 and 4 measured in CDCl3. The relative 
integral values are displayed below the signals. 
Other clues are given by the coupling constants and chemical shifts of the peaks. For example, 
the doublet signal around 6.2 ppm corresponds to the 5’ proton of the phenyl ring. If the 
phenyl ring is 2’,4’-difluorinated, the signal is shielded to 5.6 ppm and becomes a doublet of 
doublet (dd), due to its coupling with the 
19
F nuclei. Similarly, the triplet on the 3’ position 
also suffer shielding and becomes a very identifiable mixed ddd signal upon 2’,4’-
difluorination. 
2D NMR techniques such as COSY and NOESY are useful to identify series of peaks when 
two ligands display very similar signals (e.g. the two phenyl rings of 7). In this situation, 
COSY allows to distinguish the two series but not necessarily to assign them to one or the 





between the 5 position of a pyrazole (3 position of a pyridine) with the 2’ position of the 
phenyl ring. If the quality of the NOESY is good enough, it is even possible to see the 
coupling of the pyrazole position 3 (or of the pyridine position 6) with the 1 and 5 protons of 
the acac methyl groups. Because these methyl protons exhibit slightly separated signals on the 
1
H-NMR spectrum (for tris-heteroleptic complexes) they can be differentiated that way. 
2.3.4 Carbon NMR characterisation 
Once the proton assignment is complete, it is easy to assign the protonated carbon signals by 
following the information displayed by the HSQC spectrum. Just like the 
1
H spectrum, the 
13
C 
spectrum of a tris-heteroleptic complex is also the sum of the spectra of its corresponding bis-
heteroleptic complexes (Figure 2.8).  
By combining analyses of coupling constants, HSQC measurements and spectra comparison, 
the 
13
C signals of protonated carbons are relatively easy to assign. The characteristic doublet 
of doublet signals of the 3’ and 5’ positions of a 2’,4’-difluorinated phenyl (observed at 97 
and 117 ppm respectively) can be cited as examples, as well as the doublets of the dFppy-3 
and dFppz-5 (showing up at 122 and 130 ppm). 
The signals of the acac-1 and acac-5 carbons appear around 30 ppm. They are separated in 
two singlets in the case of tris-heteroleptic complexes with relatively small shifts (< 1 ppm). 
Just like for 
1
H-NMR where it always shows up around 5.25 ppm, the acac-3 
13
C signal is also 
very stable and is always visible at almost 100 ppm. 
13
C-NMR also allows observing the acac-
2 and acac-4 signals appearing around 185 ppm. Just as for acac-1 and acac-5, two distinct 
singlets can be observed for tris-heteroleptic complexes with a chemical shift difference 





Things become more complicated when considering the non protonated carbons: pyridine-2, 
phenyl-1’, phenyl-6’, 2’,4’-difluorophenyl-1’, 2’,4’-difluorophenyl-2’, 2’,4’-difluorophenyl-
4’ and 2’,4’-difluorophenyl-6’. 
 
Figure 2.8: Aromatic regions of the 
13
C-NMR spectra of 10, 5 and 1 measured in CDCl3. 
These signals exhibit a very low intensity and require a very good measurement quality to be 
properly distinguishable from the baseline. Even then, their resolution is often poor and it can 
be difficult to observe their multiplicity. Among them, the signals with the better resolution 
are the singlets from the non fluorinated ligands (ppy-2, -1’, -6’ and ppz-1’ and -6’). The ppy-
2 signal is especially easy to assign as it remains around 168 ppm for all the complexes 
containing the ppy ligand (1: 168.72 ppm, 3: 168.54 ppm, 7: 169.31 ppm and 10: 169.07 





165.49 ppm, 8: 166.03 ppm, 9: 166.25 ppm). The fluorinated carbons can also be assigned if 
the signal is strong enough as they are doublets of doublets with a large 
1
JC-F coupling 
constant (180 – 250 Hz) and a small 
3
JC-F-coupling constant (10 -15 Hz). 
The most problematic assignments reside in distinguishing 1’ and 6’ phenyl carbons. As they 
are often close to each other and could be interchanged quite easily. Furthermore, the dFppy 
and dFppz-1’ and 6’ carbons exhibit signals with very low intensities and badly defined 
splittings. 
In an attempt to distinguish them, HMBC experiment was performed on compound 6. The 
problem was that both 1’ and 6’ carbons were anticipated to couple with 3’ and 5’ protons for 
dFppz and potentially with 2’, 3’, 4’ and 5’ for ppz. The hope was to observe a 
3
JC-H coupling 
between the 1’ carbon and the pyrazole proton 5 but it is not the case (Figure 9.42). 
With the data and NMR experiments available, it is not possible to assign these signals with a 




H 2D NMR experiments 





H nuclei separated by two chemical bonds. For ppy and ppz, this 
would mean observing carbon 6’ coupling only with proton 5’ and carbon 1’ coupling only 
with proton 2’. In dFppy and dFppz, the carbon 6’ coupling with proton 5’ would remain 
visible but the carbon 1’would show no coupling as the proton is replaced by a fluorine atom. 
Nevertheless, the data provided by the experiments detailed above allow the assignment of all 






2.3.5 NMR yield calculation 
For the present series, isolated yields were judged less appropriate due to the acid induced 
degradation factor on chromatography columns. It is not guaranteed that the yield obtained 
would be representative of the reaction (since the more polar complexes stay longer on the 
column, they are subjected to more degradation). Therefore, the decision was made to study 
NMR yields (relying on the peak integral values) of the crude mixtures to still have an idea of 
which products are favoured. Furthermore, because of the purification challenge of some 
complexes and because of the high cost of the iridium starting materials, it is difficult to 
purify separately each batch from conditions A, B and C. The crudes were mixed and 
separated together. 
As expected, the 
1
H-NMR signals from the crude are a perfect combination of the signals 
from the three complexes as exemplified for complex (Figure 2.9). As the relative amount of 
each complex is accessible from integration of the signals, an average molar mass can be 
calculated from the ratio obtained, which rapidly gives access to an approximate yield for 
each complex without the need for purification.  
In an attempt to explain the results obtained one must consider the reaction processes 
involved in the cyclometalation reaction. For a general representation of our case, one can 
consider the starting material of the type IrCl to react with a first ligand to obtain an 






Figure 2.9: Comparison of the aromatic region of the 
1
H-NMR spectra (measured in CDCl3) of the 
crude from 9 (obtained after using conditions C for the first step and containing 2, 4 and 9) and the 
spectra of the purified products 2, 4 and 9. The relative integral values are shown for the signals of 
the purified products. 
Then the intermediate reacts with a second ligand to form the chloro-bridged dimer. In the 
case of conditions A, the iridium(III) starting material reacts with the ligands through 
subsequent electrophilic substitution processes. With conditions B and C, the use of an 
iridium(I) starting material implies an oxidative addition process (to yield an Ir(III)(C^N)Cl 









Table 2.2: Nmr yields of complexes 3, 6 to 10 and of their corresponding bis-heteroleptic complexes 






entry Complex A B C 
1 3 30 37 42 
2 2 19 12 15 
3 1 18 12 16 
4 overall 67 61 73 
5 6 36 14 20 
6 5 10 6 11 
7 4 22 4 4 
8 overall 68 24 35 
9 7 14 43 32 
10 1 13 23 11 
11 4 30 4 1 
12 overall 57 70 44 
13 8 29 32 25 
14 2 25 24 24 
15 5 14 5 5 
16 overall 68 61 54 
17 9 30 18 36 
18 2 22 33 17 
19 4 19 4 2 
20 overall 71 55 57 
21 10 28 16 19 
22 1 9 19 15 
23 5 22 3 7 





Overall, the results show a little influence of the solvent as conditions B and C exhibit only 
small yield differences and a clear tendency to favour the same products.  
Differences exist but they are most of the time contained within the margin of error of the 
measuring process. It is interesting to note that the tris-heteroleptic product is often favoured, 
the only exceptions being for the syntheses of 7A, 9B and 10B (Table 2.2). 
The reactions with only ppy-type ligands do not show a big reactivity difference between 
conditions A and B and C, as the overall yields are contained between 67 and 73 %, with bis-
heteroleptic complexes showing similar yields both within and between conditions sets. 
The same observation cannot be made for the all-ppz experiment (synthesis of 6) as 
conditions A show higher yields than B and C. Low yields for bis-ppz complexes were 
consistently obtained with conditions B and C (Table 2.2 entries 6B, 6C, 7B, 7C, 11B, 11C, 
15B, 15C, 19B, 19C, 23B and 23C). This underlines a decreased reactivity of the ppz and 
dFppz ligands towards oxidative addition. However, this does not affect the yield of tris-
heteroleptic complexes with mixed ligands as conditions B and C reveal some very good 
values above 30 % (entries 9B, 9C, 13B and 17C). According to these cases, conditions B and 
C could represent a way of using the ligand reactivity difference to obtain good tris-
heteroleptic yields while almost stopping the formation of one of the two by-products. 
However, the danger is to observe an increased yield of the second by-products that can reach 
or overcome the yield of the target molecule (entries 14C, 18B, 22B and 22C). 
Considering conditions A, similar tris-heteroleptic yields and the same overall yields are 
obtained for the all-pyridine and all-pyrazole experiments (entries 1A and 5A, entries 4A and 






In the case of complex 7, the major product of the reaction was the bis-ppz by-product (entry 
11A), while the synthesis of 8 shows a high yield of the bis-dFppy product, almost reaching 
the yield of the tris-heteroleptic complex (entry 14A). 
When the fluorination varies, the fluorinated ligand displays a small advantage as both bis-
dFppy and bis-dFppz complexes were favoured compared to their corresponding non 
fluorinated bis-heteroleptic counterpart (entry 18A and 23A). However, for the synthesis of 9, 
this difference is very small (only 3%). 
Generally speaking, conditions A give good results and provide good reactivity with both ppy 
and ppz-type ligands. However, conditions B and C can reach better yields and produce less 







2.4 Second series: complexes with dMeOppy ligands 
2.4.1 Choice of the ligands 
It has been shown recently that by replacing fluorine substituents on the phenyl ring with 
methoxy, a similar HOMO-LUMO energy gap can be obtained.
57
 Fluorine mostly exhibits a 
meta-directed inductive electron-withdrawing influence on a phenyl ring. Therefore, when 
placed at the meta position from a cyclometalated carbon, it has a stabilising effect on the 
metal centred HOMO. An ortho/para electron-withdrawing effect also exists but it is 
significantly smaller than the meta influence. A methoxy substituent, however, exhibits a 
small meta-directed inductive electron withdrawing effect but also a stronger ortho/para-
directed mesomeric electron donating effect. Therefore, in the case of a 2’,4’-dimethoxylated 
ppy (dMeOppy), the effect on the meta-positioned metal is electron-withdrawing and the 
effect on the ortho/para pyridine is electron donating. The result is a simultaneous HOMO 
stabilisation and LUMO destabilisation. 
The second series of ligands studied here combine this 2’,4’-dimethoxylation with an 
increasing electron donating effect inserted on the pyridine ring to incrementally destabilise 
the ligand LUMO. The standard proton on position 4 of the dMeOppy) is replaced by a 
slightly donating methyl group (2-(2,4-dimethoxyphenyl)-4-methylpyridine; dMeOMeppy) 
and by a more donating methoxy group (2-(2,4-dimethoxyphenyl)-4-methoxypyridine; 
dMeOMeOppy). This latter ligand can also be assumed to apply a further stabilising effect on 
the HOMO through stabilisation of the phenyl π orbitals via its meta-directed withdrawing 
effect. 
These ligands are combined with the standard ligands dFppy and dFppz to provide a standard 





with controlled LUMO energies in the same complex to see if they allow the formation of a 
degenerate excited state leading to a broader emission profile. 
Furthermore, from a purely synthetic point of view, the insertion of methoxylated ligands with 
alongside fluorinated ligands should drastically improve the purification process of the tris-
heteroleptic complexes formed. As the methoxy substituents are causing a polarity increase, 
Rf values are anticipated to decrease accordingly. The Rf difference between fluorinated and 





2.4.2 Synthesis details and purification 
 
Figure 2.10: Complexes of the second series: [Ir(dMeOppy)2(acac)] (11), [Ir(dMeOMeppy)2(acac)] 
(12), [Ir(dMeOMeOppy)2(acac)] (13), [Ir(dMeOppy)(dFppy)(acac)] (14), [Ir(dMeOppy) 
(dFppz)(acac)] (15), [Ir(dMeOMeppy)(dFppy)(acac)] (16), [Ir(dMeOMeppy)(dFppz)(acac)] (17), 






Complexes synthesised are presented in Figure 1.23. Conditions B were always used and gave 
good results for the dFppy complexes (14, 16, 18) but very mediocre results with the dFppz 
complexes (15, 17, 19). Conditions A were tested on the latter complexes and much better 
yields were obtained (Table 2.3). 
NMR spectra of crude products reveal that conditions A favour the formation of the bis-dFppz 
complex (5) and of the tris-heteroleptic complexes while the bis-dMeOXppy complexes (11, 
12 and 13) are only present in traces. Conditions B, present the opposite situation where the 
bis-dMeOXppy complexes are favoured, small amounts of tris-heteroleptic complexes are 
detected and 5 is virtually absent. For the crudes products of 14, 16 and 18 synthesised with 
conditions B only, the tris-heteroleptic complex (14, 16 and 18) is always the major product 
followed by the bis-dimethoxylated complexes (11, 12 and 13 respectively) and then 2. No 
major reactivity difference was observed in the crudes proton NMRs as the ratios between the 
three complexes remained unaffected. 
Table 2.3: Isolated yields (%) of complexes 14-19 when synthesised with conditions A or B. 
 
A few tests were performed on 19 to try improving the yield. First, by modification of 
conditions B, the dFppz ligand was added alone (1.1 equiv. to iridium atoms) and reacted at 
80ºC for 2h before adding the dMeOMeOppy ligand. The reaction mixture was heated at 
130ºC for an additional 3 hours. 
 
Conditions 
Complex A B 
14 - 38 
15 31 5 
16 - 56 
17 20 9 
18 - 48 





After reaction with the acac ligand, the NMR crude revealed no change compared to the 
standard B procedure. The amount of 5 was undetectable and the major product was 13. The 
signals from 19 were also almost undetectable. 
The reaction of dFppz alone with the iridium(I) for 3 hours at 130ºC, followed by the addition 
of the dMeOMeOppy ligand and heating for an additional 3 hours only led to the formation of 
more 5 alongside 13 while only traces of 19 were observed. 
Even though improving the yield of 19 with conditions B would have been a great advantage 
(due to the reduced reaction time), it is not possible to compete with conditions A when the 
dFppz ligand is involved. 
Once synthesised, 14-19 are much easier to purify than the products from the first series. As 
anticipated, the retention time of a complex on silica gel increases accordingly to the number 
of methoxy groups it carries. Therefore, the Rf differences between the three species of each 
crudes are big (Figure 2.11). This difference is especially pronounced between the tris-
heteroleptic complexes and the bis-dFppy and bis-dFppz by-products 2 and 5. Consequently, 
2 and 5 are easier to separate from the crude than the methoxylated species. 
It is interesting to note that the addition of a methyl group does not change the Rf a lot, as only 
a small increase is measured (especially for 12 compared to 11). Insertion of a third methoxy 
group on the ligand has a bigger impact, as denoted by the Rf decrease measured between 11 
and 13, and between 14 and 18. The replacement of a dFppy by a dFppz appears equivalent in 
terms of Rf than the addition of a methoxy group, as 17 and 18 show a similar decrease 
compared to 16. 
Consequently to increased Rf differences inherent to the use of methoxy groups, only one or 





satisfactory purity. Furthermore, as the Rf are low in pure DCM, it is possible to use shorter 
columns to achieve a good separation or to use a more polar eluent (such as DCM/MeCN 
mixtures). This, however, depends on how well the two methoxylated species of the crude are 
moving on the silica. It is possible than some of them leave tails or degrade more than others 
(especially when the amount of methoxy groups is high). Therefore, the complexes may be 
more difficult to separate than it looks on the TLC and longer columns may be needed in 
some cases. 
 
Figure 2.11: Schematic view of measured TLC separation for the crudes of complexes 14 to 19, with 
pure DCM as eluent and without triethylamine. 
However, with the addition of methoxy groups, a lower solubility in DCM was also observed, 
especially for the dFppz complexes 17 and 19. This does not lead to major purification issues 






2.4.3 NMR characterisations 




C as well as 2D is essentially the same than for the 1
st
 series, 
so the assignment process of these complexes is not described in details in this chapter but 
only focuses on some comparisons and new aspects. 
Proton NMR of complexes 11-19 are characterised by the presence of the two perfectly 
distinguishable methoxy singlets 8’a and 10’a appearing with excellent reliability in the range 
of 3.86-3.88 ppm (8’a) and 3.47-3.56 ppm (10’a). The chemical shift difference is a 
consequence of the metalation process which is shielding the 10’a signal significantly but is 
almost not influencing the 8’a signal. Proton NMR spectra of the free ligands show the 8’a 
and 10’a peaks appearing very close to each other between 3.81 and 3.83 ppm. The carbon 
signals are also distinguishable but they are separated by less than one ppm (54.5-55.1 range) 
and the shift differences from the free ligands are also below 1 ppm. 
The 
1
H signals are assigned easily by COSY NMR as both 8’a and 10’a signals couple with 
the 3’a proton and while only the 10’a proton couples with the 5’a proton as well (even if 
these protons are far apart, a signal is often observed in COSY and always in NOESY). 
NOESY experiments also bring additional information, as a coupling between the protons 8’a 
and 3a is often observed (Figure 2.12). 
The methyl singlet of complexes 12, 16 and 17, and the additional methoxy singlet of 
complexes 13, 18 and 19 appear respectively between 2.52 and 2.56 ppm and between 2.96-
3.98 ppm. The methyl singlet 7a is easily spotted, as it is the only signal in the 2.5 ppm area. 
Its 
13





The singlet signal from proton 8a appears just downfield from 8’a and 10’a at 3.96-3.98 ppm 
and is also easily assigned by its COSY and NOESY couplings with the pyridine protons 3a, 
5a and sometimes 6a. 
 
Figure 2.12: Zoomed NOESY spectrum of [Ir(dMeOMeOppy)2(acac)] (13) in CDCl3, the solvent peak 
is assigned to residual CHCl3. 
On 
13
C spectra, non protonated carbons 4a appear around 148 ppm when the pyridine is 
methylated (12, 16 and 17) and around 166 ppm for the 4-methoxypyridine (13, 18, 19). A 
HMBC experiment performed on 19 allowed to identify the 2’a and 4’a 
13
C signals at 159.20-
159.47 ppm and 160.21-160.81 ppm due to their respective couplings with protons 8’a and 
10’a. This experiment did not bring more information to assign the signals from the 1’and 6’ 
positions, still missing from the 1
st





2.5 Third series: complexes with phenyl imidazole ligands 
2.5.1 Choice of the ligands 
The 1
st
 series focussed on the synthesis of tris-heteroleptic complexes using ligands differing 
by their degree of fluorination, by the nature of their heterocycle, or both. It showed that by 
playing with the ligands properties, it is possible to create similar complexes with similar Rf 
and structural properties but that differ in their purification difficulty. The first series also 
mixed ligands with drastically different LUMO energies with the stable pyridine and the most 
destabilised pyrazole. 
The second series proposed a way of improving the purification challenge by increasing the 
Rf difference of the bis-heteroleptic complexes present in the mixture. The 2’,4’-
dimethoxylated ppy ligands allow to do so, while keeping a HOMO-LUMO gap similar to 
those obtained with difluorinated ligands. Furthermore, the LUMO energy of the ligands was 
increased stepwise, adding more subtlety in the energy levels of the tris-heteroleptic products. 
The third series studies a phenyl imidazole (pim) ligand, known for providing both broad 
emitting as well as fragile complexes.
115
 These ligands have also been understudied in the past 
as only a few examples of complexes bearing 2-phenylimidazole ligands exist.
55
 The most 




Pim has a LUMO energy that lies midway between ppy and ppz. The goal is to mix a pim 
with both dFppy and dFppz to compare what happens when mixed with ligands of higher and 
lower LUMO energies. The low stability of the pim ligand has been attributed to ligand 
degradation by reaction with molecular oxygen, leading to a ring opening oxidation process of 





the original 1-methyl is replaced by a much more bulky 1-mesityl group, which sterically 
restrain the access of the imidazole ring to molecular oxygen. 
Mespim is also mixed with a special ligand 1-phenyl-4-(trifluoromethyl)pyrazole (CF3ppz) 
where the electron withdrawing trifluoromethyl group should stabilise the LUMO of the ppz 
ligand. 
 
Figure 2.13: Complexes of the third series: [Ir(mespim)2(acac)] (20), [Ir(mespim)(dFppy)(acac)] (21), 






2.5.2 Synthesis & purification 
This series started with the synthesis of the bis-heteroleptic complex 20. Conditions A were 
used and the complex was obtained in good yield (75%, Table 2.4) after reaction with acac 
and a simple precipitation in MeOH/water. This complex appears very sensitive to silica and 
attempts at improving the purity by chromatography column or preparative TLC led to a 
certain amount of degradation by dimer formation, even when the silica was treated with 
triethylamine (this degradation can be seen on the TLC analysis as the complex leaves a spot 
on the base line and a tail on the migration path). Nevertheless, standard chromatography 
techniques can be used to remove impurities such as side products of the reaction or a 
hypothetical excess of ligand but it will always result in the formation of a small amount of 
dimer. 
An alternative way of purifying this complex is to use recrystallisation. Complexes 1 to 19 
were all recrystallysed easily by slow diffusion of the complex (dissolved in DCM) in hexane. 
Unfortunately, the solubility of 20 in most organic solvents (including hexane and diethyl 
ether) is increased. Recrystallisation by diffusion does not work but slow evaporation of the 
solvent produces a good amount of crystal. A very pure product (Figure 9.69) was obtained 
with this method, even if they the crystals were most of the time not fitted for X-ray 
crystallography. 
Products 21, 22, 23 and 24 were all synthesised from conditions A. The bis-heteroleptic 
complex 23 is obtained easily in good yield with no purification other than a simple 






Table 2.4: Isolated yields (%) of complexes 20-24 when synthesised with conditions A. 
 
Purification of 21 is fairly straightforward as only two Chromatography columns are required 
to obtain the product with a good purity. The low yield obtained for this complex is explained 
by the increased solubility of the dimer and acac complex in methanol, leading to a loss of 
product during filtrations. Alternatively, using conditions B could also improve the reaction 
yield. But as enough material was synthesised to perform all the experiments needed, 
alternative conditions were not tested. 
Purifications of 22 and 24 are more difficult and respectively 5 and 7 columns are required to 
separate the entire product and a few more preparative TLC plates are necessary to obtain 
them perfectly clean. 











Figure 2.14: Schematic view of measured TLC separation for the crudes of complexes 20 to 24, with 
pure DCM as eluent and without triethylamine. 
Preparative TLC purification for both 22 and 24 revealed an impurity migrating slightly 
below the product that can be isolated. 
Mass spectrometry analyses revealed three peaks for both impurities corresponding to the 
complex without acac ([M – acac]
+
), and to the complex with the acac replaced by one or two 
acetonitrile molecule ([M – acac + MeCN]
+
 and [M – acac + 2MeCN]
+
. Even if no 
acetonitrile is used during the entire synthesis and purification process, it is not unusual to 
observe such peaks consequently to a formation in the mass spectrometer. The most probable 
hypothesis, confirmed by mass spectrometry, is that the impurities are complexes where the 





NMR analyses of the impurity from 22 (Figure 2.15) show a duplication of all signals as well 
as an important downfield shift of signals from the protons pointing towards the ancillary 
ligand (4a and 3b). The downfield shift tends to indicate the presence of a chloro-bridged 
dimer but the splitting of the peaks indicates the presence of two species. As the integration of 





H-NMR spectra of 22 compared to the isolated impurity (measured in CDCl3). 
This result is coherent with a dimer mixture where two different enantiomer couples can 
coexist (arrangements of Δ/Δ and Λ/Λ configurations. It is believed that Λ/Δ configurations 
are sterically disfavoured as the ligands of the two Ir centres are pointing toward each other) 





Interestingly, the spectrum for the impurity from 24 does not show these two sets so clearly. 
An hypothesis is that the increased steric hindrance introduced by the CF3 substituent is 










2.5.3 NMR analyses 
The NMR spectra of this series show new features introduced by the bigger mespim ligand. 
Four new non protonated carbons correspond to the mesityl positions 1’’, 2’’, 4’’ and 6’’ as 
well as the Imidazole-2 carbon. The 
1
H spectra exhibit some interesting effects due to the 
particular spacial configuration of the complexes. 
One effect is the 
1
H magnetic anisotropy of 7’’a and 9’’ due to the mesityl group being almost 
perpendicular to the mespim core axis. As a result, one of the methyl group (defined here as 
7’’a) points towards the phenyl ring of the second cyclometalated ligand while the other 
methyl group (defined as 9’’a) points towards the acac ligand. 
 





Both proton signals show a NOESY coupling with the 3’’a and 5’’a, as well as with the 5a 
and 2’a signals but only the 7’’a protons displayed a NOESY coupling with the 5’ proton of 
the other ligand. This effect, shown for complex 21 on Figure 2.17, was observed for all 
complexes involving a mespim ligand (20, 22, 24). Another manifestation of such anisotropy 
is the increased chemical shift difference between the 3’’a and 5’’a signals appearing when 
the second mespim is replaced by another ligand (Figure 2.18). This signal is mixed and 
appears as a singlet for 20. It splits into two partly separated singlets (chemical shift 
difference of 0.04 ppm) for 22 with the replacement of one mespim by a dFppz ligand. The 
shift difference is slightly increased with 21, as dFppy is slightly longer and than dFppz. 
Crystal structure comparisons of 20 and 21 show the whole Imidazole-mesityl structure being 
pushed away from the difluorinated phenyl ring. As a result, the local symmetry is disrupted, 






Figure 2.18: Aromatic region of the 
1
H-NMR spectra of complexes 22 (top), 20 (middle) and 4 
(bottom) measured in CDCl3. 
Another interesting magnetic effect is the shielding of the 2’a proton of 20. On a standard 
non-fluorinated ligand such as ppz in 4, the 2’a proton appears around 7.15 ppm. The same 
proton in 20 appears to be shielded by approximately 1 ppm and is observed around 6.15 
ppm. This effect is a consequence of the spatial arrangement of the mespim ligand that results 
in the 2’a proton pointing towards the centre of the mesityl ring, undergoing the strong 
shielding effect of the local magnetic field. This effect decreases as protons get further away 
from the mesityl ring. The 3’a proton is then shifted by 0.35-0.4 ppm and 4’a only by around 
0.1 ppm. The opposite effect is observed for the 5’a proton for which a downfield shift of 
around 0.3 ppm is observed compared to the same proton on 4. This effect can be interpreted 





ring. The local magnetic field generated by the mesityl ring is therefore deshielding the 5’a 
proton signal. This effect disappears when the second mespim is replaced by another ligand, 
such as dFppz for 22, in which case the 5’a signal appears at the much more standard shift of 
6.1 ppm. When the second mespim ligand is replaced (21, 22 and 24), this deshielding 
influence of the mesityl group is reported on the 5’b protons (of dFppy, dFppz or CF3ppz) 
which are shifted downfield by nearly 0.4 ppm (compared to the shift observed for the 
corresponding bis-heteroleptic complexes 2, 5 and 23). 
The remaining positions are assigned by using the techniques described earlier. The non 
protonated carbon signal 2a from the imidazole is observed at 157-158 ppm and is confirmed 
by HMBC coupling with the 
1
H signals from 4a, 5a and 2’a. The non protonated carbons of 
the mesityl ring are also assigned through HMBC couplings. For the 1’’a carbon, a strong 
coupling is observed with the 7’’a and 9’’a methyl protons and a weaker coupling occurs with 
the 3’’a/5’’a protons. The 2’’a and 6’’a carbons distinctively couple with their corresponding 
methyl protons only (7’’a or 9’’a), and the 4’’a carbon has the only signal coupling with the 
8’’a methyl protons. Unfortunately, the 1’ and 6’ carbon signals can still not be assigned for 
sure. 
Other noticeable patterns are the carbon-4 and carbon-6 of the CF3ppz that display two very 
distinguishable quartets with JC-F coupling constants of respectively 39.8 and 266.7 Hz 






2.5.4 Failed attempts and syntheses 
During the synthesis of the 3
rd
 series, other phenyl imidazole ligands than mespim have been 
tested to synthesise tris-heteroleptic complexes either in combination with a ppz-type ligand 
or with a second pim ligand. These pim ligands are 4-methyl-1,2,5-triphenylimidazole and 
1,4-dimethyl-2,5-diphenylimidazole. Both were selected for the presence of bulky phenyl 




Complex F1 (failed 1, Figure 2.19) was synthesised by using conditions A, and the dimer 
mixture was reacted with acacNa by following the standard procedures. The crude mixture 
had to be filtered on silica gel but the 
1
H-NMR spectrum obtained was promising as (Figure 
2.20). 
 
Figure 2.19: Failed complexes F1, F2 and F3. 
If it shows that the main product is the bis-heteroleptic complex 5, the presence of a small 
amount of F1 is also highlighted. This is shown by the small signals at 7.5 and 8.3 ppm, 
appearing just next to the 3a and 5a signals from 5. As the product is purified by preparative 





remain. After 5 purifications, the product is almost pure but traces of 5 are still present. 
Furthermore, the product is degrading under normal atmospheric conditions (protected from 
light) and on silica and a brown baseline is observed on the baseline of every preparative TLC 
plate. Consequently, only a few milligrams were isolated after five purification rounds and the 




H-NMR spectra in CDCl3 of F1 at various purification stages, compared to the 
spectrum of pure [Ir(dFppz)2(acac)] (5). 
Among the investigations of the imidazole series, a CF3dFppz ligand was synthesised. The 
goal of such a ligand is to provide more stabilized LUMO on the pyrazole ring and while 





Using this ligand and mespim, the synthesis of complex F2 was attempted with conditions A. 
The reaction mixture looked bad and only a black precipitate was obtained which did not lead 
to any product when reacted with acacNa. After careful repetition of the reaction with 
conditions A and repeated failure, the iridium source was changed and conditions B were 
used. 
After reaction with the ligands, the precipitate obtained was better looking with a yellow 
colour. Unfortunately, attempted reactions with acac only led to a black precipitate without 
any traces of product. The synthesis of F3 with conditions A was attempted to simplify the 
reaction and test the reactivity of the CF3dFppz ligand. 
The result showed no dimer formation as a black precipitate was obtained. When reacted with 
acacNa, no product was obtained. From these results, it is supposed that the reactivity loss is 
due to the complementary effect of the trifluoromethyl and fluorine substituents as both 
CF3ppz and dFppz show good reactivity (at least with conditions A). Therefore, it can be 
assumed that the addition of too much electron-withdrawing character is killing reducing the 
reactivity of the ligand, no matter what conditions are used. As both oxidative addition 
(conditions B) and electrophilic substitution (conditions A) processes rely on heterocycle 
coordination via donation of the nitrogen lone pair to the metal prior to the metalation 
process. It is reasonable to assume that the increased electron-withdrawing influence is 
causing a basicity decrease of the nitrogen lone pair, making it unreactive (or not reactive 






2.6 Fourth series: pic complexes 
On the side of the first series, tests were made to study the effect of different ancillary ligands 
in replacement of acac. Screening experiments were designed (see below) but they do not 
allow studying the properties of each complex individually. Furthermore, the introduction of 
asymmetrical ancillary ligands in the context of tris-heteroleptic complexes poses new 
purification challenges as well introducing interesting synthetic possibilities. 
The attention has been especially focused on picolinate (pic) ancillary ligand as it produces 
complexes that are less sensitive to acidic degradation than acac, while being simple and 
commercially available. Furthermore, [Ir(dFppy)2(pic)] (FIrpic) is a well known sky-blue 
emitter that offers a valuable and well documented comparison point. 
For the need of the study the acac ligands of complexes 3 and 9 were removed with BF3 in 
acetonitrile to obtain the bis-acetonitrile complexes 3MeCN and 9MeCN (Figure 1.24). As 
these complexes carry an overall positive charge, they were stirred in an aqueous KPF6 
solution in order to obtain a [complex][PF6] salt that offers an increased solubility in organic 
solvents. 
The picolinate ligand was added by refluxing the bis-MeCN complexes and picolinic acid in 
DCM overnight in the presence of Tetrabutylammonium hydroxide (TBAOH). The reaction 
achieves very good yield and the products are obtained after a simple precipitation in 
MeOH/water. The products are obtained as a mixture of the two pseudo-mer isomers differing 
by the orientation of their pic ligand. Each of these isomers is divided into two enantiomers Λ 
or Δ (Figure 2.21). By convention, the isomers where the pyridine of the fluorinated ligand 
(here dFppy) is pointing towards the pyridine ring of the pic complex are called “a” and the 





“b”. The eight complexes synthesised here are then Λ-3a, Δ-3a, Λ-3b, Δ-3b and Λ-9a, Δ-9a, 
Λ-9b, Δ-9b. 
 
Figure 2.21: The two pairs of enantiomers generated by the synthesis of tris-heteroleptic pic 
complexes. In isomer-a, the C1^N1 ligand points towards the nitrogen of the N^O ligand. In the isomer-
b, the C2^N2 ligand points towards the Nitrogen of the N^O ligand. 
Since the Λ/Δ enantiomers are not separated, and do not present any distinction of interest 
here, their presence is omitted for clarity and the pic complexes are usually presented under 
their Λ form only (Figure 2.22). 
 





The challenge of the synthesis resides in the separation of isomers a and b, as they are 
expected to display very similar solubility and polarity, making them difficult to separate by 
standard chromatography techniques. The separation of the isomers on silica is likely to 
depend on how different the two cyclometalated ligands are, as polarity change induced by 
the orientation of the pic ligand will be more significant. This hypothesis is confirmed in the 
present situation with the isomers 9a and 9b being easier to separate than 3a and 3b, due to 
the replacement of the second pyridine by a pyrazole. The isomers 9a and 9b could be 
separated by preparative TLC plates, using multiple elutions and an eluent with reduced 
polarity. Even if multiple plates are necessary to obtain pure products, it is achievable 
whereas 3a and 3b remained completely mixed. 
Preparative HPLC on reversed phase silica was used to separate the reaction mixtures. The 
method was developed for the 3a/3b mixture directly on the preparative column, as attempts 
to transpose analytical HPLC methods to preparative HPLC failed. The first parameters 
investigated were the solvent polarity by using MeCN/water mixtures (60/40, 50/50, 45/55, 
40/60, Figure 2.23). The samples were run by injecting 2 mL of a 10 mg/mL solution in 
MeCN. The polarity of the eluent was successively increased up to 60%. Tests with eluents 
containing more water were not performed by fear of the complex precipitating in the column. 
Furthermore, the 40/60 mixture does not provide a satisfactory separation as does none of the 






Figure 2.23: Preparative HPLC chromatograms of 3a/3b mixtures eluted with different mixtures of 
MeCN/water. All samples were run with 2mL injections of a 10mg/mL solution. 
Proton NMR analyses performed on fractions harvested around the four visible bumps of the 
broad peak from the 40/60 chromatogram reveal that the first and last bumps are composed of 
pure 3a and 3b. The two middle bumps (that contain the majority of the product) contain 
mixtures of both. Therefore, using this method to separate the isomers would be very time 
consuming and not very reliable, as a small variation in the harvesting method can lead to a 
bad separation. 
Of all the organic solvents available and compatible with the preparative HPLC machine, 
acetonitrile is the only one providing sufficient complex solubility (especially as no 
temperature control was available with this machine). It is also the most polar one, but it is not 
polar enough to separate the complexes. Therefore, only MeCN/water mixtures are likely to 
provide the polarity needed to achieve an acceptable degree of separation. The problem is that 
complexes are not soluble in water. Therefore, increasing its percentage too much can induce 






Drastically reducing the complex concentration of the injected sample from 10 mg/mL to 1 
mg/mL does not change the profile at all, but it was thought that maybe it could allow 
increasing the water proportion by delaying the precipitation process. Unfortunately, the 
amount of complex injected was too small and the profile too broad for the separation to be 
very efficient. The last parameter to change was the injected volume which was decreased 
from 2 mL to 1 and 0.5 mL (Figure 2.24) 
 
Figure 2.24: Preparative HPLC chromatograms of 3a/3b mixtures eluted with MeCN/water 40/60. All 
samples were injected with a 10mg/mL solution. The injected volume was changes from 2 mL to 1 mL 
and 0.5 mL. 
When injecting only 0.5 mL at a time, the chromatogram profile appears as two distinct peaks 
and even if the separation is still not perfect, it is good enough to obtain purified (or at least 
enriched) isomers and this method can also be used with multiple injections. The products 
obtained are not pure and a second round of HPLC is necessary to get the well separated 
isomers. Nevertheless, despites the time consuming aspect of the method, it allows to obtain 
pure isomers with no degradation. After HPLC, the acetonitrile is evaporated and the products 





A similar method was used to separate 9a and 9b, keeping the same injection concentration 
and volume but with a less polar eluent (MeCN/water 50/50). The decreased retention time, 
the narrower peaks and the better separation obtained for these complexes allow separating 
the isomers in only one round of HPLC purification in a relatively short time using multiple 
injections (Figure 2.25). 
 
Figure 2.25: Preparative HPLC chromatograms of 9a/9b mixtures eluted with MeCN/water 50/50. All 
samples were injected with a 10mg/mL solution and 0.5 mL at a time. 
2.6.1 Applicability of preparative HPLC techniques for the separation of acac 
complexes. 
Before discussing the NMR characteristic of pic complexes, it is useful to take a moment to 
discuss the HPLC methodology in the context of separating tris-heteroleptic acac complexes. 
As explained above, one of the main challenges when synthesising tris-heteroleptic 
complexes is the separation of the target product from the two corresponding bis-heteroleptic 
complexes present as by-products of the reaction. Until now, only standard, normal pressure 
chromatography techniques such as silica gel columns or preparative TLC have been 
considered. These techniques have been shown to be successful at separating all the 





expensive in term of both solvent and silica usage. Preparative HPLC appears as a legitimate 
alternative as it provides a better separation, allows savings of solvent and silica and should 
not degrade the acac products, as the silica column used is packed with non acidic C18-
functionalised silica. In the past, H pressure chromatography techniques with chiral phases 
have been especially useful to separate Δ and Λ isomers.
134–137
 
Tests were realised on a crude mixture of complex 7 which is the most challenging complex 
to purify from the first series. It quickly appeared that a good separation is possible within one 
round of purification, by using a 65/45 MeCN/water mixture, a 10 mg/mL solution and a 0.5 
mL injection volume. 
Unfortunately, 
1
H-NMR analyses reveal the presence of a small amount of dimers in all the 
fractions (Figure 2.26), indicating that the complexes are being degraded. As the C18 silica is 
not supposed to be acidic, a potential explanation can be that remaining traces of 
trifluoroacetic acid (TFA, used during peptide purification and known to be particularly 








H-NMR spectra in CDCl3 of 4, 7 and 1 in their elution order, purified by preparative 
HPLC. 
Attempts to remove these remaining TFA traces (by washing the system with solvents) did 
not improve the purity of the separated products. 
Nevertheless, the results are satisfactory and the HPLC separation of complex 7 is all in all 
faster and more efficient than using only standard chromatography columns and plates. The 
small amount of dimers generated can be removed quite easily with a short filtration on 
standard silica gel. 
But the main concern that forbids the extensive use of HPLC during this work is the long term 
contamination of the column with dimer traces. As dimers are known for their low solubility 
in most solvents, the risk of contaminating the column with precipitated dimer is high. These 





the column. Because of the high cost of a preparative column, the risk was judged too high for 
the HPLC purifications to be continued. 
A valid alternative to preparative HPLC would be to use automated chromatography systems 
with pre packed disposable columns. Quick tests on such a system performed on a crude 
mixture of 7 showed that one round of purification was enough to completely separate the bis-
heteroleptic complexes from each other, leaving two fractions containing respectively 1/7, and 
4/7. This result suggests a much better separation than with a first standard column, obtained 
within a significantly reduced time with a significantly reduced volume of eluent. With this 
technique, it can be anticipated that a tris-heteroleptic complex such as 7 could be purified in 
one day instead of one week without the risk of contaminating precious shared equipments 






2.6.2 NMR analyses 
Depending on the orientation of the pic ligand around the iridium centre, the local magnetic 
field experienced by protons can be significantly changed, leading to drastic NMR signal 
shifts from one isomer to the other. 
The most significant shift is experienced by protons pointing towards the pic ligands (protons 
6 of ppy/dFppy and 3 of ppz) as they find themselves trapped in the pyridine magnetic 
influence (Figure 2.27). These effects are believed to be mostly caused by spatial positioning 
around the pyridine ligand and not to the chemical bond rearrangement inherent to isomeric 
structural changes. 
 
Figure 2.27: ORTEP representations of 9a (top) and 9b (bottom). The left side shows the ligands 
pointing towards the pyridine ring of the pic ancillary ligand. The right side shows the ligands 





The changes are very similar between complexes 3a/3b and 9a/9b so the latter couple is 
mostly used as an example during the present discussion, as the increased ligand difference 
facilitates the exemplification. 
Considering first complex 9a, the signal submitted to the most significant changes belongs to 
proton 6a which is pointing directly towards the pyridine ring of the pic ligand. As it finds 
itself positioned above the pyridine shielding cone, its signal is shifted upfield by around 1 
ppm compared to the standard signal from the acac complex 9. The neighbouring proton 5a 
also experiences a significant (but smaller) influence with an upfield shift of around 0.2 ppm. 
The effect vanishes for protons 4a and 3a with shifts to the acac standard of respectively -0.04 









The same effect is observed on the other ligand for 9b where the pyrazole proton 3b is shifted 
upfield by 0.85 ppm and 4b by 0.15 ppm. 
The pic pyridine ring also exerts a deshielding influence on the phenyl protons of the second 
ligand as they are located in the prolongation of its plane. The effect is smaller than the 
previously described upfield shift but it is significant. Therefore, the ppz phenyl proton 
signals 2’b, 3’b, 4’b and 5’b in 9a are shifted downfield by respectively 0.08, 0.13, 0.12 and 
0.18 ppm compared to 9. The influence on protons 3’a and 5’a of 9b is of the same magnitude 
with 0.14 and 0.15 ppm shifts compared to 9.  
The last significant chemical shift difference with acac complexes is found for the protons 
pointing towards the carboxylate part of the pic ligand that undergo a downfield shift 
produced by a decreased shielding effect of the carboxylate group in comparison with acac. 
The 3b signal of 9a and the 6a signal of 9b are therefore shifted downfield by respectively 
0.17 and 0.33 ppm compared to 9. This latter increase in the chemical shift difference is 
coherent with the fact that pyridine is longer than pyrazole which brings its protons closer to 
the influential area. A difference is also observed when ppz is replaced with ppy, as proton 6b 
of 3a is shifted by 0.22 ppm, while proton 6a of 3b is shifted by 0.36 ppm compared to 3 
(Figure 9.83). This effect is the manifestation of the molecule spatial geometry as X-ray 
crystallography measurements show that the dFppy proton 6 is further apart from the pic 
oxygen than the ppy proton 6 (by 0.055 Å). 
One last observation to make regarding these chemical shift differences between spectra is 
that the signal from the pic pyridine protons 3c, 4c, 5c and 6c only undergo chemical shift 
differences of less than 0.10 ppm both between isomers a and b but also when comparing 





The understanding of these chemical shift differences between isomers is very useful for the 
assignments of 
1
H-NMR signals of these series. This is especially true when considering 
complexes such as 3a and 3b where many pyridine and phenyl signals can be mixed, making 
the COSY, NOESY, HSQC and HMBC spectra difficult to untangle. Nevertheless, certain 
specificities of the 2D spectra obtained are worth noting. The NOESY coupling between the 
phenyl-5’ and the pyrazole-3 or pyridine-6 protons of the opposite ligand is always observed 
and is quite strong compared to most of the acac complexes (Figure 2.29, rectangles). Another 
NOESY specificity of the pic complexes is the coupling obtained between the pic 6c position 
and the protons from the heteroaromatic ring pointing towards it and from the phenyl-5’ of the 
other ligand (Figure 2.29, circles). 
 





The local magnetic field effects are not as important on 
13
C-NMR spectra and only small 
variations (around 1 ppm) are observed between isomers a and b, and with acac complexes 
(Figure 2.30). Signals from protonated carbons are easily assigned through HSQC analyses 
and only two new non protonated signals are introduced, corresponding to the pic carbons 2c 
and 7c. The 2c position appears very close to the dFppy 1’a/6’a signal. It is characterised by a 
HMBC coupling with protons 4c and 6c. The 7c signal appears around 165 ppm and is only 










2.7 Luminescence profile search; applicability of the screening approach 
In the search of interesting iridium complexes for electroluminescent applications, it is 
desirable to look for ways of speeding up the research process. With a two step synthesis 
involving chloro bridged dimer formation and ancillary ligand insertion, heteroleptic iridium 
complexes are good candidates for the design of a screening approach
58
. As most ancillary 
ligands can be inserted at room temperature, designing small scale test reaction for qualitative 
evaluation of the emission profiles is easy. This allows testing the effect on the emission 
spectrum of new ancillary ligand (to search for unexpected results) or to quickly study the 
effect of different substituents type or position in one family of ligand. This approach allows 
reacting small amount of iridium materials with small amounts of ligands and do not 
necessitate tedious purifications. 
In the present context of tris-heteroleptic synthesis, the ideal goal is designing, synthesising 
and purifying acac complexes with interesting [Ir(C1^N1)(C2^N2)] cores. The pure acac 
complex can be turned in a pure dimer or in a bis-MeCN complex (Figure 1.24) to be used as 
a screening precursor. 
The limitation of this approach lies in the use of standard emission profile measurement 
methods that require recording each emission spectrum individually on machines often 
designed for high precision measurements. This is fundamentally opposed to a screening 
approach which requires a fast, bulk, low quality measurements. 
As an alternative to the standard measurement method, one can use a microplate reader with 
an integrated spectrofluorimeter. With a 96-hole plates and automated measuring of emission 
spectra, it is possible to tremendously decrease the sample preparation and the emission 





In the present work, we designed a quick screening experiment using such a microplate reader 
as a preliminary study. Due to the short availability of the machine (only available for test 
purposes), the results obtained are not optimised. 
2.7.1 Experiment design and procedure 
Stock solutions of precursors of complexes 1 to 10 (chloro-bridged dimers or bis-heteroleptics 
and bis-MeCN complexes), stock solutions of ligands and stock solution of TBAOH were 
created. In the present case, experiments were designed so that each plate would host one 
precursor, reacted with the whole ligand library for a total of 92 reactions. Some ligands were 
tested with and without TBAOH and the plate also contained a blank well filled with only 
DCM, a well filled with only the precursor solution, a well without ligand (with the precursor 
and TBAOH) and an empty well. 
The problem here was that the test plates used were made of a plastic that was not very 
resistant to solvent. The covers were made of the same plastic so it was not possible to 
measure any spectrum while using a cover as they would turn opaque. Furthermore, the 
machine itself was not guaranteed to be resistant to excessive solvent vapours so using a plate 
filled with solvent without a cover was out of the question. Hopefully, the machine detctor is 
located above the plate so the solvent was left to evaporate and the spectra were measured on 
the solidified complexes while the plate was uncovered.  
Of course these measurements could be made in solution, if adequate quartz plates and cover 
are available. But for this test experiment, it was not worth investing on such expensive 








Ten plates were then prepared with the precursor solutions, left to dry, and spectra were 
measured using the microplate reader. The generated spectra were of various qualities, from 
only noise to profiles approaching those of pure complexes. A spectra comparison between 
the screening conditions and the standard method for acac complexes 1 and 2 (Figure 2.31) 
reveal changes in the emission profile. The emission maxima are slightly blue shifted and the 
intensities of the lower energy regions of the spectra are reduced, leading to narrower 
emission profiles. 
 
Figure 2.31: Emission spectra of 1 and 2 measured pure in DCM under argon atmosphere and under 
screening conditions. 
This change is likely to be due to the interaction with the plastic of the plate which changes 
the complex environment. These changes are big enough to prevent the detection of 
potentially broad emitter. If a significant part of the emission profile is quenched for acac 





























emitting complexes. This effect, added to oxygen quenching that lowers the detection of less 
efficient complexes seriously reduces the chances of detecting broad emitting complexes with 
the present experimental setup. 
Potentially interesting profile displaying blue emission profiles were also detected and a few 
reproducibility tests were performed with limited success. 
As it is, the method shows two kinds of drawbacks that limit the production of good results. 
The major problem is the use of plastic plates instead of quartz plates with covers. This led to 
modified spectra and might potentially forbid the detection of interestingly broad profiles. 
The second major problem is the lack of atmospheric control. As phosphorescent emitters are 
efficiently quenched by oxygen, measuring spectra under inert atmosphere would 
tremendously increase the detection limit of the method and some profiles appearing as very 
weak or as noise could become interesting. Furthermore, free ligand fluorescent emission 
would also become weaker in comparison with the complex phosphorescence. The profile 
measured would be closer to the one of the pure complex. 
The great advantage of this method is to allow measuring more than 900 emission profiles in 
one week, the time consuming parts of the process being samples preparation and plate filling 
as it involves an important amount of pipetting. It is believed that if the problems inherent to 
this particular test are corrected, the use of a microplate reader would greatly improve the 







This chapter focused on the synthesis and purification of tris-heteroleptic complexes, using 
various combinations of ligand cores or substitutions. It examined different reaction condition 
sets, varying solvents and iridium starting materials. These syntheses revealed the influence of 
the iridium starting materials on the reactivity of some ligands and highlighted the possibility 
to improve the purification process of a complex by changing the location of the fluorine 
substituents. 
This chapter also paid extensive attention to the examination of NMR spectra to characterise 
the products. The variety of methods available, their excellent precision and the rapid results 
they provide makes NMR the perfect tool for the characterisation of tris-heterolpetic iridium 
complexes. Simple 
1
H spectra analyses already provide important structural information (like 
the orientation of a pic ligand) and 2D techniques such as NOESY allows differentiating 
signals separated by less than 0.05 ppm. 
Finally, the successful separation of pic complexes isomers and the screening experiments 
opened new synthetic possibilities and investigation methods for the developments of 






3 PHOTOPHYSICAL PROPERTIES AND REDOX 
POTENTIALS 
3.1 Introduction 
The present chapter aims at presenting the photophysical results measured from the 
complexes presented in chapter 2. The discussion follows the same order and the series of 
complexes are discussed separately in their general order of synthesis except for the pic 
complexes that are joined to the first series. If they represented a special synthetic challenge 
and deserved a sub-chapter of their own in chapter 2, it makes more sense to discuss their 
photophysical properties alongside complexes from the first series. 
More detailed procedure explanations and aims are provided as examples for the first 







3.2 First series: ppy/ppz based complexes, and pic complexes 
3.2.1 Cyclic voltammetry 
Cyclic volammetry is used in the present context to measure oxidation and reduction 
potentials of the iridium complexes. The cyclic voltammograms are measured in a 0.1 M 
TBAPF6 solution (in MeCN or DMF). The solvent is deaerated by bubbling argon directly 
from a cylinder until no more oxygen reduction peak is observed. The solvent choice is 
motivated by the complex solubility and by the availability of high purity solvents.  
Platinum electrodes are used as working, counter and reference electrodes. This choice is 
dictated by the availability of these electrodes at the time of measurement. Such a system is 
not ideal due to the increased sensitivity of platinum in comparison with glassy carbon 
electrodes but it does not represent an important issue here. The measurement is performed 
without and with ferrocene. The values are all measured vs ferrocenium/ferrocene (Fc
+
/Fc). 
On the voltammograms presented here, the reference peak is not shown and the data have 
been corrected accordingly, by placing the ferrocenium/ferrocene oxidation potential at zero 
(Figure 3.1). 
Generally speaking, the oxidation potential is interesting in the present context as it gives 
access to an easy evaluation of the HOMO energy. When the experiment is performed, the 
potential at the electrode is increased until electrons from the complexes in solution are 
transferred to the electrode, creating an current peak (anodic). When the voltage is decreased 
again, the oxidised complex is reduced back as electrons are transferred from the electrode, 
and a second current peak appears (cathodic). This corresponds to the transfer of one electron 
from the electrode to the complex and from the complex to the electrode (usually assigned to 





the HOMO. The oxidation potential (measured as the average of the potentials obtained at the 
anodic and cathodic peaks maxima) can then be related to the HOMO energy. 
 
Figure 3.1: Cyclic voltammograms of 1 to 10 (top to bottom), measured in MeCN (0.1 M TBAPF6) vs 
Fc
+
/Fc at 1 V/s scan rate. 
In the case of 1, 2 and 3, a higher potential is required for the oxidation of 2 to happen than 
for 1, consequently to the HOMO stabilisation induced by the presence of fluorine 
substituents. In comparison with 1 and 2, the oxidation potential of 3 appears as the average 
of the two others, as its HOMO is of intermediate energy. 
The HOMO energy can be estimated, as the Fc
+
/Fc oxidation potential lies 4.8 eV below the 
vacuum level.
138





Even though this approach has limitations,
139
 it provides an easy estimation method to 
compare complexes within a series and, to a certain extent, with complexes from other 
studies. 
 
Figure 3.2: Cyclic voltammograms of 3a, 3b, 9a and 9b (top to bottom), measured in MeCN (0.1 M 
TBAPF6) vs Fc
+
/Fc at 1 V/s scan rate. 
By the same logic, the reduction potential can be related to the LUMO energy and trends can 
be observed as complexes known for their higher LUMO energies also display lower 
reduction potentials. Ppz complexes which are known for their high LUMO energy exhibit 
low reduction potentials.
140
 In the present work, the reduction potential of complexes 4, 5 and 
6, were not measurable, as they lied outside of the observable window for the conditions used. 
If the ligands of a tris-heteroleptic complex are different enough, the reduction potential can 





location. However, this assertion is valid only if the ligands exhibit sufficiently distinct 
reduction potentials. 
Table 3.1: Oxidation and reduction potentials for complexes 1 to 10 and 3a, 3b, 9a and 9b.  
Measurements performed with all Pt electrodes in deaerated MeCN (0.1 M TBAPF6) vs Fc
+
/Fc. The 
values displayed between brackets are from literature.
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In the context of the first series, the oxidation potential is strongly influenced by the degree of 
fluorination of the phenyl rings of the ligands but also (to a losser extent) by the nature of 
their heterocycles. For complexes with ligands that vary only by their fluorination degree 
(such as 1, 2 and 3 or 4, 5 and 6), the oxidation potential of the tris-heteroleptic is the average 
value of the oxidation potentials measured for the corresponding bis-heteroleptics (Table 3.1). 
The complexes are separated by very consistent 0.15 V increments related to their number of 
fluorine substituents (0, 2 or 4). The replacement of pyridine by pyrazole when comparing 1, 
2, 3 with 4, 5, 6 reveals a constant 0.06 V increase of the oxidation potential (0.03 per 
pyrazole). This effect is small in comparison to the changes induced by the difluorination of 
the phenyl ring but it appears significant, especially in the light of its consistency. 
 
Eox (V) Ered (V) 
1 0.43 (0.41) -2.57 (-2.60) 
2 0.73 (0.76) -2.45 (-2.44) 
3 0.58 (0.57) -2.51 (-2.52) 
4 0.49 - 
5 0.79 - 
6 0.64 - 
7 0.45 -2.58 
8 0.75 -2.44 
9 0.61 -2.50 
10 0.60 -2.52 
3a 0.73 -2.33 
3b 0.72 -2.34 
9a 0.76 -2.35 





When the ligands are mixed, the oxidation potential remains the average of the two 
corresponding bis-heteroleptic complexes but, for 9 and 10, but it also lies in-between the 
oxidation potentials of 3 and 6, due to the addition of pyrazole rings. The increments 
measured for complexes 1 to 6 are still valid even though small variations occur. 
Importantly, what seems to influence the oxidation potential is the number of fluorinated 
phenyl and pyrazole rings on the ligands and not how they are arranged around the iridium 
centre. This is highlighted by complexes 9 and 10 which have very similar oxidation 
potentials even though their fluorination/pyrazole ring are not on the same ligands. This is 
important, as it describes complexes with similar HOMO energies but with different ligand 
combinations. As explained in chapter 2, these ligand combinations can play a significant role 
in simplifying the purification process of the complexes so it represent an important parameter 
for the design of new tris-heteroleptic complexes. 
Reduction potentials also follow the same trends and seem to be influenced mostly by the 
number of difluorinated phenyl rings. The variance, however, is smaller than for the oxidation 
potentials and adding a fluorinated phenyl only increases the potential by around 0.06 V. 
As the pyrazole reduction is too low to be measured, the reduction potentials of the tris-
heteroleptic complexes 7 to 10 can be attributed to the pyridine ligand, pointing at it as being 
the LUMO location. 
For complexes 3a, 3b, 9a and 9b, both oxidation and reduction currents are observed and 
reversible. The oxidation and reduction potentials being shifted towards more positive values 
by approximately 0.15 V in comparison with the corresponding acac complexes. The 
differences between isomers a and b are very small and measured respectively for oxidation 





3.2.2 UV-visible and luminescence spectroscopy 
The UV-visible (absorption) and luminescence (emission) spectra were measured in DCM. 
The emission solutions have been deaerated by bubbling argon to minimise the emission 
quenching by oxygen. The absorption and emission profiles from complexes 1 to 10 are 
presented below (Figure 3.3, Figure 3.4 and Figure 3.5). Key properties calculated from the 
spectra are also presented (Table 3.2). All spectra presented here are plotted on a wavelength 
scale (nanometres, nm). Wavenumbers are only used in the present work to report the full-
width-at-half-maximum values (FWHM, Table 3.2). 
UV-visible spectra of complexes 1 to 10 are dominated by strong absorption bands with large 






) between 250 and 260 nm attributed 








 The next region between 300 and 440 nm shows 






) of charge transfer character (CT) attributed to 
















The absorption profiles of bis-ppz complexes 4, 5 and 6 were found to be blue shifted 
compared to the ppy containing complexes. As they are not luminescent at room temperature, 
(and in addition to non-measurable reduction potentials) this is in agreement with high energy 
LUMOs. Consequently, the MLCT region of the absorption spectra for mixed ppy-ppz tris-
heteroleptic complexes is dominated by ppy-like transitions with reduced molar extinction 
coefficients (approximately twice as low as for bis-ppy complexes, Figure 3.3, Figure 3.4 and 
Figure 3.5). 
The higher energy part of the spectra (260 to 350 nm) seem to show a more ppz-like character 





especially true for complexes 7 (Figure 3.3), 9 and 10 (Figure 3.5) where the transition around 
300 nm from the corresponding bis-ppz complex is also observed. 
 
Figure 3.3: Absorption (left) and emission (right) spectra of 1 (dashed line), 4 (dotted line) and 7 






Figure 3.4: Absorption (left) and emission (right) spectra of 2 (dashed line), 5 (dotted line) and 8 
(solid line) measured in aerated DCM (abs.) and deaerated DCM (em.) solutions. 
 
Figure 3.5: Absorption (left) and emission (right) spectra of 3 (solid line), 6 (small dotted line), 9 







Figure 3.6: Absorption (left) and emission (right) spectra of 3a (solid line), 3b (dotted line), 9a 
(dashed line) and 9b (small dotted line) measured in aerated DCM (abs.) and deaerated DCM (em.) 
solutions. 
The UV-visible spectra of pic complexes 3a-b and 9a-b follow the general trends of similar 
complexes. The molar absorptivity values of 9a-b are decreased compared to those of 3a-b 
due to the presence of the ppz ligand. Interestingly, the molar absorptivity values of the 
isomers b are also decreased compared to isomers a without easy explanation. This difference 










differences attenuate at higher wavelength and both isomers show similar onset absorptions. 
The UV-visible and emission spectra are used to calculate an approximate HOMO-LUMO 
energy gap as the E0-0 energy.
59,142
 Converted into eV and normalised, the intersection of the 
spectra gives a good approximation of the E0-0 energy (the energy separating the most stable 
excited state from the ground state). Therefore, this value is added to the previously calculated 





observed with the reduction potentials but present the advantage of providing data when the 
reduction potential is not available (e.g. ppz complexes) or difficult to calculate due to a low 
reversibility of the reduction peak. 
The emission profiles of the tris-heteroleptic complexes follow the trend of the oxidation 
potentials and strongly denote ppy based LUMO made of pyridine π
*
 orbitals. The emission 
maxima follow the ones of the corresponding bis-ppy complexes (Table 3.2). Therefore, 
complexes 1 and 7 or 2 and 8 display maxima at respectively 519 and 482/483 nm according 
to the number of fluorinated phenyl they carry. The same observation is made for 9 (503 nm) 
and 10 (502 nm) that both show emission maxima close to the one of 3 (503 nm). 
The presence of the ppz ligand causes a slight broadening of the emission profile with FWHM 
values typically increased by 200 – 300 cm
-1
. All tris-heteroleptic complexes with mixed ppy-
ppz ligands experience this broadening compared to their all-ppy counterparts. Fluorination 
seem to slightly increase this effect, as 8 shows a difference of 30 1 cm
-1
 with 2, while the 
difference between 7 and 1 is only 232 cm
-1
. Even though they both display bigger FWHM 
values than 3, the FWHM value of 9 is larger than the one of 10 by an additional 97 cm
-1
, due 
to the broadening observed in the high energy part of its spectrum. 
The emission spectra of 3a-b and 9a-b show blue shifted emission profiles compared to the 
acac complexes with emission maxima at 498/485 nm (3a/3b) and 499/498 (9a/9b). This is 
coherent with the stabilised HOMO and increased E0-0 energies calculated for these 
complexes compared to their corresponding acac complexes. This is also coherent with 








The emission profile broadness of pic complexes follows the trends observed for their 
corresponding acac complexes with an increase of the FWHM values induced by the 
introduction of the ppz ligand. It seems, however, that the presence of the pic ligand induces a 
further FWHM increase of around 200 and 350 cm
-1
 for 3a-b and 9a-b compared to 3 and 9 
respectively. However, no coherent broadening is observed between isomers and 3a-b show a 
slight 80 cm
-1
 FWHM decrease while 9a-b show a small 69 cm
-1
 increase. 








 the emission spectra were recorded with 
excitation wavelength of 350 nm. E0-0 was calculated as the crossing of the normalised absorption and 
emission spectra expressed on an energy scale, HOMO = - (Eox + 4.8eV), LUMO = HOMO + E0-0. 
 





















260 (39.15), 340 (9.15), 405 (4.02), 459 
(2.88), 489 (1.32) 
519 (520)
c 
2.58 -5.23 -2.65 2487 
2 
253 (45.72), 328 (11.44), 389 (4.72), 435 
(2.23), 466 (0.82) 
482 (484)
c 
2.74 -5.53 -2.79 2525 
3 
256 (42.97), 334 (10.34), 398 (4.29), 449 
(2.44), 479 (0.79) 
503 (503)
c 
2.65 -5.38 -2.73 2526 
4 
252 (34.04), 275 (23.69), 297 (15.15), 330 
(8.57), 377 (2.77), 418 (0.19) 
- - -5.29 - - 
5 253 (31.19), 321 (8.06), 359 (2.23), 400 (0.29) - - -5.59 - - 
6 
251 (33.18), 269 (25.53), 294 (13.89), 325 
(8.61), 370 (2.21), 408 (0.15) 
- - -5.44 - - 
7 
256 (36.36), 295 (17.76), 335 (8.81), 374 
(4.14), 405 (2.35), 456 (1.27), 487 (0.38) 
519 2.61 -5.25 -2.64 2719 
8 
253 (40.40), 289 (18.86), 325 (10.349), 361 
(3.95), 385 (2.52), 430 (0.95), 461 (0.31) 
483 2.78 -5.55 -2.77 2826 
9 
254 (35.00), 291 (16.91), 330 (8.85), 369 
(3.63), 392 (2.21), 437 (1.01), 469 (0.37) 
503 2.72 -5.41 -2.69 2826 
10 
257 (35.63), 295 (17.39), 328 (9.17), 360 
(4.28), 396 (2.36), 430 (1.46), 478 (0.32) 
502 2.67 -5.40 -2.73 2729 
3a 
261 (37.55), 289 (20.99), 323 (10.15), 345 
(5.81), 390 (3.87), 431 (2.33), 462 (0.27) 
489 2.73 -5.53 -2.80 2771 
3b 
259 (32.69), 289 (18.54), 305 (13.67), 322 
(9.37), 345 (5.39), 389 (3.66), 430 (2.14), 470 
(0.23) 
485 2.73 -5.52 -2.79 2691 
9a 
253 (36.20), 283 (20.92), 303 (14.62), 321 
(10.91), 341 (6.86), 383 (3.28), 415 (1.65), 
432 (0.93), 460 (0.24) 
499 2.80 -5.56 -2.76 3139 
9b 
258 (31.18), 281 (16.35), 302 (12.57), 322 
(7.66), 341 (4.18), 384 (2.34), 414 (1.42), 431 
(0.84), 458 (0.19) 





3.2.3 Excited state lifetimes and quantum yields 
The luminescence lifetime measurement was performed in solution using DCM as solvent. 
The solution was deaerated by bubbling argon for 40 minutes to remove a maximum of the 
oxygen. Due to the low boiling point of the solvent used, the concentration was not 
determined precisely. 
The quantum yield (ΦPL) measurements were performed on DCM solutions deaerated by 
freeze-pump-thaw cycles and calculated using quinine sulphate as a reference (in aqueous 
H2SO4 0.5M: ΦPL = 0.546).
143–146
 
From the quantum yield, the radiative (kr) and non radiative (knr) constants are calculated 
assuming unitary intersystem crossing. 
Excited state lifetimes measured for complexes 1 to 3 show similar results than previously 
reported in literature.
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 In comparison with these values, quantum yields for complexes 7 to 
10 are lowered by approximately a factor of two. Therefore, the radiative constants are 
significantly lowered as well. Complexes 7 and 8 show lifetime values in agreement with their 
number of fluorine substituents as they display similar values than 1 and 2 respectively. 
However, the significantly lowered quantum yield of 7 in comparison with 1 is pointing 
towards a less efficient emission, influenced by less efficient radiative (decrease of kr) 
deactivation. 
In the case of 8, the reduced lifetime and quantum yields compared to 2 also lead to a 
decreased radiative constant. More importantly, results show a drastic increase of the non 
radiative constant. Therefore, unlike 2, the low lifetime of 8 is explained by favoured non 











 kr = ΦPL / τ, knr = (1 - ΦPL) / τ. 
Complexes 9 and 10 share similar structural properties, as they both have one pyridine and 
one fluorinated ligand. They also share quasi identical oxidation potential, emission maxima 
and quantum yield. Their emission profiles are similar and so are their absorption profiles. In 
these conditions, one would expect the two complexes to share similar excited state lifetime 
values as well. But 9 has a much lower value than 10 (837 vs 1537 ns). This unexpected result 
highlights the possibility of obtaining complexes with similar overall properties but differing 






























 5.64 2.53 
7 1592 0.26 1.63 4.65 
8 619 0.22 3.55 12.60 
9 837 0.32 3.82 8.12 
10 1575 0.30 1.90 4.44 
3a 1850 0.49 2.65 2.76 
3b 1559 0.43 2.76 3.66 
9a 1004 0.42 4.18 5.78 





3.3 Second series: complexes with methoxylated ligands 
3.3.1 Cyclic voltammetry 
Cyclic voltammograms of complexes 11 to 19 were recorded vs Fc
+
/Fc with all platinum 
electrodes. However, due to the poor solubility of some complexes, the MeCN had to be 
replaced with DMF. This change does not affect the data obtained and the redox potentials 
can still be compared with the data from the 1
st
 series. 
The cyclic voltammograms of these complexes (Figure 3.7) are characterised by oxidation 
peaks with decreased reversibility, causing a lowering of the cathodic current peak. This 
effect is already observed bis-heteroleptic complexes 11 to 13 but becomes more important 
for tris-heteroleptic complexes 14 to 19. 
Reduction profiles of complexes 11 to 13 also show low reversibility and only the cathodic 
potentials are reported (Table 3.4) for 12 and 13. Nevertheless the signal is pushed to more 
negative values as the LUMO is becoming increasingly destabilised by the influence of the 
methyl (12) and methoxy substituents (13, a schematic view of HOMO-LUMO energies is 
presented in Figure 3.8). 
This destabilisation translates into increasing E0-0 energies going from 2.69 to 2.75 eV which 
in turns translates into increasing calculated LUMO energies going from -2.51 to -2.38 eV. 
These E0-0 values are very close to the one calculated for 2 which are what is expected with 






Figure 3.7: Cyclic voltammograms of 11 to 19 (top to bottom), measured in DMF (0.1 M TBAPF6) vs 
Fc
+
/Fc at 1 V/s scan rate. 
The effect of the methyl/methoxy substituent on the oxidation potential is less striking. The 
oxidation potential of 12 is reduced by 0.04 V compared to the one of 11, in agreement with 
Hammett parameter analysis predicting a slight destabilising effect of the methyl group on the 
meta position (here: on the phenyl ring, on the HOMO).
147,148
 On the other hand, the oxidation 
potential of 13 is decreased by 0.07 V compared to the one of 11, suggesting a HOMO 
destabilisation which goes against the predictions based on Hammett parameters for methoxy 
substituents. When looking at the oxidation potentials of complexes 14 to 19, no significant 






Table 3.4: Redox potential and photophysical data measured on complexes 2, 5 and 11 to 19 











cathodic peak only, E0-0 was calculated as the crossing of the normalised absorption and 
emission spectra expressed on an energy scale, HOMO = - (Eox + 4.8) eV, LUMO = HOMO + E0-0. 
This is expectable considering the relatively high distance separating the pyridine-4 position 
from the M-C bond. 
Generally speaking, the oxidation potentials of the tris-heteroleptic complexes are all 
comprised between 0.54 and 0.57 V which corresponds roughly to the average oxidation 
potential between the bis-dMeOppy and the bis-dFppy/dFppz complexes. 
This is coherent with HOMO orbitals being delocalised over the d orbitals of the iridium 
centre and π orbitals of the phenyl rings of both ligands. 
Reduction profiles of complexes 14, 16 and 18 exhibit the quasi reversible peaks of bis-dFppy 
complex (2) but with a shift towards more negative voltage of around 0.12 V. 
According to the model considered here, HOMOs of these complexes are expected to be 
destabilised compared to the HOMO of 2, due to the lower withdrawing influence of the 
methoxy substituents in comparison with the fluorines (this point fits with the oxidation 
potential values). On the other hand, the LUMO orbital of such tris-heteroleptic complexes is 
 









 2.74 -5.53 -2.79 
5 0.79
a
 - - -5.59 - 
11 0.40 (0.42)
b 
-2.78 2.69 -5.20 -2.51 
12 0.36 -3.04
c 
2.71 -5.16 -2.45 
13 0.33 -3.10
c 
2.75 -5.13 -2.38 
14 0.55 -2.56 2.68 -5.35 -2.67 
15 0.56 -2.72 2.74 -5.36 -2.62 
16 0.54 -2.58 2.67 -5.34 -2.67 
17 0.54 -3.02
c 
2.81 -5.34 -2.53 
18 0.54 -2.58 2.67 -5.34 -2.67 





expected to be located on the pyridine ring providing the most stable π
*
 orbitals. In other 
words, the LUMO is expected to be located solely on the dFppy pyridine. Therefore, the E0-0 
energy should be decreased and the reduction potential and calculated LUMO energy are 
expected to be close to the values obtained for 2. Surprisingly, stable reduction potentials (-
2.56/-2.58 V) and LUMO energies of (-2.68/-2.67 eV) are observed instead, which are 
significantly lower/higher than the values of 2 (-2.45 V/-2.79 eV). It seems that the LUMO 
energies reach a compromise value in between the energies of the two ligands. 
Similarly to complexes 14, 16 and 18, the oxidation potentials obtained for complexes 15, 17 
and 19 are very close. A small variation ±0.01 V is observed around the value of 15. The 
potential is increased for 17 and decreased for 19. Even if these changes fit the model of 
HOMO destabilisation/stabilisation by the pyridine methyl/methoxy substituents, they are of 






Figure 3.8: Representation of HOMO-LUMO energy levels and optical energy gaps E0-0 for complexes 
2 and 11 to 19. 
The reduction curves of these complexes show a decrease in the reversibility, coupled to a 
decrease in the peaks potential. Therefore, the reduction potential of 19 is not detectable with 
the conditions used. 
Due to low reversibility or low measurability, it is not possible to rely on reduction potentials, 
for the present discussion. However, as these complexes are luminescent at room temperature 
(unlike 4, 5 and 6), their E0-0 and calculated LUMO values offer a good alternative. 
In this regard, E0-0 energies of 15 (2.74 eV), 17 (2.81 eV) and 19 (2.83 eV) are gradually 
increased. This is coherent with the increasing LUMO destabilisation induced by the methyl 
and methoxy influences. Therefore, because of the large E0-0 difference, the LUMO energy of 





potential measured for 19 and despites a larger E0-0 energy, the calculated LUMO energy of 
19 (-2.54 eV) is very close to the one of 17. These values are found to be significantly 
stabilised (by respectively -0.11, -0.08 and -0.16 eV) compared to the calculated LUMO 
energies obtained for the corresponding bis-heteroleptic complexes 11, 12 and 13. 
In the first series, the LUMO energy trends are following the number of fluorine substituents 
with little influence from the nature of the second heterocycle and its location around the 
iridium centre. 
In the second series, this behaviour seems to be repeated. DFppy complexes (14, 16 and 18) 
can then be understood as bearing a dFppy based LUMO which is destabilised to an extent by 
the presence of the dimethoxylated phenyl ring of the second ligand. For these complexes, no 
influence of the second pyridine ring on the LUMO energy is observed. 
In the case of dFppz complexes (15, 17 and 19), the LUMO bearing ligand is also the one 
with the pyridine and as this pyridine is being substituted, a direct influence on the LUMO 
energy is observed. However, the LUMO energies of these complexes also feel a sort of 
stabilisation from the difluorinated phenyl ring. Again, the influence of the second aromatic 






3.3.2 UV-visible and luminescence spectroscopy 
UV-visible spectra of complexes 11, 12 and 13 (Figure 3.9) are characterised by strong bands 






) that are red shifted compared to 2. They 






). In the MLCT region, the 
profile of 13 is slightly blue shifted compared to 11 and 12. 
The dFppz complexes show systematically lower molar absorptivity values than their dFppy 
equivalents, as it was already observed for the first series. All complexes show high molar 
absorptivity values in the 310 to 360 nm region where all complexes (11 to 19) show 
significantly higher molar absorptivity values than 2. 
 
Figure 3.9: Absorption (left) and emission (right) spectra of 11 (solid line), 12 (dashed line) and 13 
(dotted line) measured in aerated DCM (abs.) and deaerated DCM (em.) solutions. 
The luminescence spectra of 11, 12 and 13 (Figure 3.9) show standard profile shapes for 





respectively (Table 3.5) are obtained as in agreement with LUMO destabilisation induced by 
the addition of the methyl and methoxy substituents. 
Complexes with dFppy show less structured profiles with very similar onset emissions. Their  
maxima are measured at 500 (14), 504 (16) and 509 nm (18). 
Assuming a LUMO located on the pyridine of the dFppy ligand, and following the Hammett 
parameter model, an emission red shift should be observed between 14 and 16 due to the 
meta-directing electron donating properties of the methyl substituent, which slightly 
destabilise the HOMO. Furthermore, a blue shift should be observed between 14 and 16, as 
meta electron withdrawing character of the methoxy substituent is stabilising the HOMO. 
However, the similar oxidation potential values and onset emission values suggest a 
negligible influence of the pyridine substituent on the HOMO energy. 
 
Figure 3.10: Absorption (left) and emission (right) spectra of 14 (solid line), 16 (dashed line) and 18 





The reason behind the observed red shift should then be looked for in differences in 
transitions probabilities between the excited state and vibrational levels of the ground state. 
The pyridine methoxy substituent seems to influence the spectrum shape by causing a 
broadening of the entire low energy half of the profile. This effect translates into a FWHM 
value that is significantly increased for 18 (+291 cm
-1
) compared to 14 (Table 3.5). 
However, the significant red shift observed compared to 2 (around 20 nm) reflects the 
calculations well and is coherent with a decreased E0-0 energy. 
The absence of a significant blue shift also suggests that the LUMO is not directly influenced 
by the pyridine substituents and is therefore located solely on the dFppy ligand. 
 
Figure 3.11: Absorption (left) and emission (right) spectra of 15 (solid line), 17 (dashed line) and 19 
(dotted line) measured in aerated DCM (abs.) and deaerated DCM (em.) solutions. 
The emission profiles of complexes 15, 17 and 19 show an increasingly blue shifted onset 
emission, as expected in a situation where the HOMO-LUMO energy gap is gradually 





which is the same blue shift than between the corresponding bis-heteroleptic complexes (11 
and 12). A new feature of the profiles is the increasing intensity of the second emission peak 
at 512 and 507 nm. In the case of complex 19, this peak becomes the major peak and the 
emission maximum is red shifted to 498 nm. However, the first peak of the emission profile 
can still be measured at 469 nm. The 14 nm blue shift observed between this peak and the 
emission maximum of 15 is very close from the 15 nm separating the emission maxima of the 
bis-heteroleptic complexes 11 and 13. In other words, the increments in the blue shift of the 
emission spectra are believed to be caused by the direct influence of the pyridine substituents 
on the LUMO energy which is located on the pyridine ring. 
In this situation, the pyrazole is believed to be only playing a disruptive role on the emission 
profile. It does not influence the HOMO or LUMO energies directly but still has an influence 
on the emission spectra by influencing the spectra vibronic progression. Therefore, as the 
second and third emission bands are gradually increased, the emission profile is broaden with 
FWHM values increasing form 2425 cm
-1












deaerated DCM, the emission spectra were recorded with excitation wavelength of 
350 nm, E0-0 was calculated as the crossing of the normalised absorption and emission spectra 
expressed on an energy scale, EHOMO = - (Eox + 4.8) eV, ELUMO = EHOMO + E0-0, kr = ΦPL / τ, knr = (1 - 
ΦPL) / τ. 
  
 





































260 (37.25), 275 (40.09), 322 
(26.49), 339 (21.64), 400 (5.20), 
426 (3.03), 445 (2.20), 475 (0.70) 
495 997 0.39 3.91 6.12 2641 
12 
260 (35.17), 277 (38.76), 318 
(26.84), 335 (22.19), 395 (5.12), 
420 (3.31), 440 (2.22), 470 (0.66) 
488 368 0.20 5.43 21.74 2636 
13 
278 (37.56), 295 (32.47), 314 
(26.07), 391 (4.75), 425 (2.65), 
433 (2.12), 462 (0.5) 
480 93 0.03 3.55 103.98 2641 
14 
257 (39.91), 270 (35.27), 288 
(29.00), 330 (17.36), 390 (4.70), 
418 (2.88), 440 (2.02), 470 (0.80), 
500 1136 0.35 3.10 5.71 2772 
15 
259 (31.05), 288 (20.70), 312 
(16.03), 336 (13.78), 387 (3.01), 
415 (1.78), 439 (0.61), 471 (0.19) 
483 682 0.19 2.75 11.91 2425 
16 
257 (40.03), 273 (35.15), 288 
(30.51), 327 (18.08), 383 (5.23), 
397 (4.50), 422 (2.50), 440 (1.90), 
470 (0.82),  483 (0.38) 
504 1053 0.52 4.89 4.60 2686 
17 
258 (31.80), 290 (21.99), 310 
(17.38), 332 (14.65), 358 (6.88), 
382 (3.33), 408 (1.98), 464 (0.14) 
476 157 0.04 2.61 61.09 2849 
18 
258 (39.81), 273 (36.94), 287 
(32.35), 318 (20.13), 340 (13.05), 
376 (5.60), 400 (3.97), 442 (1.57), 
473 (0.67) 
509 1017 0.52 5.07 4.76 3063 
19 
258 (33.51), 290 (24.20), 309 
(19.50), 325 (16.71), 353 (6.48), 
376 (3.98), 400 (2.14), 458 (0.1) 





3.3.3 Excited state lifetimes and quantum yields 
The excited state lifetimes of the bis-heteroleptic complexes 11 to 13 show a drastic decrease. 
The initial measured value of 997 ns falls to 368 ns with the addition of the methyl 
substituent. When the methyl is replaced by a methoxy, the lifetime experiences an additional 
decrease falls down to 93 ns. These decreased lifetimes are coupled to a significant quantum 
yield decrease from 0.39 to 0.20 and down to 0.03. This seems to be due to an increase of non 
radiative deactivation mechanisms, as the radiative constants stay rather small, while the non 













The same pattern is observed for the tris-heteroleptic dFppz complexes 15, 17, 19 (where the 
LUMO is believed to be located on the substituted pyridine) with lifetimes of 682, 157 and 43 
ns respectively. Here again the quantum yields are decreased from 0.19 to 0.04 and 0.01 while 














Moreover, the tris-heteroleptic dFppy complexes 14, 16 and 18 (where the LUMO is believed 
to be located on the non substituted pyridine of the dFppy ligand) show very close lifetimes 
with values of 1136, 1053 and 1017 ns. Quantum yields are comprised between 0.35 and 0.52 







This observation strongly demonstrates the effect of the direct influence of the increasing 
LUMO destabilisation by the introduction of donor substituents on the pyridine. When the 
LUMO is located on the substituted pyridine, an effect is measured. When it is located on the 
other ligand, no effect is measured. 
However, it is believed that the LUMO destabilisation induced by the pyridine methyl and 





complexes bearing similarly substituted ppy type ligands do not show these tremendous 
decreases in lifetimes and quantum yields. 








 exhibited blue shifted emission maxima of 477 and 471 nm 
compared to 2 (482 nm) but did not show any decrease in lifetime and quantum yields (their 
quantum yields values were 0.89 and 0.60 respectively while the lifetime for the bis-
F2MeOppy complex was measured at 590 ns). 
Another study on an acac complex using the methylated ligand 4-methyl-2-phenylpyridine 
(Meppy)
151
 reported a blue shifted emission maximum of 511 nm compared to 1 (519 nm), a 
quantum yield of 0.51 and a lifetime of 1400 ns. Another study looked at cationic bpy 
complexes with ppy main ligand and observed significant decrease in quantum yields and 
excited state lifetimes when the methoxy group was placed on the phenyl-3 instead of phenyl-
4 carbon.
152
 In this example the LUMO of such a complex is located on the ancillary ligand so 
the observed perturbation of the photophysical properties is not due to LUMO destabilisation. 
In the context of this work, it appears that the increased perturbations are encountered as a 
result of mixing the 2,4-dimethoxylation of the phenyl and substitution of the pyridine-4 
position. 2,4-dimethoxylation alone does not cause these effects (as revealed with 11) and 
neither does the substituted pyridine alone. Furthermore, the present work reveals that the 
perturbation is observed only when other results strongly suggest a direct involvement of the 
modified pyridine as the LUMO bearer. 
An explanation for the drastic decrease in quantum yield is the population of thermally 
accessible MC state (d-d
*





pathway for organometallic complexes
41,44
 and for iridium complexes with high LUMO 
energies such as ppz complexes
45
. It is also observed for complexes with dFppy ligands such 
as the sky blue emitter FIrpic.
38
 
The population of such states would have been made possible by the joint LUMO 
destabilisation induced by the phenyl and pyridine substituents and would explain the higher 
performances observed for the dFppy complexes 14, 16 and 18 where this destabilisation do 
not matter. 
Another possible explanation for the excited state non radiative deactivation is a more 
favoured vibrational decay mechanism as vibronic coupling between the excited state 
isoenergetic vibrational states of the ground state is increased. This effect is a long-known 




This series of complexes 11 to 19 studied the effect of ligands with increasingly destabilised 
LUMO energies on the properties of tris-heteroleptic iridium complexes. The results show a 
broadening of the emission profile when the methoxylated ligand is used either with dFppy 
(FWHM: + 290-420 cm
-1
) or dFppz (FWHM: + 820-1040 cm
-1
). The modest increase of 
FWHM value of the dFppy complexes was not coupled with any photophysical performance 
decrease, while the large broadening of the dFppz complex goes with significant decreases in 







3.4 Third series: pim complexes 
3.4.1 Cyclic voltammetry 
The cyclic voltammetry measurements were performed in DMF (0.1 M TBAPF6) with 
platinum counter and reference electrodes and a glassy carbon working electrode. All 
measurements were made vs Fc
+
/Fc at 1 V/s scan rate. 
The oxidation profiles (Figure 3.12) show quasi-reversible oxidation processes. The oxidation 
potential of the bis-mespim complex (20) is measured at 0.25 V (Table 3.6), in range with 
other iridium complexes bearing phenylimidazole ligands with non substituted phenyl 
rings.
55,115
 Oxidation potentials values of 21, 22 and 24 are measured close to the average of 
their respective corresponding bis-heteroleptic complexes (2/20 and 5/20 and 20/23). 
 
Figure 3.12: Cyclic voltammograms of 20 to 24 (top to bottom), measured in DMF (0.1 M TBAPF6) vs 
Fc
+





The oxidation potential of 23 is increased by 0.14 V compared to complex 4. This shift is 
coherent with the strong electron withdrawing effect of the trifluoromethyl substituent that 
stabilises both the HOMO and the LUMO. 
The reduction potential of 20 is measured as an irreversible current at -3.25 V. The value is in 
agreement with reported complexes with similar ligands. The replacement of one mespim 
ligand with a dFppy ligand induces a significant positive shift with the reduction potential of 
complex 21 being measured at -2.60 V. In addition, the reduction current signal is quasi 
reversible and the E0-0 value (2.64 eV) is very close to the one calculated for 3 (2.65 eV). 
These results are coherent with a HOMO located on the iridium centre and phenyl rings of the 
ligands while the LUMO stays mainly on the pyridine of the dFppy ligand. This situation is 
similar to what was described for complexes 14, 16 and 18. 
Table 3.6: Redox potential and photophysical data measured on complexes 20 to 24.  




cathodic peak only, E0-0 was 
calculated as the crossing of the normalised absorption and emission spectra expressed on an energy 
scale, EHOMO = - (Eox + 4.8) eV, ELUMO = EHOMO + E0-0. 
In the same way, observations made on 22 match with the ones made on 19. As dFppy is 
replaced with dFppz, the LUMO is transferred to the second ligand and the reduction potential 
and E0-0 energy are significantly increased but the LUMO energies are stabilised in 
comparison with the corresponding bis-heteroleptic complex. For 19, this stabilisation of the 
LUMO energy is calculated at 0.16 eV (below 13) while in the case of 22, the stabilisation is 
only 0.09 eV (below 20). 
 
Eox (V) Ered (V) E0-0 (eV) HOMO (eV) LUMO (eV) 
20 0.25 -3.25
a
 2.75 -5.05 -2.30 
21 0.50 -2.60 2.64 -5.30 -2.66 
22 0.53 -2.80
a
 2.94 -5.33 -2.39 
23 0.63 - - -5.43 - 





The oxidation potential of 24 is measured at 0.45 V, slightly lower than the one of 22. This is 
due to the larger HOMO stabilisation induced by the phenyl 2,4-difluorination compared to 
the pyrazole trifluoromethyl substituent. The E0-0 values and calculated LUMOs are similar, 
despites the non measureable reduction potential that suggested a more destabilised LUMO. 
 
Figure 3.13: Representation of HOMO-LUMO energy levels and optical energy gaps E0-0 for 






3.4.2 UV-visible, luminescence spectroscopy and excited state lifetimes 
The UV-visible spectra of complexes 20 to 24 are characterised by intense peaks between 248 
and 260 nm attributed to LC transitions. The peak of complex 20 is red shifted (260 nm) 
compared to the other three profiles (peak at 255 nm) and followed by a second marked peak 
at 268 nm. The profile exhibiting the highest molar absorptivity values is 21 and the lowest 
epsilons are obtained with 22. This corresponds to what is expected when replacing dFppy 
with dFppz. In the MLCT region (300 to 375 nm), the profiles are mixed and if some peaks 
are distinguishable, the overall epsilon values are similar for 20, 21 and 24 while the 
absorptivity of 22 is lowered. It is interesting to note the increased absorptivity of the CF3ppz 
ligand (24) compared to the dFppz ligand (22) over the entire spectrum. 
The low absorptivity region (425 to 500) is marked by the higher epsilon values of 21 over the 
other complexes. Its onset absorption appears at a significantly lower energy (500 nm) than 
for the other complexes of the series: 20 (475 nm), 24 (440 nm) and 22 (430 nm). These 
increased and decreased molar absorptivities of the dFppy and dFppz complexes are in 






Figure 3.14: Absorption (left) and emission (right) spectra of 20 (small dashed line), 21 (solid line), 
22 (dotted line) and 24 (dashed line) measured in aerated DCM (abs.) and deaerated DCM (em.) 
solutions. 
The emission spectrum of complex 20 (in DCM) is defined by broad partly structured profile 
with three visible main peaks at 477, 515 and 587 nm with the emission maximum appearing 
at 587 nm (Table 3.7). The profile is very similar in shape to what was measured for the white 
emitting complex N966 that exhibited a maximum intensity at 570 nm.
115
 The radiative 
lifetime is measured at 36 ns. This significantly shorter than the 1.96 µs measured for N966. 
Short lifetimes have been reported for all complexes of the series except 21, suggesting that 
non radiative deactivation pathways are favoured. 
The replacement of one mespim ligand by a dFppz or CF3ppz ligand (22 and 24) caused a 
large broadening of the spectrum by increasing the intensity of the low wavelength peaks. The 
areas where the maximum intensity of 20 was recorded also show a decreased intensity for 





maximum is now measured at 533 and 537 nm on a peak that was absent from the spectrum 
of 20. 
Due to the significantly more intense signal arising from the high energy part of the spectra, 
the FWHM values for 22 and 24 are calculated at 5933 and 5991 cm
-1
. They are increased by 
roughly 910 and 970 cm
-1
 compared to the FWHM of 20. 




deaerated DCM, the emission spectra were recorded with an excitation wavelength of 
380 nm, Lifetimes were measured at the λmax of emission and no differences were observed with 
lifetimes measured at shoulder peaks. 
By comparison, the replacement of a mespim ligand by a dFppy ligand is narrowing the 
emission profile and the FWHM is decreased by 1950 cm
-1
. It is interesting to note that 
emission profiles from complexes 18 and 21 are very similar (Figure 3.15) due to close 
photophysical properties such as FWHM (3063 vs 3072 cm
-1
), lifetime (1017 vs 1169 ns), 
emission maxima (509 vs 518) and E0-0 energies (2.67 vs 2.64 eV). 
This underlines the important role played by the dFppy ligand in the emission process of both 
complexes. The structure of the second ligand does not matter too much as long as the orbitals 
of its heteroaromatic ring are higher in energy than the pyridine π
*
-orbitals of the dFppy. In 
 






















260 (35.16), 268 (33.79), 284 (22.80), 307 
(13.27), 325 (9.95), 353 (6.99), 379 (5.18), 
411 (3.40), 463 (0.32) 
587 36 5022 
21 
255 (38.05), 268 (33.75), 296 (17.94), 327 
(10.23), 337 (9.64), 364 (5.80), 396 (3.54), 
440 (1.32), 474 (0.61) 
518 1169 3072 
22 
255 (29.52), 274 (21.77), 296 (13.21), 326 
(7.94), 362 (3.95), 387 (2.29), 420 (0.19) 
533 28 5933 
23 
243 (31.21), 251 (30.92), 268 (22.81), 277 
(20.61), 296 (13.36), 320 (9.47), 377 (3.06), 
419 (0.16) 
- - - 
24 
248 (32.62), 254 (32.90), 266 (29.09), 279 
(21.89), 300 (14.74), 328 (98.15), 364 
(4.77), 392 (3.37), 430 (0.38) 





this situation, the second ligand is only responsible for a slight increase of the vibronic 
progression (inducing a small broadening of the emission profile in comparison to all-ppy 
complexes) and for a shift in the HOMO-LUMO energy gap (therefore in E0-0 energies and 
emission maxima) mainly through stabilisation/destabilisation of its phenyl π-orbitals that 
participate in the HOMO. 
 
Figure 3.15: Emission spectra of, 18 (dashed line) and 21 (solid line) measured in deaerated DCM. 
Additionally, observation of the emission profiles of 19 and 22 emphasises the important role 
played by dFppz in broadening the emission profiles. The FWHM values of these complexes 
are significantly increased by respectively 822 and 911 cm
-1
 (compared to the FWHM of the 
corresponding bis-heteroleptic complexes 13 and 20). 
In both cases, the first emission peaks are blue shifted due to the stabilising effect of the 2,4-
difluorination on the HOMO energy. The first emission peak is then shifted from 476 to 469 





In 19, the presence of dFppz induced an increase of the low energy peaks of the emission 
spectrum and an emission maximum shift from the first to the second peak. The high energy, 
more structured peaks are assigned to ligand centred (
3
LC) transitions and the lower energy, 




 Therefore, the 
change in emission profiles can be understood by a change in the nature of the excited state 
containing more or less of the LC/MLCT characters. 
 
Figure 3.16: Emission spectra of, 19 (dashed line) and 22 (solid line) measured in deaerated DCM. 
The situation is inverted for 20 and 22 as the low energy part of the spectrum becomes less 
intense when dFppz replaces one mespim ligand. The emission maximum is significantly blue 
shifted from 587 to 533 nm. 
In order to estimate these changes, the emission profiles have been fitted with Gaussian 





very basic and qualitative, they provide a good comparative tool to observe changes between 
the spectra. 
Table 3.8: Result of the Gaussian fitting for the emission spectra of 13, 19, 20 and 22.  
 
The emission spectra of 13 and 19 are fitted using 4 Gaussians. The blue shift discussed above 
is observed with the Gaussians as the three first curves are calculated with blue shifted 
maximum intensities in 19 (higher energies). However, it also reveals a significant intensity 
decrease in the high energy curves (1 & 2) falling from 0.8 and 0.61 to 0.45 (on the 
normalised intensity scale). Therefore, this shows that the apparent increase of the second 
peak on the emission spectrum of 19 is probably not due to more intense high energy 
transitions with LC character but to the increase of the lower energy transitions of increased 
CT character represented by Gaussians 3 and 4. 
 




1 2.60 0.80 0.051 
2 2.46 0.61 0.075 
3 2.33 0.28 0.113 
4 2.24 0.12 0.245 
19 
1 2.66 0.45 0.042 
2 2.52 0.45 0.067 
3 2.40 0.58 0.135 
4 2.23 0.19 0.227 
20 
1 2.61 0.32 0.052 
2 2.45 0.27 0.067 
3 2.26 0.45 0.140 
4 2.07 0.62 0.161 
5 1.85 0.30 0.207 
22 
1 2.68 0.56 0.048 
2 2.53 0.64 0.063 
3 2.37 0.64 0.098 
4 2.18 0.40 0.126 





The emission profile of complexes 20 and 22 was simulated using five Gaussian curves. The 
result confirms the effect suspected above. The emission of 20 is dominated by a broad 
Gaussian centred in the lower energy region of the spectra (2.07 eV) and followed in intensity 
by another broad curve of higher energy (2.26 eV). The two higher energy curves centred at 
2.45 and 2.61 eV show only low intensities. The profile of 22 is marked by a significant 
intensity increase of the three higher energy Gaussians (at 2.37, 2.53 and 2.68 eV) at the 
expense of the lower energy one (centred at 2.18 eV).  
From these results, it is difficult to clearly establish the role played by the dFppz ligand in 
broadening the emission profile and the exact mechanism taking place. Nonetheless, it is 
possible to underline a few noteworthy observations. 
The broadening of the emission profile is achieved when combining high LUMO ligands with 
dFppz. Results from the first and second series show only a small increase in FWHM values 
except when a more destabilised LUMO is introduced by using the dMeOMeOppy ligand. 
This result is confirmed in the third series where the replacement of dFppz by dFppy leads to 
a drop in FWHM value. 
The shape of the emission spectra suggests that the electron transfer associated with light 
emission arises from the other main ligand (mespim or dMeOMeOppy). The dFppz ligand 
plays a role in favouring/disfavouring some transitions probably by 
stabilisation/destabilisation of the LC/MLCT exited states. 
The photophysical properties obtained for bis-heteroleptic complexes 13 and 20 indicates that 
the introduction of a dFppz ligand is not responsible for the low emission lifetime and 
quantum yields. These properties are inherent to the mespim and dMeOMeOppy ligands used. 





radiative deactivation pathways, especially in complexes with increased HOMO-LUMO 
energy gaps.
157
 The increase of the FWHM value is then achieved at the expense of the 
emission intensity. 
3.4.3 Different solvents 
The emission spectra were measured in different media as a way to test the consistency of the 
emission profile in different environments. 
The first tests were performed on 22 to test the influence of solvent polarity on the emission 
profile. If the polarity of the solvent is increased, a red shift in the emission maximum is 
expected, due to the enhanced stabilisation of the excited state in polar solvents.
158–160
 For the 
mixed LC/MLCT excited states of interest here, an increased polarity would accommodate the 
CT character more than the LC as it is more polar.
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Tests were performed in DCM/hexane (50/50) mixture for a lower polarity solvent (pure 
hexane was not suitable because of the low solubility of most complexes in this solvent), in 
MeCN for a higher polarity solvent and in CCl4 for a low polarity halogenated solvent. In 
order to test solid state emission in thin films, pmma solutions were prepared and deposited 
on quartz plates (the films were prepared to contain 5-10 % of complex). 
The results (Figure 3.17) show almost no changes in emission profile shape between DCM 
and MeCN. The DCM/hexane profile displays a slight decrease in the low energy transitions 
but it is rather small. 
The pmma thin film emission exhibits a significant loss of low energy intensity and presents a 
more structured profile with a maximum of emission blue shifted by 38 nm. This suggests an 
increase of the LC character of the excited state probably due to the rigidity of the matrix. 





MLCT states are restricted by the rigidity of the matrix. Therefore, the LC transitions are 
favoured. Even if such effects are expected, their amplitude in the present context is 
surprising, especially when considering the almost unchanged profile of the N966 complex in 
thin films. Here, the loss of the low energy emission peaks is apparently inherent to the 
mespim ligand, since the same effect was observed for 20 (em. max. blue shift of 76 nm), 22 
and 24 (em. max. blue shift of 40 nm. Figure 3.17 and Figure 3.18 and Table 3.9) 
Moreover, the CCl4 profiles show a quasi total shut down of the high energy transitions 
associated with a LC character of the excited state. Therefore, the emission maxima of 20, 22 
and 24 are red shifted by respectively 18, 52 and 44 nm. 
 
Figure 3.17: Emission spectra of 22 measured in deaerated DCM, CCl4, hexane/DCM mixture, MeCN 
and pmma film under normal atmosphere. 
Again, this effect can be assigned to the use of the mespim ligand as it has been observed in 
all the complexes where it is present except 21. More precisely, these effects are observed in 





LUMO is located on the ppy ligand do not show such drastic perturbations of the emission 
profiles. Therefore, the profile of 21 is barely modified in pmma film with only a 2 nm red 
shift of its maximum intensity. The modifications induced by CCl4 are opposed to what is 
observed for the rest of the series with an emission profile actually becoming more structured 
and blue shifted. The emission maximum is observed at 499 nm (19 nm blue shift) with a 
second peak at 529 nm and a shoulder at 580 nm. 
Generally speaking, 21 behaves like most other ppy complexes from the first and second 
series where the pmma only induces minor changes in emission maxima and profile shapes 
while CCl4 generates a more structured and blue shifted profile (Figure 9.2 to Figure 9.17). It 
is interesting to note that, for these complexes the changes observed in CCl4 are the ones 
normally expected from a solvent with low polarity (blue shift of emission maximum, more 
structured emission profile). 
 
Figure 3.18: Emission spectra of 20 measured in deaerated DCM, deaerated CCl4 and pmma film 





The CCl4 emission spectra obtained from 20, 22 and 24 are unexpected in the sense that they 
do not fit with standard solvatochromic shifts attributed to solvent polarity. Nevertheless, the 
effect of solvent interaction on the emission spectra is manifest. Therefore, one possibility 
would be to consider other solvent properties than the polarity, such as the higher 
polarizability of CCl4.
161
 A similar effect has been described for some organic dye (oxazine) 
and may apply in the present context.
162
  
Table 3.9: Emission maxima of the different peaks observed on the emission spectra of complexes 20, 
21, 22 and 24. 
Data measured in DCM, CCl4 and in pmma films, the values are expressed in nm, max denotes the 
maximum intensity of the spectrum, sh denotes a shoulder signal. 
Another factor that could influence the emission profile in CCl4 is the complex solubility in 
the solvent. Indeed, a slightly decreased solubility in CCl4 compared to DCM can induce the 
formation of aggregates and appearance of π-stacking interactions, leading to a red shift in the 
emission profile.  
In the current state of the present research, it is believed that further investigations would be 
necessary to determine the exact nature of the emission mechanisms of these complexes. An 
extended solvent analysis would be useful to determine the exact solvent parameters inducing 
complex medium peak 1 peak 2 peak 3 peak 4 
20 
DCM 477 515 - 587 (max) 
CCl4 - - - 605 
pmma 480 511 (max) 547 (sh) 597 (sh) 
21 
DCM 518 - - - 





DCM 462 496 533 (max) 570 (sh) 
CCl4 465 496 (sh) - 585 (max) 
pmma 463 495 (max) 528 (sh) 572 (sh) 
24 
DCM 467 500 537 (max) 570 (sh) 
CCl4 465 500 540 (sh) 581 (max) 





the observed changes. Studies of different complex/pmma ratios could also be tested to 
optimise the emission profile in thin films and in different polymers and host materials. 
Finally, theoretical calculations would be extremely helpful in understanding the nature of the 
excited state involved in the light emission process as well as in explaining the reason behind 







The present work focused on the design, synthesis and characterisation of new tris-
heteroleptic iridium complexes for electroluminescent application. The aim was to study these 
complexes and their photophysical properties to develop a broad emitting molecule with 
white emission. The complexes were divided in four series corresponding to the type of 






F spectroscopy as well as 2D techniques. 
The first series with ppy/ppz type ligands showed challenging purification processes. It 
highlighted the possibility to play on ligand combinations to ease the purification process 
without drastically changing the complexes physical and photophysical properties. Even 
though these complexes showed limited emission broadening, they were useful to study 
reaction yields and observe reactivity differences, between ligands, and depending on the 
iridium starting material used. The second series using dimethoxylated ppy ligands with 
increasing LUMO energies in combination to dFppy or dFppz ligands offered much easier 
purification processes as the polarity differences between the complexes formed are increased 
by the presence of the methoxy substituents. Their photophysical properties displayed a 
significant broadening when high LUMO ligands were mixed with dFppz. Unfortunately, the 
low quantum yield observed with the corresponding bis-heteroleptic complex was conserved. 
This series also underlined the dominant role of the dFppy ligand in the emission process, if 
the energy of the second LUMO is increased. In this case, redox potentials and emission 
spectra pointed to a dFppy based emission, with the second ligand only playing a secondary 





The fourth series used a mespim ligand in combination with dFppy, dFppz and CF3ppz. The 
photophysical properties confirmed the importance played by the dFppz in the emission 
broadening with an increase of FWHM values of nearly 1000 cm
-1
 between bis-mespim, the 
tris-heteroleptic dFppz and CF3ppz complexes. The emission lifetime values of the bis-
mespim and tris-heteroleptic complexes were similarly short (below 50 ns), indicating fast 
nonradiative processes generated by the mespim ligand. 
Finally, the synthesis and separation of isomers of pic complexes was successfully achieved, 
using two main ligand combinations to obtain two pairs of structural isomers. These isomers 
were characterised in details by NMR spectroscopy, X-ray christallography, and by their 
photophysical properties. Even though the pic orientation induced little effect on the 
photophysical properties of these complexes, it opens the way to interesting synthesis 
possibilities, increasing the number of available parameters for the design of new iridium 
emitters. 
In general, this work demonstrated the concept of using tris-heteroleptic complexes to develop 
broad emitting molecules. Moreover, by investigating different types of ligands, it highlighted 
clues on how to achieve this goal. Unfortunately, these broad emitting molecules obtained 
suffer from low emission lifetimes due to fast radiationless deactivation processes. However, 
this work also highlighted ways to improve the research methodology of tris-heterolpectic 






5 FUTURE PROSPECTS 
The future work focused on the synthesis and purification of tris-heteroleptic iridium 
complexes with acac ancillary ligands in an effort to broaden the shape of the emission 
spectra to obtain white emission. The results obtained show a significant increase of the 
FWHM but always at the expense of the emission intensity. Effort should be made to correct 
this drawback. In this prospect, it is believed that the use of the dFppz ligand as a high LUMO 
bearer should be avoided. Since the use of pim ligands seem to generate broad spectra, it 
would be interesting to mix them with more emissive ligands that have high LUMO energies, 
such as pim-based carbene ligands or ppy with destabilised LUMOs (but not dMeOMeOppy 
as this ligand induces too much non radiative decay). Investigation on the ancillary ligand also 
needs to be done, opening infinite possibilities. Many interesting classes of symmetrical 




 have been used to tune the 
photophysical properties. The use of non-symmetrical ancillary ligands can also be 
investigated as the resulting isomers can be isolated by HPLC. In this regard, the field is also 
infinite with examples as wide as asymmetrical acac
165
, ketoiminate and diketiminates, pic 
derivatives, and all the neutral aromatic ring combinations. The screening methodologies 
briefly described above can be developed to investigate rapidly the effect of a large number of 
ancillary ligands on many dimers or bis-MeCN precursors with minimal effort and cost. 













)] could be attempted as it has already been explored for bis-heteroleptic 
complexes
45,157
 and as a new synthetic methodology
108,109







6 EXPERIMENTAL PROCEDURES 
6.1 General considerations 
All the starting materials and solvents were commercially available and used as received 
except ethyl acetate that was distillated using a rotary evaporator before use. Solvent and 
acids were generally purchased from Fisher except for diethyl ether (Sigma-Aldrich), acetone 
(VWR), ethyl acetate (VWR) and ethoxyethanol (Acros Organics). Silica gel (60, 0.040-
0.063mm, 230-400 mesh) was ordered from Alfa Aesar. 
1
H spectra were recorded using a Bruker AVIII 300, a Bruker AVIII 400 or a Brucker DRX 
500 spectrometer; 
13
C spectra were recorded using a Bruker AVIII 400 or a Brucker DRX 500 
spectrometer; 
19
F were recorded using on a Bruker AVIII 300 spectrometer. Chemical shifts 
(δ) are expressed in ppm and referenced to the CHCl3 residual peak (
1
H: 7.26 ppm, 
13
C: 77.16 
ppm). Coupling constants (J) are in hertz (Hz). 
Mass spectrometry experiments were performed by means of electrospray ionisation on a 
Synapt G2-S HDMS mass spectrometer (Waters LTD, Manchester, UK). 
Elemental microanalyses were measured with a CE instruments elemental analyser EA1110, 
CHNS version. 
Analytical HPLC chromatograms were recorded on a Shimadzu LC-20AD/T device, using a 
Phenomenex Kinetex 5 µ, C18, 100 Å column at a constant temperature of 35 C (isocratic 
solution of ACN/water at 1mL/min). 
Preparative HPLC was performed with a Phenomenex Kinetex 5micron, C18, 100 Angstrom, 





Cyclic voltammetry was measured using a Metrohm Autolab PGSTAT101 potentiostat. All 
samples were measured in a degassed acetonitrile/TBAPF6 0.1M solution at RT, using a Pt 




FT-IR analyses were made on a Perkin Elmer Spectrum100 FT-IR spectrometer 
UV-Visible spectra were measured in aerated dichloromethane on a CARY5000 spectrometer. 
Emission spectra and excited state lifetimes were measured using an Edinburgh Instruments 
FLSP920 spectrometer. All samples were prepared with dichloromethane degassed by careful 
argon bubbling for 40 minutes. 
Quantum yield measurements were performed using a JobinYvon–Horiba Fluorolog 







6.2 Syntheses of Ligands 
6.2.1 Synthesis of 2-(2,4-difluorophenyl)pyridine (dFppy) 
2-Bromopyridine (1 g, 0.6 mL, 6.33 mmol, 1 equiv.), 2,4-difluorophenylboronicacid (1.4 g, 
8.862 mmol, 1.4 equiv.) were added to a round bottomed flask and dissolved in a 7:3 (v/v) 
THF : 2M aqueous Na2CO3 (anhydrous, VWR) solution 32 mL) and degassed with argon. 
Tetrakis(triphenylphosphine)palladium(0) (Aldrich, 0.315 g, 0.308 mmol, 5 mol%) was then 
added. After more degassing, the mixture was heated to reflux (70 °C) overnight under argon 
atmosphere. The mixture was poured into water and extracted with CH2Cl2 (150 mL). The 
organic phases were combined and dried over magnesium sulfate. After filtration of MgSO4 
(anhydrous, Sigma-Aldrich), CH2Cl2 was evaporated under vacuum. DFppy was purified by a 
first silica gel chromatography column using an n-hexane and Et2O eluent (80 : 20) to remove 
the remaining catalyst and purified further by a pure CH2Cl2 column on silica. 
The product obtained was a slightly yellow oil at room temperature and a white solid when 
stored in the freezer (melting point ≈ 20°C). Yield: 98%. 




H NMR (400 MHz, CDCl3) δ 8.63 (d, J = 4.8 Hz, 1H, 6), 7.96 (td, J = 8.9, 6.7 Hz, 1H, 6’), 
7.72 – 7.55 (m, 2H, 3/4), 7.20 – 7.07 (m, 1H, 5), 6.97 – 6.88 (m, 1H, 5’), 6.83 (ddd, J = 11.3, 
8.8, 2.5 Hz, 1H, 3’).  
13
C NMR (101 MHz, CDCl3) δ 164.75 – 159.13 (m, 2’/4’), 152.67 (d, J = 1.8 Hz, 2), 149.90 
(6), 136.62 (4), 132.27 (dd, J = 9.6, 4.4 Hz, 6’), 124.35 (d, J = 9.3 Hz, 3), 123.92 (dd, J = 
11.8, 3.4 Hz, 1’), 122.56 (5), 112.01 (dd, J = 21.1, 3.4 Hz, 5’), 104.49 (t, J = 26.2 Hz, 3’). 
19





6.2.2 Synthesis of 1-(2,4-Difluorophenyl)pyrazole (dFppz) 
1,1,3,3-tetramethoxypropane (2 g, 2 mL 12 mmol, 1 equiv.) was dissolved in 95% ethanol (20 
mL) and an aqueous solution of concentrated HCl (37%) was added (2 mL). 1-(2,4-
difluorophenyl)hydrazine hydrochloride (2.15 g, 12 mmol, 1 equiv.) was added to the solution 
with 40 mL of 95% ethanol. The mixture was then refluxed for 4 hours and cooled down to 
room temperature. 
The reaction mixture was then dried under vacuum, dissolved again in ethanol and neutralized 
with a saturated aqueous solution of Na2CO3. The remaining Na2CO3 was removed by 
filtration. After evaporation of the solvent under vacuum, the product was purified by column 
chromatography (hexane : ethyl acetate, 20 : 1). The product obtained was a slightly yellow 
oil .Yield: 62%. 




H NMR (400 MHz, CDCl3) δ 7.88 (t, J = 2.8 Hz, 1H, 5), 7.86 – 7.76 (m, 1H, 6’), 7.69 (d, J = 
1.7 Hz, 1H, 3), 6.99 – 6.87 (m, 2H, 3’/5’), 6.41 (dd, J = 2.4, 1.9 Hz, 1H, 4). 
13
C NMR (101 MHz, CDCl3) δ 160.76 (dd, J = 249.3, 11.3 Hz, 4’), 153.56 (dd, J = 251.6, 
12.1 Hz, 2’) 140.82 (3), 130.49 (d, J = 9.4 Hz, 5), 125.47 (d, J = 10.8 Hz, 6’), 111.96 (dd, J = 
22.4, 3.7 Hz, 5’), 107.45 (4), 105.22 – 104.54 (m, 3’). 
19






6.2.3 Synthesis of 2-(2,4-dimethoxyphenyl)pyridine (dMeOppy) 
2-Bromopyridine (0.95 mL, 19 mmol, 1 equiv.), (2,4-dimethoxyphenyl)boronic acid (2.73 g, 
15 mmol, 1.5 equiv.) were added to a round bottomed flask and dissolved in a 6:4 (v/v) THF : 
2M aqueous Na2CO3 (anhydrous, VWR) solution 70 mL) and degassed by bubbling argon. 
Tetrakis(triphenylphosphine)palladium(0) (Aldrich, 0.115 g, 0.1 mmol, 1 mol%) was then 
added. After more degassing, the mixture was heated to reflux (70 °C) overnight under argon 
atmosphere. The mixture was poured into water and extracted with CH2Cl2 (150 mL). The 
organic phases were combined and dried over magnesium sulfate. After filtration of MgSO4 
(anhydrous, Sigma-Aldrich), CH2Cl2 was evaporated under vacuum. DMeOppy was purified 
by two silica gel columns following a literature procedure.
57
 
Product: 1.627 g, 7.563 mmol, yield: 75 % 




H NMR (400 MHz, CDCl3) δ 8.64 (ddd, J = 4.9, 1.9, 1.0 Hz, 1H, 6), 7.82 – 7.71 (m, 2H, 
3/6’), 7.63 (ddd, J = 8.0, 7.4, 1.9 Hz, 1H, 4), 7.12 (ddd, J = 7.4, 4.9, 1.2 Hz, 1H, 5), 6.61 (dd, 
J = 8.5, 2.4 Hz, 1H, 5’), 6.54 (d, J = 2.4 Hz, 1H, 3’), 3.82 (s, 3H, 10’), 3.81 (s, 3H, 8’). 
13
C NMR (101 MHz, CDCl3) δ 161.35 (4‘), 158.13 (2‘), 155.88 (2), 149.25 (6), 135.60 (4), 







6.2.4 2-(2,4-dimethoxyphenyl)-4-methylpyridine (dMeOMeppy) 
The same reaction conditions were used than for dMeOppy. 
2-bromo-4-methylpyridine: 1.720 g, 10 mmol, 1 equiv. 
2,4-dimethoxyphenyl)boronic acid: 2.377 g, 13 mmol, 1.3 equiv. 
The product was purified by column chromatography on silica gel using hexane/THF (80/20) 
as eluent. Product: 1.684 g, 7.345 mmol, yield: 73 % 
1
H NMR (400 MHz, CDCl3) δ 8.51 (dd, J = 5.0, 0.8 Hz, 1H, 6), 7.71 (d, J = 8.5 Hz, 1H, 6‘), 
7.58 (dt, J = 1.7, 0.8 Hz, 1H, 3), 6.97 (ddd, J = 5.0, 1.7, 0.8 Hz, 1H, 5), 6.59 (dd, J = 8.5, 2.4 
Hz, 1H, 5‘), 6.54 (d, J = 2.4 Hz, 1H, 3‘), 3.83 (s, 3H, 8‘/10‘), 3.82 (s, 3H, 8‘/10‘), 2.35 (s, 3H, 
7). 
13
C NMR (101 MHz, CDCl3) δ 161.23 (4‘), 158.07 (2‘), 155.82 (2), 149.02 (6), 146.54 (4), 







6.2.5 2-(2,4-dimethoxyphenyl)-4-methoxypyridine (dMeOMeOppy) 
The same reaction conditions were used than for dMeOppy and dMeOMeppy. 
2-bromo-4-methoxypyridine: 1 g, 5.32 mmol, 1 equiv. 
2,4-dimethoxyphenyl)boronic acid: 1.94 g, 10.64 mmol, 2 equiv. 
Pd(cat): 0.3 g, 5 mol% 
The product was purified by column chromatography on silica gel using hexane/THF (80/20) 
as eluent. Product: 1.190 g, 4.851 mmol, yield: 91 % 
1
H NMR (400 MHz, CDCl3) δ 8.46 (d, J = 5.7 Hz, 1H, 6), 7.77 (d, J = 8.5 Hz, 1H, 6’), 7.35 
(d, J = 2.5 Hz, 1H, 3), 6.68 (dd, J = 5.7, 2.5 Hz, 1H, 5), 6.58 (dd, J = 8.6, 2.4 Hz, 1H, 5’), 6.52 
(d, J = 2.4 Hz, 1H, 3’), 3.81 (s, 3H, 8/8’/10’), 3.81 (s, 6H, 8/8’/10’). 
13
C NMR (101 MHz, CDCl3) δ 165.41 (4), 161.30 (4‘), 158.08 (2‘), 157.27 (2), 150.28 (6), 
131.91 (6‘), 121.96 (1‘), 110.72 (3), 107.41 (5), 105.00 (5‘), 98.86 (3‘), 55.57 (8/8‘/10‘), 






6.2.6 1-phenyl-4-(trifluoromethyl)pyrazole (CF3ppz) 
In a dry 50 mL RB flask, 3,3,3-trifluoropropanoic acid (1.280 g, 10 mmol, 1 equiv.) was 
dissolved in 10 mL of dry DMF and the mixture was heated at 70ºC. Phosphorus oxychloride 
(POCl3, 4.600 g, 30 mmol, 3 equiv.) was carefully added and the mixture was allowed to react 
at 70ºC for 1 hour. The mixture was cooled down to room temperature and slowly poured into 
50 mL of an ice cold aqueous KPF6 solution. The precipitate was filtered, washed with ice 
cold water and dried under vacuum. 
The dried solid was dissolved to 30 mL of MeCN contained in a 250 mL RB flask. Phenyl 
hydrazine (1.5 mL, around 15 mmol) was added and the mixture was stirred for 1 hour at 
room temperature. Trifluoroacetic acid (TFA, 2 mL, 26 mmol) was added and the closed flask 
was heated at 70ºC for 4 hours. The reaction was stopped and the MeCN volume was reduced 
under vacuum. The mixture was poured in water and extracted with DCM. The organic phase 
was dried over MgSO4 and the DCM volume was reduced under vacuum. Silica was added to 
the flask to adsorb the mixture and dried under vacuum. Hexane was added to wet the silica 
and it was deposited on top of a silica gel column prepared with hexane. The mixture was 
then eluted with hexane/EtOAc 90/10 as eluent to obtain the pure product. 
1.099 g, 5.180 mmol, yield: 51%. 
1
H NMR (400 MHz, CDCl3) δ 8.18 (t, J = 1.0 Hz, 1H, 3), 7.91 (s, 1H, 5), 7.72 – 7.64 (m, 2H, 
2’/6’), 7.54 – 7.44 (m, 2H, 3’/5’), 7.42 – 7.33 (m, 1H, 4’). 
13
C NMR (101 MHz, CDCl3) δ 139.45 (1’), 138.33 (q, J = 3.1 Hz, 5), 129.79 (2’/6’), 127.89 
(4’), 126.42 (d, J = 3.7 Hz, 3), 122.61 (q, J = 266.2 Hz, 6), 119.90 (3’/5’), 115.63 (q, J = 37.9 
Hz, 4). 
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6.2.7 1-mesityl-2-phenylimidazole (mespim) 
2,4,6-trimethylaniline (2 g, 14.79 mmol, 2.1 mL, 1 equiv.) and glyoxal 40% w./w. aq.(2.146 
g, 14.79 mmol, 1.7 mL, 1 equiv.) were mixed in a 500 mL round bottomed flask filed with 40 
mL of methanol degassed by argon bubbling. The mixture was stirred for 1 hour and a yellow 
precipitate formed. Additional degassed methanol 40 mL was added. Benzaldehyde (3.29 g, 
31.06 mmol, 3.3 mL, 2.1 equiv.) was added, followed by ammonium chloride (1.58 g, 29.58 
mmol, 2 equiv.). The mixture was heated to reflux for 1 hour and phosphoric acid (14 mL) 
was slowly added. The mixture was heated to reflux for 8 hours. 
The heating was stopped and the cooled solution was neutralized with a sodium carbonate 
aqueous solution. The product was extracted with DCM and the organic phse dried over 
MgSO4. After evaporation of the solvent (to dryness, to remove all traces of methanol), the 
crude was dissolved in the minimum amount of DCM and adsorbed on silica. The silica was 
dried under vacuum and hexane was added for deposition on top of a hexane packed silica gel 
column. The product was eluted with hexane/EtOAc (60/40) and obtained as a brown solid. 
0.434 g, 1.654 mmol, yield: 11% 
1
H NMR (400 MHz, CDCl3) δ 7.43 – 7.39 (m, 2H, 2’/6’), 7.30 (d, J = 1.2 Hz, 1H, 4), 7.23 – 
7.18 (m, 3H, 3’/4’/5’), 6.95 (q, J = 0.8 Hz, 2H, 3’’/5’’), 6.88 (d, J = 1.2 Hz, 1H, 5), 2.34 (s, 
3H, 8’’), 1.92 (s, 6H, 7’’/9’’). 
13
C NMR (101 MHz, CDCl3) δ 146.44 (2), 138.91 (4‘‘), 135.34 (2‘‘/6‘‘), 134.77 (1‘‘), 130.85 
(1‘), 129.50 (4), 129.45 (3‘‘/5‘‘), 128.41 (3‘/5‘), 128.26 (4‘), 126.83 (2‘/6‘), 122.03 (5), 21.22 






6.3 First series of complexes: 1 to 10 
6.3.1 Synthesis of Chloro-bridged dimers 
Three reactions A, B and C were made using different methodologies
55,61
. Each of them used 
two different ligands (1 equiv each). A was made using IrCl3xH2O (1 equiv), B and C were 
made using {Ir(COD)Cl}2 (0.5 equiv). 
A: IrCl3xH2O was added to a round bottomed flask containing 10 mL of a 7:3 (v/v) 
ethoxyethanol/water mixture. The solution was degassed by bubbling argon and the ligands 
were added together with 10 more mL of the ethoxyethanol/water mixture. After further 
degassing, the solution was placed under argon atmosphere and heated at 130°C overnight 
while stirring (a reflux condenser was used). 
B: [{Ir(COD)Cl}2] was weighted in a 25 mL round bottomed flask and solubilized in 2 mL of 
ethoxyethanol. The solution was degassed. The two ligands and 1 mL of ethoxyethanol were 
added. After further degassing, the flask was sealed under argon atmosphere and the mixture 
was heated at 130°C for 3h under stirring.  
C: [{Ir(COD)Cl}2] was weighted in a 25 mL round bottomed flask and solubilized in 2 mL of 
xylenes. The solution was degassed. The two ligands and 1 mL of xylenes were added. After 
further degassing, the flask was sealed under argon atmosphere and the mixture was heated at 
130°C for 3h while stirring. 
The reaction mixtures were cooled down to room temperature. Water was added to A and B 
and hexane was added to C. The three mixtures were kept in the fridge for two hours and 
filtered. The solid from reactions A and B were washed with cold MeOH. The solid from 





6.3.2 Syntheses of the acac complexes 




The dimer mixture was added to a round bottomed flask and dissolved in 20 mL of 
DCM/MeOH (9:1). AcacNa was added and the solution was degassed with argon and heated 
to reflux (40°C) under stirring and argon atmosphere overnight. 
After the reaction ended, the solvent was evaporated under vacuum and a MeOH/water 
mixture was added (the proportion was not really important but a better precipitation was 
obtained when adding more MeOH than water). The solution was cooled in the fridge for 2 
hours and filtered. The residue was washed with a minimal amount of cold MeOH. The 
residue was added to a flask by dissolving in CH2Cl2 and dried under vacuum. 
1
H NMR spectra of the four crudes were made and products of reactions A, B and C were 
purified together on a silica gel chromatography column using pure CH2Cl2. 
As the products tended to be degraded by the acidic silica, 1 mL of triethylamine was added 






6.3.3 Synthesis of [Ir(dFppy)(ppy)(acac)] (3) 
The three reactions, A, B and C were made following the general procedure with 2-
phenylpyridine (ppy, 0.1 g, 0.64 mmol, 1 equiv), 2-(2,4-difluorophenyl)pyridine (dFppy, 
0.123 g, 0.64 mmol, 1 equiv), {Ir(COD)Cl}2 (0.216 g, 0.32 mmol, 0.5 equiv) and IrCl3xH2O 
(0.227 g, 0.64 mmol, 1 equiv).  
The solids obtained were reacted separately with sodium acetylacetonate (acacNa, 0.225 g, 
1.61 mmol) following the general procedure to obtain yellow crude powders: A: 0.275 g B: 
0.255 g, C: 0.294 g. 
Once analysed, the different crude were mixed and purified all together. The product was 
purified according to the procedure and isolated as a yellow solid: 0.237 g. m/z: calc 636.0 
found 636.1207. Anal Calcd. For C27H21F2IrN2O2: C, 51.01; H, 3.33; N, 4.41. Found: C, 
50.86; H, 3.19; N, 4.55. 
1
H NMR (500 MHz, CDCl3) δ 8.51 (dd, J = 5.7, 0.8 Hz, 1H, 6b), 8.44 (dd, J = 5.7, 0.7 Hz, 
1H, 6a), 8.23 (d, J = 8.3 Hz, 1H, 3a), 7.87 (d, J = 8.1 Hz, 1H3b), 7.78 – 7.74 (m, 2H, 4a/4b), 
7.56 (dd, J = 7.8, 1.0 Hz, 1H, 2’b), 7.19 – 7.14 (m, 2H, 5a/5b), 6.86 (td, J = 7.7, 1.2 Hz, 1H, 
3’b), 6.73 (td, J = 7.4, 1.3 Hz, 1H, 4’b), 6.27 (ddd, J = 12.2, 9.3, 2.4 Hz, 1H, 3’a), 6.21 (dd, J 
= 7.6, 0.8 Hz, 1H, 5’b), 5.71 (dd, J = 9.0, 2.3 Hz, 1H, 5’a), 5.23 (s, 1H, 3c), 1.81 (s, 3H, 
1c/5c), 1.78 (s, 3H, 1c/5c). 
13
C NMR (101 MHz, CDCl3d) δ 184.99 (2c/4c), 184.92 (2c/4c) , 168.54 (2b), 152.80 (d, J = 
6.9 Hz, 1’a), 148.27 (6a/6b), 146.47 (1’b), 144.78 (6’b), 137.50 (4a/4b), 137.40 (4a/4b), 
133.05 (5’b), 129.31 (4’b), 124.06 (2’b), 122.49 (d, J = 18.8 Hz, 3a), 121.79 (5a/5b/3’b), 
121.43 (d, J = 8.8 Hz, 5a/5b/3’b), 118.78 (3b), 115.52 – 115.10 (m, 5’a), 100.66 (3c), 96.91 (t, 






F NMR (282 MHz, CDCl3) δ -109.40 (d, J = 10.1 Hz), -111.68 (d, J = 9.9 Hz). 
6.3.3.1 [Ir(ppy)2(acac)] (1) 
Anal Calcd. For C27H23IrN2O2: C, 54.08; H, 3.87; N, 4.67. Found: C, 54.36; H, 3.63; N, 4.93. 
1H NMR (400 MHz, CDCl3) δ 8.52 (ddd, J = 5.8, 1.6, 0.8 Hz, 2H, 6a), 7.84 (dt, J = 8.1, 1.1 
Hz, 2H, 3a), 7.71 (ddd, J = 8.1, 7.4, 1.6 Hz, 2H, 4a), 7.54 (dd, J = 7.7, 1.4 Hz, 2H, 2’a), 7.13 
(ddd, J = 7.3, 5.7, 1.4 Hz, 2H, 5a), 6.81 (td, J = 7.5, 1.3 Hz, 2H, 3’a), 6.69 (td, J = 7.4, 1.4 Hz, 
2H, 4’a), 6.27 (dd, J = 7.5, 1.2 Hz, 2H, 5’a), 5.22 (s, 1H, 3c), 1.79 (s, 6H, 1c/5c). 
13
C NMR (101 MHz, CDCl3) δ 184.71 (2c/4c), 168.72 (2a), 148.28 (6a), 147.72 (1’a), 144.86 
(6’a), 136.91 (4a), 133.17 (5’a), 129.21 (4’a), 123.92 (2’a), 121.52 (5a), 120.83 (3’a), 118.50 
(3a), 100.49 (3c), 28.89 (1c/5c). 
6.3.3.2  [Ir(dFppy)2(acac)] (2) 
m/z: calc 672.1012, found 672.1017. Anal Calcd. For C27H19F4IrN2O2: C, 48.28; H, 2.85; N, 
4.17. Found: C, 48.12; H, 2.84; N, 4.28. 
1
H NMR (500 MHz, CDCl3) δ 8.44 (dd, J = 5.7, 0.8 Hz, 2H, 6a), 8.25 (d, J = 8.4 Hz, 2H, 3a), 
7.79 (td, J = 8.0, 1.1 Hz, 2H, 4a), 7.19 (ddd, J = 7.2, 5.8, 1.2 Hz, 2H, 5a), 6.33 (ddd, J = 12.2, 
9.3, 2.3 Hz, 2H, 3’a), 5.65 (dd, J = 8.8, 2.3 Hz, 2H, 5’a), 5.26 (s, 1H, 3c), 1.81 (s, 6H, 1c/5c). 
13
C NMR (101 MHz, CDCl3) δ 185.16 (2c/4c), 165.49 (d, J = 6.8 Hz, 2a), 164.24 – 159.52 
(m, 2’a/4’a), 151.43 (d, J = 6.9 Hz, 1’a), 148.20 (6a), 138.00 (4a), 128.77 (6’a), 122.76 (d, J = 
19.1 Hz, 3a), 121.74 (5a), 115.23 (dd, J = 16.9, 2.5 Hz, 5’a), 100.83 (3c), 97.45 (t, J = 26.9 
Hz, 3’a), 28.81 (1c/5c). 
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6.3.4 Synthesis of [Ir(dFppz)(ppz)(acac)] (6) 
The three reactions, A, B and C were made following the general procedure with 2-
phenylpyrazole (ppz, 0.1 g, 0.69 mmol, 1 equiv), and 1-(2,4-Difluorophenyl)pyrazole (dFppz , 
0.125 g, 0.69 mmol, 1 equiv), {Ir(COD)Cl}2 (0.233 g, 0.35 mmol, 0.5 equiv) and IrCl3xH2O 
(0.245 g, 0.69 mmol, 1 equiv). 
The solids obtained were reacted separately with acacNa (0.243 g, 1.73 mmol) following the 
general procedure to obtain yellow crude powders: A: 0.284 g, B: 0.101 g, C: 0.150 g. 
The product was purified according to the procedure and obtained as a grey solid: 0.1577 g. 
m/z: calc 635.0980, found 635.0986. Anal Calcd. For C23H19F2IrN4O2: C, 45.02; H, 3.12; N, 
9.13. Found: C, 45.05; H, 3.27; N, 8.86. 
1
H NMR (500 MHz, CDCl3) δ 8.32 (d, J = 2.7 Hz, 1H, 5a), 8.05 (d, J = 2.8 Hz, 1H,5b), 7.59 
(dd, J = 3.6, 2.3 Hz, 2H, 3a/3b), 7.16 (d, J = 7.9 Hz, 1H, 2’b), 6.86 (td, J = 7.7, 1.1 Hz, 1H, 
3’b), 6.68 (td, J = 7.4, 1.0 Hz, 1H, 4’b), 6.66 – 6.63 (m, 3H, 4a/4b), 6.38 (ddd, J = 11.8, 8.9, 
2.4 Hz, 1H, 3’a), 6.20 (dd, J = 7.5, 1.0 Hz, 1H, 5’b), 5.69 (dd, J = 8.6, 2.4 Hz, 1H, 5’a), 5.24 
(s, 1H, 3c), 1.83 (s, 3H, 1c/5c), 1.81 (s, 3H, 1c/5c). 
13
C NMR (101 MHz, CDCl3) δ 185.47 (2c/4c), 185.38 (2c/4c), 159.42 (dd, J = 249.3, 10.8 
Hz, 4’a), 148.53 (dd, J = 251.1, 13.1 Hz, 2’a), 144.41 (6’b), 138.03 (3a/3b), 137.53 (3a/3b), 
134.86 (5’b), 134.46 (d, J = 5.2 Hz, 1’a), 130.37 (d, J = 14.6 Hz, 5a), 128.90 – 128.35 (m, 
6’a), 127.27 (1’b), 126.06 (5b), 125.55 (4’b), 121.98 (3’b), 116.85 (dd, J = 18.5, 2.0 Hz, 5’a), 
110.74 (2’b), 107.74 – 107.10 (m, 4a/4b), 107.04 (4a/4b), 100.33 (3c), 97.31 (dd, J = 28.1, 
23.6 Hz, 3’a), 28.48 (1c/5c), 28.40 (1c/5c). 
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6.3.4.1 [Ir(ppz)2(acac)] (4) 
m/z: calc 578.1294, found 578.1293. Anal Calcd. For C23H21IrN4O2: C, 47.82; H, 3.66; N, 
9.70. Found: C, 47.61; H, 3.67; N, 9.86. 
1
H NMR (500 MHz, CDCl3) δ 8.04 (d, J = 2.4 Hz, 2H, 5a), 7.61 (dd, J = 2.1, 0.4 Hz, 2H, 3a), 
7.13 (dd, J = 7.9, 1.0 Hz, 2H, 2’a), 6.81 (td, J = 7.7, 1.3 Hz, 2H, 3’a), 6.66 – 6.61 (m, 4H, 
4’a/4a), 6.25 (dd, J = 7.5, 1.2 Hz, 2H, 5’a), 5.22 (s, 1H, 3c), 1.81 (s, 6H, 1c/5c). 
13
C NMR (101 MHz, CDCl3) δ 185.25 (2c/4c), 144.61 (6’a), 137.90 (3a), 135.02 (5’a), 128.46 
(1’a), 125.73 (5a/4’a), 125.47 (5a/4’a), 121.42 (3’a), 110.55 (2’a), 106.76 (4a), 100.16 (3c), 
28.49 (1c/5c). 
6.3.4.2 [Ir(dFppz)2(acac)] (5) 
m/z: calc 650.0917, found 650.0912. Anal Calcd. For C23H17F4IrN4O2: C, 42.52; H, 2.64; N, 
8.62. Found: C, 42.43; H, 2.53; N, 8.80. 
1
H NMR (500 MHz, CDCl3) δ 8.33 (d, J = 2.9 Hz, 2H, 5a), 7.58 (d, J = 2.2 Hz, 2H, 3a), 6.66 
(t, 2H, 4a), 6.44 (ddd, J = 11.7, 8.9, 2.5 Hz, 2H, 3’a), 5.65 (dd, J = 8.4, 2.5 Hz, 2H, 5’a), 5.26 
(s, 1H, 3c), 1.84 (s, 6H, 1c/5c). 
13
C NMR (101 MHz, CDCl3) δ 185.64 (2c/4c), 159.41 (dd, J = 250.0, 10.7 Hz, 4’a), 148.56 
(dd, J = 251.7, 13.1 Hz, 2’a), 137.69 (3a), 133.18 (d, J = 5.9 Hz, 1’a), 130.70 (d, J = 14.7 Hz, 
5a), 128.80 – 128.38 (m, 6’a), 116.78 (dd, J = 18.9, 2.9 Hz, 5’a), 107.49 (4a), 100.52 (3c), 
97.87 (dd, J = 28.2, 23.5 Hz, 3’a), 28.37 (1c/5c). 
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6.3.5 Synthesis of [Ir(ppy)(ppz)(acac)] (7) 
The three reactions, A, B and C were made following the general procedure with ppz (0.1 g, 
0.69 mmol, 1 equiv), ppy (0.108 g, 0.69 mmol, 1 equiv), {Ir(COD)Cl}2 (0.233 g, 0.35 mmol, 
0.5 equiv) and IrCl3xH2O (0.245 g, 0.69 mmol, 1 equiv). 
The solids obtained were reacted separately with acacNa (0.243 g, 1.73 mmol) following the 
general procedure to obtain yellow crude powders: A: 0.237 g, B: 0.288 g, C: 0.164 g. 
The product was separated according to the procedure, obtained as a yellow solid: 0.0612 g. 
m/z: calc 610.1216, found 610.1248. Anal Calcd. For C25H22IrN3O2: C, 51.01; H, 3.77; N, 
7.14. Found: C, 51.09; H, 3.57; N, 7.32. 
1
H NMR (500 MHz, CDCl3) δ 8.56 (d, J = 5.7 Hz, 1H, 6a), 8.04 (d, J = 2.8 Hz, 1H, 5b), 7.83 
(d, J = 8.1 Hz, 1H, 3a), 7.72 (td, J = 7.9, 1.5 Hz, 1H, 4a), 7.59 (d, J = 2.0 Hz, 1H, 3b), 7.54 (d, 
J = 7.7 Hz, 1H, 2’a), 7.15 – 7.11 (m, 2H, 5a/2’b), 6.84 – 6.77 (m, 2H, 3’a/3’b), 6.72 (td, J = 
7.5, 1.2 Hz, 1H, 4’a), 6.65 – 6.60 (m, 2H, 4b/4’b), 6.28 (d, J = 7.6 Hz, 1H, 5’a), 6.22 (dd, J = 
7.5, 1.0 Hz, 1H, 5’b), 5.22 (s, 1H, 3c), 1.81 (s, 3H, 1c/5c), 1.79 (s, 3H, 1c/5c). 
13
C NMR (101 MHz, CDCl3) δ 185.37 (2c/4c), 184.69 (2c/4c), 169.31 (2a), 148.49 (6a), 
146.91 (1’a), 144.72 (6’a/6’b), 137.80 (3b), 137.04 (4a), 134.29 (5’a/5’b), 133.81 (5’a/5’b), 
129.42 (4’a), 129.21 (1’b), 125.65 (5b/4’b), 125.34 (5b/4’b), 123.91 (2’a), 121.50 
(5a/3’a/3’b), 121.26 (5a/3’a/3’b), 120.94 (5a/3’a/3’b), 118.50 (3a), 110.60 (2’b), 106.79 (4b), 






6.3.6 Synthesis of [Ir(dFppy)(dFppz)(acac)] (8) 
The three reactions, A, B, and C were made following the general procedure with dFppy (0.14 
g, 0.73 mmol, 1 equiv), dFppz (0.132 g, 0.73 mmol, 1 equiv), {Ir(COD)Cl}2 (0.246 g, 0.34 
mmol, 0.5 equiv) and IrCl3xH2O (0.257 g, 0.73 mmol, 1 equiv). 
The solids obtained were reacted separately with acacNa (0.256 g, 1.83 mmol) following the 
general procedure to obtain yellow crude powders: A: 0.330 g, B: 0.296 g, C: 0.264 g, . 
The product was separated according to the procedure, obtained as a yellow solid: 0.1586 g. 
m/z: calc 682.0839, found 682.0843. Anal Calcd. For C26H19F4IrN2O2: C, 45.45; H, 2.75; N, 
6.36. Found: C, 45.61; H, 2.67; N, 6.50. 
1
H NMR (500 MHz, CDCl3) δ 8.49 (dd, J = 5.7, 0.9 Hz, 1H, 6a), 8.34 (d, J = 2.9 Hz, 1H, 3b), 
8.24 (d, J = 8.3 Hz, 1H, 3a), 7.79 (td, J = 8.1, 1.2 Hz, 1H, 4a), 7.55 (d, J = 2.2 Hz, 1H, 5b), 
7.18 (ddd, J = 7.3, 5.8, 1.3 Hz, 1H, 5a), 6.66 (t, J = 2.6 Hz, 1H, 4b), 6.42 (ddd, J = 11.8, 8.9, 
2.5 Hz, 1H, 3’b), 6.34 (ddd, J = 12.3, 9.3, 2.3 Hz, 1H, 3’a), 5.68 (dd, J = 8.7, 2.4 Hz, 1H, 5’a), 
5.61 (dd, J = 8.5, 2.5 Hz, 1H, 5’b), 5.27 (s, 1H, 3c), 1.84 (s, 3H, 1c/5c), 1.83 (s, 3H, 1c/5c). 
13
C NMR (101 MHz, CDCl3) δ 185.79 (2c/4c), 185.13 (2a), 166.03 (d, J = 7.0 Hz, 
2’a/4’a/4’b), 163.18 (dd, J = 200.0, 13.5 Hz, 2’a/4’a/4’b), 161.81 – 159.39 (m, 2’a/4’a/4’b), 
159.37 (dd, J = 249.6, 10.6 Hz, 2’a/4’a/4’b), 150.39 (d, J = 6.9 Hz, 1’a), 148.66 (dd, J = 
251.7, 13.3 Hz, 2’b), 148.37 (6a), 138.14 (4a/5b), 137.64 (4a/5b), 134.12 (d, J = 4.4 Hz, 1’b), 
130.66 (d, J = 14.9 Hz, 3b), 128.95 – 128.47 (m, 6’a/6’b), 122.74 (d, J = 19.0 Hz, 3a), 121.74 
(5a), 116.47 – 115.58 (m, 5’a/5’b), 107.51 (4b), 100.68 (3c), 98.28 – 97.12 (m, 3’a/3’b), 28.59 
(d, J = 15.7 Hz, 1c/5c). 
19
F NMR (282 MHz, CDCl3) δ -108.45 (d, J = 10.2 Hz), -111.15 (d, J = 10.2 Hz), -114.81 (d, 





6.3.7 Synthesis of [Ir(dFppy)(ppz)(acac)] (9) 
The three reactions, A, B and C were made following the general procedure with ppz (0.1 g, 
0.69 mmol, 1 equiv), dFppy (0.132 g, 0.69 mmol, 1 equiv), {Ir(COD)Cl}2 (0.233 g, 0.35 
mmol, 0.5 equiv) and IrCl3xH2O (0.245 g, 0.69 mmol, 1 equiv). 
The solids obtained were reacted separately with acacNa (0.243 g, 1.73 mmol) following the 
general procedure to obtain yellow crude powders: A: 0.307 g, B: 0.247 g, C: 0. 246 g. 
The product was purified according to the procedure obtained as a yellow solid: 0.1870 g. 
m/z: calc .1153, found 625.1157. Anal Calcd. For C25H20F2IrN3O2: C, 48.07; H, 3.23 N, 6.73. 
Found: C, 48.03; H, 3.15; N, 6.73 
1
H NMR (500 MHz, CDCl3) δ 8.55 (dd, J = 5.7, 0.9 Hz, 1H, 6a), 8.22 (d, J = 8.3 Hz, 1H, 3a), 
8.06 (d, J = 2.7 Hz, 1H, 5b), 7.77 (td, J = 8.3, 1.2 Hz, 1H, 4a), 7.56 (d, J = 2.0 Hz, 1H, 3b), 
7.18 – 7.14 (m, 2H, 2’b/5a), 6.85 (td, J = 7.7, 1.3 Hz, 1H, 3’b), 6.68 – 6.64 (m, 2H, 4b/4’b), 
6.29 (ddd, J = 12.1, 9.3, 2.4 Hz, 1H, 3’a), 6.17 (dd, J = 7.5, 1.2 Hz, 1H, 5’b), 5.72 (dd, J = 
8.9, 2.4 Hz, 1H, 5’a), 5.24 (s, 1H, 3c), 1.82 (s, 3H, 1c/5c), 1.80 (s, 3H, 1c/5c). 
13
C NMR (101 MHz, CDCl3) δ 185.56 (2c/4c), 184.97 (2c/4c), 166.25 (d, J = 7.6 Hz, 2a), 
151.84 (d, J = 7.2 Hz, 1’a), 148.45 (6a), 144.55 (6’b), 137.98 (3b), 137.65 (4a), 134.14 (5’b), 
128.12 (1’b), 125.99 (5b/4’b), 125.43 (5b/4’b), 122.48 (d, J = 18.7 Hz, 3a), 121.84 (3’b), 
121.48 (5a), 115.84 (d, J = 16.8 Hz, 5’a), 110.81 (2’b), 107.08 (4b), 100.50 (3c), 97.04 (t, J = 
27.1 Hz, 3’a), 28.67 (1c/5c), 28.61 (1c/5c). 
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6.3.8 Synthesis of [Ir(dFppz)(ppy)(acac)] (10) 
The three reactions, A, B and C were made following the general procedure with ppy (0.1 g, 
0.64 mmol, 1 equiv), dFppz (0.116 g, 0.64 mmol, 1 equiv), {Ir(COD)Cl}2 (0.216 g, 0.32 
mmol, 0.5 equiv) and IrCl3xH2O (0.227 g, 0.64 mmol, 1 equiv). 
The solids obtained were reacted separately with acacNa (0.225 g, 1.61 mmol) following the 
general procedure to obtain yellow crude powders: A: 0.236 g, B: 0.150 g, C: 0.164 g. 
The product was purified according to the procedure, obtained as a yellow solid: 0.1266 g. 
m/z: 625.1153, found 625.1157. Anal Calcd. For C25H20F2IrN3O2: C, 48.07; H, 3.23; N, 6.73. 
Found: C, 48.05; H, 3.12; N, 6.65. 
1
H NMR (500 MHz, CDCl3) δ 8.50 (d, J = 5.3 Hz, 1H, 6a), 8.33 (d, J = 2.8 Hz, 1H, 5b), 7.85 
(d, J = 8.1 Hz, 1H, 3a), 7.75 (td, J = 8.0, 1.5 Hz, 1H, 4a), 7.58 (d, J = 2.1 Hz, 1H, 2’a/3b), 
7.56 (d, J = 7.7 Hz, 1H, 2’a/3b), 7.16 (ddd, J = 7.2, 5.8, 1.3 Hz, 1H, 5a), 6.88 (td, J = 7.7, 1.0 
Hz, 1H, 3’a), 6.77 (td, J = 7.5, 1.2 Hz, 1H, 4’a), 6.65 (t, J = 2.5 Hz, 1H, 4b), 6.37 (ddd, J = 
11.7, 8.9, 2.5 Hz, 1H, 3’b), 6.24 (d, J = 7.5 Hz, 1H, 5’a), 5.67 (dd, J = 8.6, 2.4 Hz, 1H, 5’b), 
5.25 (s, 1H, 3c), 1.85 (s, 3H, 1c/5c), 1.80 (s, 3H, 1c/5c). 
13
C NMR (101 MHz, CDCl3) δ 185.61 (2c/4c), 184.87 (2c/4c), 169.07 (2a), 159.39 (dd, J = 
249.3, 11.0 Hz, 4’b), 148.62 (dd, J = 250.9, 13.3 Hz, 2’b), 148.40 (6a), 145.49 (1’a/6’a), 
144.65 (1’a/6’a), 137.52 (4a/3b), 137.46 (4a/3b), 135.30 (d, J = 4.9 Hz, 1’b), 133.68 (5’a), 
130.33 (d, J = 14.9 Hz, 5b), 129.51 (4’a), 128.77 (6’b), 124.02 (2’a), 121.76 (5a/3’a), 121.49 
(5a/3’a), 118.77 (3a), 116.20 (dd, J = 18.3, 2.1 Hz, 5’b), 107.33 – 107.12 (m, 4b), 100.49 (3c), 
97.50 – 77.38 (m, 3’b), 28.78 (1c/5c), 28.52 (1c/5c). 
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6.4 Second series of complexes: 11 to 19 
6.4.1 Dimers of 14, 16 and 18 
[{Ir(COD)Cl}2] (0.222 g, 0.330 mmol, 0.5 equiv.) was weighted in a 25 mL round bottomed 
flask and solubilized in 2 mL of ethoxyethanol. The solution was degassed. The two ligands 
(0.726 mmol, 1.1 equiv.) and 1 mL of ethoxyethanol were added. After further degassing, the 
flask was sealed under argon atmosphere and the mixture was heated at 130°C for 3h under 
stirring. 
Table 6.1: Quantity of ligands used for the syntheses of 14, 16 and 18. 
 
6.4.2 Dimers of 7, 9 and 11 
IrCl3xH2O (0.233 g, 0.660 mmol, 1 equiv.) was added to a round bottomed flask containing 
10 mL of a 7:3 (v/v) ethoxyethanol/water mixture. The solution was degassed by bubbling 
argon and the ligands (0.726 mmol, 1.1 equiv.) were added together with 10 more mL of the 
ethoxyethanol/water mixture. After further degassing, the solution was placed under argon 
atmosphere and heated at 130°C overnight while stirring (a reflux condenser was used). 
Table 6.2: Quantity of ligands used for the syntheses of 15, 17 and 19. 
 
  
 14 (g) 16 (g) 18 (g) 
dFppy 0.139 0.139 0.139 
dMeOppy 0.156 - - 
dMeOMeppy - 0.166 - 
dMeOMeOppy - - 0.178 
 15 (g) 17 (g) 19 (g) 
dFppz 0.131 0.131 0.131 
dMeOppy 0.156 - - 
dMeOMeppy - 0.166 - 





6.4.3 Acac complexes 14 to 19 
The dimer mixture was added to a round bottomed flask and dissolved in 40 mL of 
DCM/MeOH (9:1). AcacNa was added and the solution was degassed with argon and heated 
to reflux (40°C) under stirring and argon atmosphere overnight. 
After the reaction ended, the solvent was evaporated under vacuum and a MeOH/water 
mixture was added (the proportion was not really important but a better precipitation was 
obtained when adding more water than MeOH). The solution was cooled in the fridge for 2 
hours and filtered. The residue was washed with a minimal amount of cold MeOH. The 
residue was added to a flask by dissolving in CH2Cl2 and dried under vacuum. 
The product was purified by column chromatography on silica gel using pure CH2Cl2 as 
eluent. As the products tended to be degraded by the acidic silica, 1 mL of triethylamine was 
added to the silica when preparing the column. 
Complexes 11, 12 and 13 were harvested as by-products of the reactions. 
6.4.4 [Ir(dMeOppy)2(acac)] (11) 
m/z: calc 743.1709, found 743.1716. Anal Calcd. For C31H31IrN2O6: C, 51.73; H, 4.34; N, 
3.89. Found: C, 50.34; H, 4.21; N, 3.81. 
1
H NMR (500 MHz, CDCl3) δ 8.53 (dt, J = 8.5, 1.2 Hz, 2H, 3a), 8.45 (ddd, J = 5.7, 1.7, 0.7 
Hz, 2H, 6a), 7.63 (ddd, J = 8.6, 7.3, 1.7 Hz, 2H, 4a), 6.98 (ddd, J = 7.3, 5.8, 1.5 Hz, 2H, 5a), 
5.96 (d, J = 2.3 Hz, 2H, 3’a), 5.39 (d, J = 2.2 Hz, 2H, 5’a), 5.19 (s, 1H, 3c), 3.86 (s, 6H, 8’a), 
3.47 (s, 6H, 10’a), 1.77 (s, 6H, 1c/5c). 
13
C NMR (101 MHz, CDCl3) δ 184.53 (2c/4c), 167.84 (2a), 160.47 (4’a), 159.40 (2’a), 152.86 
(1’a/6’a), 147.78 (6a), 136.58 (4a), 126.19 (1’a/6’a), 122.34 (3a), 119.21 (5a), 109.82 (5’a), 





6.4.5 [Ir(dMeOMeppy)2(acac)] (12) 
m/z: calc 771.7022, found 771.2023. Anal Calcd. For C33H35IrN2O6: C, 53.00; H, 4.72; N, 
3.75. Found: C, 53.39; H, 4.45; N, 3.59. 
1
H NMR (500 MHz, CDCl3) δ 8.35 (d, J = 1.9 Hz, 2H, 3a), 8.28 (d, J = 5.8 Hz, 2H, 6a), 6.84 
– 6.79 (m, 2H, 5a), 5.96 (d, J = 2.2 Hz, 2H, 3’a), 5.43 (d, J = 2.2 Hz, 2H, 5’a), 5.16 (s, 1H, 
3c), 3.87 (s, 6H, 8’a), 3.49 (s, 6H, 10’a), 2.52 (s, 6H, 7), 1.75 (s, 6H, 1c/5c). 
13
C NMR (126 MHz, CDCl3) δ 184.39 (2c/4c), 167.15 (2a), 160.21 (4‘a), 159.20 (2’a), 152.88 
(1’a/6’a), 147.81 (4a), 147.18 (6a), 126.33 (1’a/6’a), 123.01 (3a), 120.48 (5a), 110.29 (5’a), 
100.30 (3c), 91.75 (3’a), 54.92 (8’a), 54.56 (10’a), 28.91 (1c/5c), 21.79 (7a). 
6.4.6 [Ir(dMeOMeOppy)2(acac)] (13) 
m/z: calc 803.1920, found 803.1927. Anal Calcd. For C33H35IrN2O8: C, 50.82; H, 4.52; N, 
3.59. Found: C, 50.58; H, 4.36; N, 3.41. 
1
H NMR (500 MHz, CDCl3) δ 8.22 (d, J = 6.5 Hz, 2H, 6a), 8.12 (d, J = 2.8 Hz, 2H, 3a), 6.60 
(dd, J = 6.6, 2.9 Hz, 2H, 5a), 5.95 (d, J = 2.3 Hz, 2H, 3’a), 5.46 (d, J = 2.2 Hz, 2H, 5’a), 5.15 
(s, 1H, 3c), 3.96 (s, 6H, 8’a), 3.86 (s, 6H, 8a), 3.51 (s, 6H, 10’a), 1.75 (s, 6H, 1c/5c). 
13
C NMR (126 MHz, CDCl3) δ 184.34 (2c/4c), 168.69 (2a), 166.42 (4a), 160.28 (4’a), 159.25 
(2’a), 153.05 (1’a/6’a), 148.44 (6a), 126.62 (1’a/6’a), 110.47 (5’a), 107.51 (3a), 106.33 (5a), 






6.4.7 [Ir(dMeOppy)(dFppy)(acac)] (14) 
0.177 g, 0.254 mmol, yield: 38 %, m/z: calc 719.1309, found 719.1307. Anal Calcd. For 
C29H25F2IrN2O4: C, 50.06; H, 3.62; N, 4.03. Found: C, 49.74; H, 3.34; N, 4.43. 
1
H NMR (500 MHz, CDCl3) δ 8.56 (d, J = 8.4 Hz, 1H, 3a), 8.50 (dd, J = 5.7, 0.8 Hz, 1H, 6b), 
8.38 (dd, J = 5.7, 0.9 Hz, 1H, 6a), 8.22 (d, J = 8.4 Hz, 1H, 3b), 7.78 – 7.72 (m, 1H, 4b), 7.67 
(ddd, J = 8.8, 7.5, 1.7 Hz, 1H, 4a), 7.14 (ddd, J = 7.2, 5.8, 1.2 Hz, 1H, 5b), 7.02 (ddd, J = 7.2, 
5.8, 1.4 Hz, 1H, 5a), 6.32 – 6.24 (m, 1H, 3’b), 6.00 (d, J = 2.2 Hz, 1H, 3’a), 5.70 (dd, J = 9.0, 
2.3 Hz, 1H, 5’b), 5.33 (d, J = 2.2 Hz, 1H, 5’a), 5.22 (s, 1H, 3c), 3.88 (s, 3H, 8’a), 3.50 (s, 3H, 
10’a), 1.79 (s, 6H, 1c/5c). 
13
C NMR (101 MHz, CDCl3) δ 184.91 (2c/4c), 184.78 (2c/4c), 167.55 (2a), 165.76 (d, J = 7.1 
Hz, 2b), 163.20 (dd, J = 183.4, 13.0 Hz, 4’b), 160.66 (dd, J = 187.0, 12.6 Hz, 2’b), 160.57 
(4’a), 159.47 (2’a), 153.12 (d, J = 6.9 Hz, 1’b/6’b),151.15 (1’a/6’a), 148.34 (6b), 147.60 (6a), 
137.44 (4b), 137.13 (4a), 128.99 – 128.74 (m, 1’b/6’b), 125.97 (1’a/6’a), 122.69 (3a), 122.41 
(d, J = 19.1 Hz, 3b), 121.32 (5b), 119.66 (5a), 115.36 (dd, J = 16.7, 2.1 Hz, 5’b), 109.96 (5’a), 
100.63 (3c), 96.90 (t, J = 26.9 Hz, 3’b), 92.08 (3’a), 55.00 (8’a), 54.63 (10’a), 28.89 (1c/5c). 
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6.4.8 [Ir(dMeOppy)(dFppz)(acac)] (15) 
0.142 g, 0.207 mmol, yield: 31 %, m/z: calc 708.1262, found 708.1267. Anal Calcd. For 
C27H24F2IrN3O4: C, 47.54; H, 3.64; N, 6.12. Found: C, 47.36; H, 3.53; N, 6.14. 
1
H NMR (500 MHz, CDCl3) δ 8.55 (d, J = 8.5 Hz, 1H, 3a), 8.43 (dd, J = 5.7, 0.9 Hz, 1H, 6a), 
8.31 (d, J = 2.8 Hz, 1H, 5b), 7.70 – 7.64 (m, 1H, 4a), 7.57 (d, J = 2.1 Hz, 1H, 3b), 7.01 (ddd, J 
= 7.2, 5.9, 1.3 Hz, 1H, 5a), 6.63 (t, J = 2.5 Hz, 1H, 4b), 6.37 (ddd, J = 11.6, 8.9, 2.5 Hz, 1H, 
3’b), 6.01 (d, J = 2.2 Hz, 1H, 3’a), 5.66 (dd, J = 8.7, 2.3 Hz, 1H, 5’b), 5.34 (d, J = 2.2 Hz, 1H, 
5’a), 5.23 (s, 1H, 3c), 3.88 (s, 3H, 8’a), 3.56 (s, 3H, 10’a), 1.82 (s, 3H, 1c/5c), 1.81 (s, 3H, 
1c/5c). 
13
C NMR (101 MHz, CDCl3) δ 185.53 (2c/4c), 184.74 (2c/4c), 168.11 (2a), 160.81 (4’a), 
159.42 (2’a), 159.40 (dd, J = 249.3, 11.0 Hz, 4’b), 150.25 (1’a/6’a), 149.89 (d, J = 13.1 Hz, 
2’b), 147.76 (6a), 137.47 (3b), 137.25 (4a), 135.67 (d, J = 5.1 Hz, 1’b/6’b), 130.23 (d, J = 
15.0 Hz, 5b), 128.81 (1’b/6’b), 125.89 (1’a/6’a), 122.68 (3a), 119.61 (5a), 116.61 – 116.00 
(m, 5’b), 110.31 (5’a), 107.16 (4b), 100.46 (3c), 97.12 (dd, J = 28.1, 23.7 Hz, 3’b), 92.25 
(3’a), 54.98 (8’a), 54.75 (10’a), 28.75 (1c/5c), 28.58 (1c/5c). 
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6.4.9 [Ir(dMeOMeppy)(dFppy)(acac)] (16) 
0.245 g, 0.371 mmol, yield: 56 %, m/z: calc 733.1466, found 733.1465. Anal Calcd. For 
C30H27F2IrN2O4: C, 50.77; H, 3.83; N, 3.95. Found: C, 46.69; H, 3.54; N, 3.91. 
1
H NMR (500 MHz, CDCl3) δ 8.50 (dd, J = 5.7, 0.9 Hz, 1H, 6b), 8.38 (d, J = 0.6 Hz, 1H, 3a), 
8.21 (d, J = 6.0 Hz, 2H, 6a/3b), 7.76 – 7.71 (m, 1H, 4b), 7.13 (ddd, J = 7.2, 5.8, 1.2 Hz, 1H, 
5b), 6.87 (dd, J = 5.9, 1.5 Hz, 1H, 5a), 6.28 (ddd, J = 12.3, 9.3, 2.3 Hz, 1H, 3’b), 6.00 (d, J = 
2.2 Hz, 1H, 3’a), 5.74 (dd, J = 9.0, 2.3 Hz, 1H, 5’b), 5.32 (d, J = 2.3 Hz, 1H, 5’a), 5.21 (s, 1H, 
3c), 3.89 (s, 3H, 8’a), 3.49 (s, 3H, 10’a), 2.56 (s, 3H, 7a), 1.78 (s, J = 1.8 Hz, 3H, 1c/5c), 1.78 
(s, 3H, 1c/5c). 
13
C NMR (101 MHz, CDCl3) δ 184.84 (2c/4c), 184.67 (2c/4c), 166.80 (2a), 165.83 (d, J = 7.2 
Hz, 2b), 163.20 (dd, J = 183.2, 12.7 Hz, 4’b), 160.66 (dd, J = 186.7, 13.1 Hz, 2’b), 160.34 
(4’a), 159.25 (2’a), 153.40 (d, J = 7.0 Hz, 1’b/6’b), 151.06 (1’a/6’a), 148.57 (4a), 148.37 (6b), 
146.93 (6a), 137.34 (4b), 128.90 (1’b/6’b), 125.99 (1’a/6’a), 123.38 (3a), 122.35 (d, J = 19.4 
Hz, 3b), 121.28 (5b), 120.92 (5a), 115.39 (d, J = 15.9 Hz, 5’b), 110.00 (5’a), 100.56 (3c), 
96.77 (t, J = 27.0 Hz, 3’b), 92.10 (3’a), 54.99 (8’a), 54.59 (10’a), 28.89 (1c/5c), 21.83 (7a). 
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6.4.10 [Ir(dMeOMeppy)(dFppz)(acac)] (17) 
0.0948 g, 0.136 mmol, yield: 20 %, m/z: calc 722.1418, found 722.1423. Anal Calcd. For 
C28H26F2IrN3O4: C, 48.13; H, 3.75; N, 6.01. Found: C, 47.56; H, 3.77; N, 5.78. 
1
H NMR (500 MHz, CDCl3) δ 8.36 (s, 1H, 3a), 8.31 (d, J = 2.8 Hz, 1H, 5b), 8.25 (d, J = 5.9 
Hz, 1H, 6a), 7.56 (d, J = 2.1 Hz, 1H, 3b), 6.86 (dd, J = 5.9, 1.5 Hz, 1H, 5a), 6.62 (t, J = 2.5 
Hz, 1H, 4b), 6.37 (ddd, J = 11.7, 8.9, 2.5 Hz, 1H, 3’b), 6.00 (d, J = 2.2 Hz, 1H, 3’a), 5.68 (dd, 
J = 8.7, 2.3 Hz, 1H, 5’b), 5.32 (d, J = 2.2 Hz, 1H, 5’a), 5.21 (s, 1H, 3c), 3.88 (s, 3H, 8’a), 3.55 
(s, 3H, 10’a), 2.55 (s, 3H, 7a), 1.81 (s, 3H, 1c/5c), 1.80 (s, 3H, 1c/5c). 
13
C NMR (126 MHz, CDCl3) δ 185.44 (2c/4c), 184.71 (2c/4c), 167.32 (2a), 160.57 (4’a), 
159.20 (2’a), 150.10 (1’a/6’a), 148.77 (4a), 147.09 (6a), 137.48 (3b), 135.85 (1’b/6’b), 130.20 
(d, J = 15.0 Hz, 5b), 128.85 (1’b/6’b), 125.93 (1’a/6’a), 123.39 (3a), 120.92 (5a), 116.31 (d, J 
= 18.1 Hz, 5’b), 110.33 (5’a), 107.14 (4b), 100.45 (3c), 98.21 – 95.77 (m, 3’b), 92.30 (3’a), 
55.00 (8’a), 54.74 (10’a), 28.75 (1c/5c), 28.57 (1c/5c), 21.85 (7a). 
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6.4.11 [Ir(dMeOMeOppy)(dFppy)(acac)] (18) 
0.233 g, 0.321 mmol, yield: 48 %, m/z: calc 749.1415, found 749.1417. Anal Calcd. For 
C30H27F2IrN2O5: C, 49.65; H, 3.75; N, 3.86. Found: C, 49.60; H, 3.84; N, 4.14. 
1
H NMR (500 MHz, CDCl3) δ 8.51 (dd, J = 5.7, 0.9 Hz, 1H, 6b), 8.21 (d, J = 8.3 Hz, 1H, 3b), 
8.17 – 8.14 (m, 2H, 3a/6a), 7.76 – 7.71 (m, 1H, 4b), 7.13 (ddd, J = 7.2, 5.8, 1.3 Hz, 1H, 5b), 
6.65 (dd, J = 6.6, 2.8 Hz, 1H, 5a), 6.28 (ddd, J = 12.3, 9.3, 2.3 Hz, 1H, 3’b), 5.99 (d, J = 2.2 
Hz, 1H, 3’a), 5.78 (dd, J = 9.0, 2.4 Hz, 1H, 5’b), 5.31 (d, J = 2.3 Hz, 1H, 5’a), 5.21 (s, 1H, 
3c), 3.98 (s, 3H, 8a), 3.88 (s, 3H, 8’a), 3.49 (s, 3H, 10’a), 1.80 (s, 3H, 1c/5c), 1.78 (s, 3H, 
1c/5c). 
13
C NMR (126 MHz, CDCl3) δ 184.87 (2c/4c), 184.66 (2c/4c), 168.15 (2a), 166.79 (4a), 
165.96 (d, J = 6.6 Hz, 2b), 162.93 (dd, J = 230.0, 13.0 Hz, 4’b), 160.90 (dd, J = 233.7, 12.9 
Hz, 2’b), 160.40 (4’a), 159.28 (2’a), 153.35 (d, J = 6.9 Hz, 1’b/6’b), 151.02 (1’a/6’a), 148.45 
(6b), 148.14 (6a), 137.33 (4b), 129.13 – 128.85 (m, 1’b/6’b), 126.19 (1’a/6’a), 122.35 (d, J = 
18.9 Hz, 3b), 121.30 (5b), 115.48 (d, J = 16.5 Hz, 5’b), 110.05 (5’a), 107.95 (3a), 106.81 (5a), 
100.61 (3c), 96.76 (t, J = 27.0 Hz, 3’b), 92.12 (3’a), 55.49 (8a), 55.06 (8’a), 54.61 (10’a), 
28.86 (1c/5c). 
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6.4.12 [Ir(dMeOMeOppy)(dFppz)(acac)] (19) 
0.057 g, 0.080 mmol, yield; 12%, m/z: calc 738.1367, found 738.1370. Anal Calcd. For 
C28H26F2IrN3O5: C, 47.05; H, 3.67; N, 5.88. Found: C, 46.75; H, 3.71; N, 5.58. 
1
H NMR (400 MHz, CDCl3) δ 8.30 (d, J = 2.8 Hz, 1H, 5b), 8.20 (d, J = 6.6 Hz, 1H, 6a), 8.14 
(d, J = 2.9 Hz, 1H, 3a), 7.57 (d, J = 2.2 Hz, 1H, 3b), 6.64 (dd, J = 6.6, 2.9 Hz, 1H, 5a), 6.62 (t, 
J = 2.5 Hz, 1H, 4b), 6.37 (ddd, J = 11.8, 9.0, 2.5 Hz, 1H, 3’b), 5.99 (d, J = 2.3 Hz, 1H, 3’a), 
5.73 (dd, J = 8.7, 2.2 Hz, 1H, 5’b), 5.31 (d, J = 2.3 Hz, 1H, 5’a), 5.22 (s, 1H, 3c), 3.98 (s, 3H, 
8a), 3.87 (s, 3H, 8’a), 3.55 (s, 3H, 10’a), 1.81 (s, 3H, 1c/5c), 1.80 (s, 3H, 1c/5c). 
13
C NMR (101 MHz, CDCl3) δ 185.46 (2c/4c), 184.59 (2c/4c), 168.72 (2a), 166.86 (4a), 
160.63 (4’a), 159.38 (dd, J = 248.5, 10.3 Hz, 4’b), 159.23 (2’a), 150.19 (1’a/6’a), 148.60 (dd, 
J = 250.7, 13.2 Hz, 2’b), 148.30 (6a), 137.50 (3b), 135.98 (d, J = 4.9 Hz, 1’b/6’b), 130.16 (d, 
J = 14.8 Hz, 5b), 129.14 – 128.69 (m, 1’b/6’b), 126.11 (6’a), 116.83 – 116.04 (m, 5’b), 
110.42 (5’a), 107.88 (3a), 107.30 – 106.96 (m, 4b), 106.78 (5a), 100.43 (3c), 96.97 (dd, J = 
28.2, 23.8 Hz, 3’b), 92.29 (3’a), 55.50 (8a), 55.05 (8’a), 54.72 (10’a), 28.73 (1c/5c), 28.59 
(1c/5c). 
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6.5 Third series of complexes: 20 to 24 
IrCl3xH2O was added to a round bottomed flask containing 10 mL of a 7:3 (v/v) 
ethoxyethanol/water mixture. The solution was degassed by bubbling argon and the ligands 
were added together with 10 more mL of the ethoxyethanol/water mixture. After further 
degassing, the solution was placed under argon atmosphere and heated at 130°C overnight 
while stirring (a reflux condenser was used). 
Table 6.3: Quantity of reagents used for the syntheses of 20, 21, 22, 23 and 24. 
 
The acac complexes were synthesized according to the procedure described above. 
Complex 20 was obtain with good purity after a filtration on silica gel but excellent purity 
was obtained by successive crystallisation in DCM/hexane were solvent was left to evaporate 
slowly. Complex 23 was obtained with excellent purity with no other purification than the 
standard precipitation. 
Complexes 21, 22 and 24 were purified by multiple chromatography columns on silica gel 
and preparative TLC plates. 
  
ligands 
20 (g, mmol, 
eq.) 
21 (g, mmol, 
eq.) 
22 (g, mmol, 
eq.) 
23 (g, mmol, 
eq.) 
24 (g, mmol, 
eq.) 














- - - 













6.5.1.1 Ir(mespim)2(acac) (20) 
0.410 g, 0.494 mmol, yield: 75%. Anal Calcd. For C41H41IrN4O2: C, 60.50; H, 5.08; N, 6.88. 
Found: C, 60.18; H, 5.15; N, 6.53. 
1
H NMR (400 MHz, CDCl3) δ 7.23 (d, J = 1.5 Hz, 2H, 4a), 7.07 (s, 4H, 3’’a/5’’a), 6.89 (d, J 
= 1.5 Hz, 2H, 5a), 6.61 – 6.50 (m, 4H, 4’a/5’a), 6.41 (ddd, J = 7.7, 6.2, 2.2 Hz, 2H, 3’a), 6.14 
(dd, J = 7.5, 1.1 Hz, 2H, 2’a), 5.23 (s, 1H, 3c), 2.42 (s, 6H, 8’’a), 2.12 (s, 6H, 7’’a), 2.04 (s, 
6H, 9’’a), 1.82 (s, 6H, 1c/5c). 
13
C NMR (101 MHz, CDCl3) δ 184.49 (2c/4c), 157.98 (2a), 145.42 (1‘a/6’a), 139.56 (4’’a), 
136.63 (1’a/6’a/2’’a/6’’a), 136.22 (1’a/6’a/2’’a/6’’a), 135.91 (1’a/6’a/2’’a/6’’a), 134.29 (5’a), 
133.36 (1’’a), 129.60 (3’’a/5’’a), 127.73 (4’a), 126.42 (4a), 121.04 (2’a), 120.03 (3’a), 119.34 






6.5.2 Ir(mespim)(dFppy)(acac) (21) 
0.065 g, 0.087 mmol, yield: 13%. m/z: calc 766.1833, found 766.1821. Anal Calcd. For 
C34H30IrF2N3O2: C, 54.97; H, 4.07; N, 5.66. Found: C, 55.05; H, 4.36; N, 5.45. 
1
H NMR (400 MHz, CDCl3) δ 8.64 (ddd, J = 5.8, 1.7, 0.8 Hz, 1H, 6b), 8.25 – 8.21 (m, 1H, 
3b), 7.76 – 7.69 (m, 1H, 4b), 7.16 (d, J = 1.6 Hz, 1H, 4a), 7.12 (ddd, J = 7.3, 5.7, 1.4 Hz, 1H, 
5b), 7.07 (d, J = 5.5 Hz, 2H, 3’’a/5’’a), 6.91 (d, J = 1.6 Hz, 1H, 5a), 6.55 (td, J = 7.4, 1.5 Hz, 
1H, 4’a), 6.46 (td, J = 7.5, 1.3 Hz, 1H, 3’a), 6.29 (ddd, J = 12.6, 9.3, 2.4 Hz, 1H, 3’b), 6.14 
(dd, J = 7.7, 1.1 Hz, 1H, 2’a), 6.10 (ddd, J = 9.1, 4.6, 1.6 Hz, 2H, 5’a/5’b), 5.25 (s, 1H, 3c), 
2.42 (s, 3H, 8’’a), 2.12 (s, 3H, 7’’a), 2.00 (s, 3H, 9’’a), 1.85 (s, 3H1c), 1.80 (s, 3H, 5c). 
13
C NMR (101 MHz, CDCl3) δ 185.30 (2c/4c), 184.80 (2c/4c), 166.43 (d, J = 6.9 Hz, 2b), 
163.27 (dd, J = 195.0, 12.9 Hz, 4’b), 160.72 (dd, J = 199.0, 13.0 Hz, 2’b), 157.06 (2a), 153.52 
(d, J = 6.9 Hz, 1’b/6’b), 148.45 (6b), 143.42 (1’a/6’a), 139.88 (4’’a), 137.09 (4b), 136.19 
(1’a/6’a/2’’a/6’’a), 136.00 (1’a/6’a/2’’a/6’’a), 135.75 (1’a/6’a/2’’a/6’’a), 133.21 (5’a), 133.04 
(1’’a), 129.76 (3’’a/5’’a), 129.69 (3’’a/5’’a), 128.94 (1’b/6’b), 128.02 (4’a), 126.26 (4a), 
122.36 (d, J = 18.7 Hz, 3b), 121.37 (2’a/5b), 121.07 (3’a), 119.88 (5a), 116.02 – 115.60 (m, 
5’b), 100.44 (3c), 96.39 (t, J = 27.0 Hz, 3’b), 28.64 (1c/5c), 28.62 (1c/5c), 21.36 (8’’a), 17.79 
(7’’a), 17.34 (9’’a). 
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6.5.3 Ir(mespim)(dFppz)(acac) (22) 
0.133 g, 0.181 mmol, yield: 27%. m/z: calc 755.1786, found 755.1782. Anal Calcd. For 
C32H29IrF2N4O2: C, 52.52; H, 3.99; N, 7.66. Found: C, 52.34; H, 4.47; N, 7.57. 
1
H NMR (400 MHz, CDCl3) δ 8.33 (d, J = 2.9 Hz, 1H, 5b), 7.63 (d, J = 2.2 Hz, 1H, 3b), 7.16 
(d, J = 1.5 Hz, 1H, 4a), 7.07 (d, J = 3.3 Hz, 2H, 3’’a/5’’a), 6.90 (d, J = 1.6 Hz, 1H, 5a), 6.64 
(t, J = 2.6 Hz, 1H, 4b), 6.58 (td, J = 7.4, 1.5 Hz, 1H, 4’a), 6.47 (td, J = 7.5, 1.3 Hz, 1H, 3’a), 
6.37 (ddd, J = 11.8, 9.0, 2.5 Hz, 1H, 3’b), 6.14 (dd, J = 7.7, 1.3 Hz, 1H, 2’a), 6.11 (dd, J = 
7.6, 1.2 Hz, 1H, 5’a), 6.02 (dd, J = 8.8, 2.5 Hz, 1H, 5’b), 5.25 (s, 1H, 3c), 2.42 (s, 3H, 8’’a), 
2.11 (s, 3H, 7’’a), 2.00 (s, 3H, 9’’a), 1.87 (s, 3H, 1c), 1.80 (s, 3H, 5c). 
13
C NMR (101 MHz, CDCl3) δ 185.22 (2c/4c), 185.08 (2c/4c), 159.42 (dd, J = 248.6, 10.9 
Hz, 4’b), 157.67 (2a), 148.53 (dd, J = 250.8, 13.3 Hz, 2’b), 142.59 (1’a/6’a), 139.91 (4’’a), 
137.31 (3b), 136.14 (d, J = 1.8 Hz, 1’b/6’b), 136.01 (d, J = 6.3 Hz, 1’a/6’a/2’’a/6’’a), 135.71 
(1’a/6’a/2’’a/6’’a), 134.05 (5’’a), 132.95 (1’’a), 130.21 (d, J = 14.5 Hz, 5b), 129.75 
(3’’a/5’’a), 129.71 (3’’a/5’’a), 128.93 (1’b/6’b), 128.23 (4’a), 126.24 (4a), 121.33 (2’a), 
121.19 (3’a), 119.83 (5a), 116.79 (d, J = 19.7 Hz, 5’b), 107.47 – 106.83 (m, 4b), 100.27 (3c), 
96.67 (dd, J = 28.2, 23.8 Hz, 3’b), 28.53 (1c), 28.37 (5c), 21.35 (8’’a), 17.77 (7’’a), 17.38 
(9’’a). 
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6.5.3.1 Ir(CF3ppz)2(acac) (23) 
0.509 g, 0.713 mmol, yield: 84%. m/z: calc 737.0939, found 737.0944. Anal Calcd. For 
C25H19IrF6N4O2: C, 42.08; H, 2.68; N, 7.85. Found: C, 42.00; H, 2.51; N, 7.79. 
1
H NMR (400 MHz, CDCl3) δ 8.28 (s, 2H, 5a), 7.83 (s, 2H, 3a), 7.12 (dd, J = 7.9, 1.2 Hz, 2H, 
2’a), 6.83 (td, J = 7.7, 1.4 Hz, 2H, 3’a), 6.72 (td, J = 7.4, 1.3 Hz, 2H, 4’a), 6.25 (dd, J = 7.5, 
1.3 Hz, 2H, 5’a), 5.30 (s, 1H, 3c), 1.86 (s, 6H, 1c/5c). 
13
C NMR (101 MHz, CDCl3) δ 185.87 (2c/4c), 143.37 (1’a/6’a), 135.64 (q, J = 3.4 Hz, 3a), 
134.98 (5’a), 128.25 (1’a/6’a), 126.76 (4’a), 124.89 (q, J = 3.9 Hz, 5a), 122.11 (3’a), 121.83 
(q, J = 266.7 Hz, 6a), 114.65 (q, J = 39.8 Hz, 4a), 111.41 (2’a), 100.65 (3c), 28.45 (1c/5c). 
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6.5.4 Ir(mespim)(CF3ppz)(acac) (24) 
0.224 g, 0.293 mmol, yield: 20%. m/z: calc 787.1848, found 787.1851. Anal Calcd. For 
C33H30IrF3N4O2: C, 51.89; H, 3.96; N, 7.34. Found: C, 51.68; H, 3.96; N, 7.06. 
1
H NMR (400 MHz, CDCl3) δ 8.31 (s, 1H, 5b), 7.88 (s, 1H, 3b), 7.17 (dd, J = 9.4, 1.2 Hz, 2H, 
4a/2’b), 7.08 (s, 2H, 3’’a/5’’a), 6.90 (d, J = 1.6 Hz, 1H, 5a), 6.83 (td, J = 7.6, 1.4 Hz, 1H, 
3’b), 6.74 (td, J = 7.4, 1.3 Hz, 1H, 4’b), 6.62 (dd, J = 7.5, 1.4 Hz, 1H, 5’b), 6.57 (td, J = 7.4, 
1.4 Hz, 1H, 4’a), 6.45 (td, J = 7.5, 1.3 Hz, 1H, 3’a), 6.14 (td, J = 7.7, 1.2 Hz, 2H, 2’a/5’a), 
5.26 (s, 1H, 3c), 2.42 (s, 3H, 8’’a), 2.11 (s, 3H, 7’’a), 2.01 (s, 3H, 9’’a), 1.86 (s, 3H, 1c), 1.81 
(s, 3H, 5c). 
13
C NMR (101 MHz, CDCl3) δ 185.33 (2c/4c), 185.15 (2c/4c), 157.59 (2a), 143.93 (1’b/6’b), 
142.95 (1’a/6’a), 139.89 (4’’a), 136.05 (1’a/6’a/2’’a/6’’a), 135.99 (1’a/6’a/2’’a/6’’a), 135.65 
(1’a/6’a/2’’a/6’’a), 135.41 (d, J = 5.7 Hz, 3b/4’b/5’b), 133.88 (5’a), 132.97 (1’’a), 130.84 
(1’b/6’b), 129.74 (3’’a/5’’a), 129.69 (3’’a/5’’a), 128.26 (4’a), 126.28 (4a/4’b), 126.18 
(4a/4’b), 124.54 (q, J = 3.9 Hz, 5b), 122.10 (q, J = 266.7 Hz, 6b), 121.33 (2’a), 121.08 (3’b), 
121.01 (3’a), 119.67 (5a), 114.28 (q, J = 39.5 Hz, 4b), 111.10 (2’b), 100.30 (3c), 28.49 
(1c/5c), 28.44 (1c/5c), 21.34 (8’’a), 17.77 (7’’a), 17.37 (9’’a). 
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6.6 Fourth series of complexes: 3a/b and 9a/b 
6.6.1 Synthesis of [Ir(dFppy)(ppy)(MeCN)2][PF6] (3MeCN) 
In a 50 mL RB flask, complex 3 (0.050 g, 0.078 mmol) was dissolved in dry MeCN (10 mL) 
and the mixture was deaerated by bubbling argon for 15 minutes. The flask was sealed under 
argon atmosphere, BF3 (0.1 mL) was added and the mixture was stirred at RT for 1 hour. The 
flask was open and an aqueous solution of KPF6 (30 mL) was added carefully to the solution 
under vigorous stirring. The mixture was stirred for an additional half hour and the MeCN 
was slowly evaporated under vacuum until a yellow precipitate formed. The flask was left in 
the fridge for 2 hours and the precipitate was filtered and washed with water to remove the 
excess KPF6. The yellow product was dried on the filter under vacuum and dissolved and 
removed from the filter by dissolution in DCM. The DCM was evaporated under vacuum and 
product was harvested as a yellow solid (0.055 g, 0.072 mmol, yield: 92%) 
1
H NMR (400 MHz, CD3CN) δ 9.15 (ddd, J = 5.7, 1.6, 0.8 Hz, 1H), 9.05 (ddd, J = 5.9, 1.4, 
0.9 Hz, 1H), 8.32 (dt, J = 8.4, 2.2 Hz, 1H), 8.14 – 8.02 (m, 3H), 7.68 (dd, J = 7.7, 1.3 Hz, 1H), 
7.53 – 7.43 (m, 2H), 6.94 (td, J = 7.6, 1.2 Hz, 1H), 6.78 (td, J = 7.5, 1.4 Hz, 1H), 6.51 (ddd, J 







6.6.2 Synthesis of [Ir(dFppy)(ppy)(pic)] (3a & 3b) 
In a 250 mL RB flask, 3MeCN (0.3 g, 0.393 mmol, 1 equiv.) was dissolved in 50 mL of 
DCM and the mixture was deaerated by bubbling argon for 15 minutes. TBAOHx30H2O (0.8 
g, 1 mmol, 2.5 equiv.) was added. Picolinic acid (0.074 g, 0.6 mmol, 1.5 equiv.) was added 
and the mixture heated to reflux overnight under argon atmosphere. 
The heating was stopped and the solvent was evaporated to dryness. The solid was suspended 
in 30 mL of MeOH, precipitated with water (100 mL) and left in the fridge for 2 hours. The 
precipitate was filtered and washed with water (200 mL) and freezer cold MeOH (20 mL). 
The isomers mixture was dried and harvested as a yellow solid (0.1819 g, 0.276 mmol, yield: 
70%). 
The diastereomers were separated by preparative HPLC. 0.5 mL of a MeCN solution of the 3a 
& 3b mixture (10mg/mL, 0.015 M) was injected in the column and eluted at RT with a 
MeCN/water (40/60) mixture. Four injections were made per method (one every 20 minutes) 
and the method was repeated. The products were harvested in the middle of the two peaks. 
Because the peaks are not well separated, a second round of purification was necessary to 






6.6.3  [Ir(dFppy)(ppy)(pic)] (3a) 
0.077 g, 0.119 mmol, yield: 30%, m/z: calc 682.0894, found 682.0884. Anal Calcd. For 
C28H18F2IrN3O2: C, 51.06; H, 2.75; N, 6.38. Found: C, 50.97; H, 2.95; N, 6.34. 
1
H NMR (400 MHz, CDCl3) δ 8.74 – 8.71 (m, 1H, 6b), 8.33 (dt, J = 8.2, 1.0 Hz, 1H, 3c), 8.27 
(dt, J = 7.5, 1.4 Hz, 1H, 3a), 7.90 (td, J = 7.7, 1.6 Hz, 1H, 4c), 7.86 (dt, J = 8.2, 1.0 Hz, 1H, 
3b), 7.79 – 7.69 (m, 3H, 4a/4b/6c), 7.64 (dd, J = 7.8, 1.3 Hz, 1H, 2’b), 7.48 (dd, J = 5.8, 0.9 
Hz, 1H, 6a), 7.34 (ddd, J = 7.3, 5.3, 1.4 Hz, 1H, 5c), 7.16 (ddd, J = 7.1, 5.8, 1.3 Hz, 1H, 5b), 
6.99 (td, J = 7.5, 1.2 Hz, 1H, 3’b), 6.94 (ddd, J = 7.3, 5.8, 1.4 Hz, 1H, 5a), 6.85 (td, J = 7.4, 
1.4 Hz, 1H, 4’b), 6.40 – 6.30 (m, 2H, 5’b/3’a), 5.63 (dd, J = 8.9, 2.4 Hz, 1H, 5’a). 
13
C NMR (101 MHz, CDCl3) δ 172.84 (7c), 167.54 (2b), 166.15 (d, J = 7.0 Hz, 2a), 163.61 
(dd, J = 194.0, 12.9 Hz, 4’a), 161.05 (dd, J = 197.6, 12.5 Hz, 2’a), 154.15 (d, J = 6.7 Hz, 
1’a/6’a), 152.14 (2c), 148.92 (6b), 148.41 (6c), 148.17 (6a), 146.43 (1’b/6’b), 144.06 
(1’b/6’b), 138.05 (4a/4b/4c), 137.89 (4a/4b/4c), 137.75 (4a/4b/4c), 132.58 (5’b), 130.31 (4’b), 
128.51 (3c), 128.24 (5c), 124.68 (2’b), 123.21 (d, J = 20.0 Hz, 3a), 122.66 (5b), 122.12 (5a), 
121.79 (3’b), 118.88 (3’b), 114.57 (dd, J = 17.2, 2.6 Hz, 5’a), 97.73 (t, J = 26.9 Hz, 3’a). 
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6.6.4 [Ir(dFppy)(ppy)(pic)] (3b) 
0.047 g, 0.073 mmol, yield: 19%, m/z: calc 682.0894, found 682.0884. Anal Calcd. For 
C28H18F2IrN3O2: C, 51.06; H, 2.75; N, 6.38. Found: C, 51.46; H, 3.29; N, 6.25. 
1
H NMR (400 MHz, CDCl3) δ 8.80 (ddd, J = 5.8, 1.7, 0.8 Hz, 1H, 6a), 8.33 (ddd, J = 7.8, 1.5, 
0.8 Hz, 1H, 3c), 8.22 (dd, J = 8.4, 1.8 Hz, 1H, 3a), 7.96 – 7.88 (m, 2H, 3’b/4c), 7.81 (ddd, J = 
5.3, 1.6, 0.8 Hz, 1H, 6c), 7.79 – 7.69 (m, 2H, 4a/4b), 7.60 (dd, J = 7.8, 1.4 Hz, 1H, 2’b), 7.44 
– 7.38 (m, 2H, 6b/5c), 7.15 (ddd, J = 7.3, 5.8, 1.4 Hz, 1H, 5a), 6.97 – 6.88 (m, 2H, 5b/3’b), 
6.79 (td, J = 7.5, 1.4 Hz, 1H, 4’b), 6.42 (ddd, J = 12.5, 9.2, 2.4 Hz, 1H, 3’a), 6.12 (dd, J = 7.6, 
1.2 Hz, 1H, 5’b), 5.87 (dd, J = 8.9, 2.4 Hz, 1H, 5’a). 
13
C NMR (101 MHz, CDCl3) δ 172.95 (7c), 169.16 (2b), 164.68 (d, J = 6.5 Hz, 2a), 163.76 
(dd, J = 221.1, 13.2 Hz, 4’a), 161.20 (dd, J = 224.4, 13.1 Hz, 2’a), 152.60 (d, J = 6.9 Hz, 
1’a/6’a), 152.11 (2c), 149.06 (6a), 148.47 (6c), 148.02 (6b), 147.85 (1’b/6’b), 144.24 
(1’b/6’b), 138.08 (4c), 137.83 (4a/4b), 137.77 (4a/4b), 132.47 (5’b), 129.86 (4’b), 128.54 
(3c), 128.32 (5c), 124.39 (2’b), 122.58 (d, J = 18.7 Hz, 3a), 122.46 – 122.17 (m, 5a/5b/3’b), 
119.49 (3b), 114.74 (d, J = 16.4 Hz, 5’a), 97.27 (t, J = 26.9 Hz, 3’a). 
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6.6.5 Synthesis of [Ir(dFppy)(ppz)(MeCN)2][PF6] (9MeCN) 
In a 250 mL RB flask, complex 9 (0.254 g, 0.407 mmol) was dissolved in dry MeCN (50 mL) 
and the mixture was deaerated by bubbling argon for 15 minutes. The flask was sealed under 
argon atmosphere, BF3 (1 mL) was added and the mixture was stirred at RT for 1 hour. The 
flask was open and an aqueous solution of KPF6 (100 mL) was added carefully to the solution 
under vigorous stirring. The mixture was stirred for an additional half hour and the MeCN 
was slowly evaporated under vacuum until a yellow precipitate formed. The flask was left in 
the fridge for 2 hours and the precipitate was filtered and washed with water to remove the 
excess KPF6. The yellow product was dried on the filter under vacuum and dissolved and 
removed from the filter by dissolution in DCM. The DCM was evaporated under vacuum and 
the product was harvested as a yellow solid (0.366 g, 0.486 mmol, yield: quantitative) 
1
H NMR (400 MHz, CD3CN) δ 9.14 (ddd, J = 5.8, 1.6, 0.8 Hz, 1H), 8.44 (dd, J = 2.9, 0.6 Hz, 
1H), 8.31 (dt, J = 8.4, 2.2 Hz, 1H), 8.15 (dd, J = 2.3, 0.6 Hz, 1H), 8.12 – 8.06 (m, 1H), 7.49 
(ddd, J = 7.4, 5.8, 1.4 Hz, 1H), 7.39 (dd, J = 7.9, 1.2 Hz, 1H), 7.01 – 6.91 (m, 1H), 6.89 (dd, J 
= 2.9, 2.3 Hz, 1H), 6.70 (td, J = 7.5, 1.2 Hz, 1H), 6.53 (ddd, J = 12.7, 9.4, 2.4 Hz, 1H), 6.02 






6.6.6 Synthesis of [Ir(dFppy)(ppz)(pic)] (9a & 9b) 
In a 250 mL RB flask, 9MeCN (0.1 g, 0.133 mmol, 1 equiv.) was dissolved in 50 mL of 
DCM and the mixture was deaerated by bubbling argon for 15 minutes. TBAOHx30H2O 
(0.266 g, 0.332 mmol, 2.5 equiv.) was added. Picolinic acid (0.025 g, 0.12 mmol, 1.5 equiv.) 
was added and the mixture heated to reflux overnight under argon atmosphere. 
The heating was stopped and the solvent was evaporated to dryness. The solid was suspended 
in 30 mL of MeOH, precipitated with water (100 mL) and left in the fridge for 2 hours. The 
precipitate was filtered and washed with water (200 mL) and freezer cold MeOH (20 mL). 
The diastereomer mixture was dried and harvested as a yellow solid (0.094 g, 0.145 mmol, 
yield: quantitative). 
The diastereomers were separated by preparative HPLC. 0.5 mL of a MeCN solution of the 9a 
& 9b mixture (10mg/mL, 0.015 M) was injected in the column and eluted at RT with a 
MeCN/water (45/55) mixture. Up to twelve injections were made per method (one every 10 






6.6.7 [Ir(dFppy)(ppz)(pic)] (9a) 
0.035 g, 0.054 mmol, yield: 41%, m/z: calc 671.0846, found 671.0833. Anal Calcd. For 
C26H17F2IrN4O2: C, 48.22; H, 2.65; N, 8.65. Found: C, 46.57; H, 2.72; N, 7.96. 
1
H NMR (400 MHz, CDCl3) δ 8.34 (dd, J = 7.9, 1.0 Hz, 1H, 3c), 8.25 (dd, J = 8.6, 1.6 Hz, 
1H, 3a), 8.07 (d, J = 2.6 Hz, 1H, 5b), 7.93 (td, J = 7.7, 1.6 Hz, 1H, 4c), 7.83 (dd, J = 5.3, 0.8 
Hz, 1H, 6c), 7.79 – 7.70 (m, 2H, 4a/3b), 7.56 (dd, J = 5.9, 0.9 Hz, 1H, 6a), 7.37 (ddd, J = 7.0, 
5.3, 1.4 Hz, 1H, 5c), 7.24 (dd, J = 8.0, 1.0 Hz, 1H, 2’b), 6.98 (td, J = 7.7, 1.3 Hz, 1H, 3’b), 
6.94 (ddd, J = 7.3, 5.8, 1.4 Hz, 1H, 5a), 6.78 (td, J = 7.5, 1.2 Hz, 1H, 4’b), 6.63 – 6.57 (m, 1H, 
4b), 6.41 – 6.29 (m, 2H, 3’a/5’b), 5.68 (dd, J = 8.8, 2.4 Hz, 1H, 5’a). 
13
C NMR (101 MHz, CDCl3) δ 173.02 (7c), 166.61 (d, J = 6.3 Hz, 2a), 163.61 (dd, J = 212.7, 
12.9 Hz, 4’a), 161.06 (dd, J = 216.2, 12.7 Hz, 2’a), 153.30 (d, J = 6.7 Hz, 1’a/6’a), 152.20 
(2c), 148.51 (6a), 148.06 (6c), 143.74 (1’b/6’b), 138.24 (4c), 138.00 (4a/3b), 137.97 (4a/3b), 
133.70 (5’b), 128.57 (3c), 128.24 (1’b/6’b), 128.13 (5c), 126.29 (5b/4’b), 123.15 (d, J = 19.9 
Hz, 3a), 122.33 (3’b), 122.04 (5a), 115.18 (dd, J = 17.3, 2.4 Hz, 5’a), 111.38 (2’b), 107.88 
(4b), 97.84 (t, J = 27.0 Hz, 3’a). 
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6.6.8 [Ir(dFppy)(ppz)(pic)] (9b) 
0.041 g, 0.063 mmol, yield: 48%, m/z: calc 671.0846, found 671.0833. Anal Calcd. For 
C26H17F2IrN4O2: C, 48.22; H, 2.65; N, 8.65. Found: C, 48.16; H, 2.70; N, 8.57. 
1
H NMR (400 MHz, CDCl3) δ 8.88 (dd, J = 5.8, 0.9 Hz, 1H, 6a), 8.32 (dt, J = 7.7, 1.1 Hz, 1H, 
3c), 8.21 (d, J = 8.3 Hz, 1H, 3a), 8.08 (d, J = 2.8 Hz, 1H, 5b), 7.92 (td, J = 7.7, 1.6 Hz, 1H, 
4c), 7.87 (d, J = 5.4 Hz, 1H, 6c), 7.80 – 7.71 (m, 1H, 4a), 7.38 (ddd, J = 7.4, 5.3, 1.5 Hz, 1H, 
5c), 7.24 – 7.12 (m, 2H, 5a/2’b), 6.91 (td, J = 7.7, 1.4 Hz, 1H, 3’b), 6.76 – 6.66 (m, 2H, 
4’b/3b), 6.51 (t, J = 2.5 Hz, 1H, 4b), 6.43 (ddd, J = 12.1, 9.2, 2.4 Hz, 1H, 3’a), 6.12 (dd, J = 
7.5, 1.1 Hz, 1H, 5’b), 5.87 (dd, J = 8.8, 2.4 Hz, 1H, 5’a). 
13
C NMR (101 MHz, CDCl3) δ 173.02 (7c), 165.13 (d, J = 7.0 Hz, 2a), 163.74 (dd, J = 234.1, 
13.0 Hz, 4’a), 161.18 (dd, J = 237.4, 12.7 Hz, 2’a), 152.64 (2c), 151.72 (d, J = 7.1 Hz, 
1’a/6’a), 149.46 (6a), 149.26 (6c), 143.74 (1’b/6’b), 138.02 (4c), 137.89 (4a), 137.08 (3b), 
133.60 (5’b), 130.27 (1’b/6’b), 128.18 (3c), 127.84 (5c), 126.49 (5b), 125.93 (4’b), 122.72 
(3’b), 122.55 (d, J = 18.8 Hz, 3a), 122.23 (5a), 115.03 (dd, J = 17.0, 2.3 Hz, 5’a), 111.23 
(2’b), 107.79 (4b), 97.44 (t, J = 26.8 Hz, 3’a). 
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6.7 Screening experiments 
The emission spectra were measured on a BMG LABTECH CLARIOstar microplate reader. 
A chloro-bridged dimer or a bis-MeCN complex was weighted and transferred to a volumetric 
flask and dissolved in DCM. Each ligand was weighted in a 28 mL vial and dissolved in 15 
mL of DCM. A solution of TBAOH was also prepared in a 100 mL volumetric flask. 
In a 3 mL vial, 1mL of the dimer/bis-MeCN complex was added together with 1mL of the 
ligand solution and 1mL of DCM or of the TBAOH solution (depending on the ligand 
properties). The vial was close, shaked vigorously for a few seconds and left overnight at 
room temperature and protected from light. 
The reaction solutions were then transferred to their corresponding microplate well and left to 






7 ABBREVIATION LIST 
acac acetylacetonate 







CIE commission internationale de l’éclairage 
COD cyclooctadiene 
COSY COrrelated SpectroscopY 
DCM dichloromethane, CH2Cl2 
dFppy 2-(2,4-difluorophenyl)pyridine 
dFppz 1-(2,4-difluorophenyl) pyrazole 
DFT density functional theory 
















HOMO highest occupied molecular orbital 
H2BC Heteronuclear 2 Bond Correlation 
HMBC Heteronuclear Multiple Bond Correlation 
HPLC High Pressure Liquid Chromatography 
HSQC Heteronuclear Single Quantum Correlation 
ISC inter-system crossing 
ITO Indium Tin Oxide 
LC ligand centred 
LEC/LEEC light emitting electrochemical cell 
LUMO lowest unoccupied molecular orbital 
MC metal centred 




MLCT metal to ligand charge transfer 
nm nanometer 
NMR Nuclear Magnetic Resonance 
NOESY Nuclear Overhauser Effect SpectroscopY 












Rf retention factor (for TLC) 
RT room temperature 
s second 
SOC spin-orbit coupling 
TBA Tetrabutylammonium 
TD-DFT time-dependent density functional theory 
TFA 2,2,2-trifluoroacetic acid 
OTf Triflate 
TPD N,N′-Bis(3-methylphenyl)-N,N′-diphenylbenzidine  
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9 SUPPORTING INFORMATION 
9.1 SCREENING LIGANDS 
 





9.2 CRYSTALLOGRAPHIC DATA 
9.2.1 1st series 
Table 9.1: Crystal data and structure refinement for [Ir(dFppz)(ppz)(acac)] (6). 
  
Empirical formula C25D2Cl6F2H19IrN4O2 
Formula weight 854.38 
Temperature/K 100.01(10) 
Crystal system triclinic 




















 0.2387 × 0.1552 × 0.1321 
Radiation CuKα (λ = 1.5418) 
2Θ range for data collection/° 5.714 to 140.116 
Index ranges -11 ≤ h ≤ 11, -12 ≤ k ≤ 11, -12 ≤ l ≤ 18 
Reflections collected 10147 





Final R indexes [I>=2σ (I)] R1 = 0.0253, wR2 = 0.0644 
Final R indexes [all data] R1 = 0.0258, wR2 = 0.0649 







Table 9.2: Crystal data and structure refinement for [Ir(ppy)(ppz)(acac)] (7) 
 
  
Empirical formula C25H22IrN3O2 
Formula weight 588.65 
Temperature/K 100.01(10) 
Crystal system monoclinic 




















 0.1511 × 0.111 × 0.0671 
Radiation CuKα (λ = 1.54184) 
2Θ range for data collection/° 9 to 140.114 
Index ranges -12 ≤ h ≤ 8, -21 ≤ k ≤ 20, -14 ≤ l ≤ 12 
Reflections collected 8569 





Final R indexes [I>=2σ (I)] R1 = 0.0284, wR2 = 0.0664 
Final R indexes [all data] R1 = 0.0373, wR2 = 0.0726 







Table 9.3: Crystal data and structure refinement for [Ir(dFppy)(dFppz)(acac)] (8) 
 
  
Empirical formula C25H18F4IrN3O2 
Formula weight 660.62 
Temperature/K 100.01(10) 
Crystal system orthorhombic 




















 0.2052 × 0.1163 × 0.1047 
Radiation CuKα (λ = 1.54184) 
2Θ range for data collection/° 9.31 to 140.126 
Index ranges -12 ≤ h ≤ 19, -12 ≤ k ≤ 18, -21 ≤ l ≤ 19 
Reflections collected 11194 





Final R indexes [I>=2σ (I)] R1 = 0.0259, wR2 = 0.0601 
Final R indexes [all data] R1 = 0.0309, wR2 = 0.0631 







Table 9.4: Crystal data and structure refinement for [Ir(dFppy)(ppz)(acac)] (9) 
 
  
Empirical formula C25H20F2IrN3O2 
Formula weight 624.64 
Temperature/K 100.00(10) 
Wavelength/Å 1.5418 
Crystal system Monoclinic 
Space group P 21/n 





















 0.2169 x 0.1295 x 0.0714 
Theta range for data collection/° 4.476 to 74.320 
Index ranges -12<=h<=11, -11<=k<=21, -14<=l<=8 
Reflections collected 7159 
Independent reflections 4182 [R(int) = 0.0168] 
Completeness to theta = 67.684° 98.3 % 
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 1.00000 and 0.55430 
Refinement method Full-matrix least-squares on F
2
 




Final R indices [I>2sigma(I)] R1 = 0.0217, wR2 = 0.0572 
R indices (all data) R1 = 0.0240, wR2 = 0.0593 
Extinction coefficient n/a 
Largest diff. peak and hole/ e.Å
-3





Table 9.5: Crystal data and structure refinement for [Ir(dFppz)(ppy)(acac)] (10) 
 
  
Empirical formula C25H20F2IrN3O2 
Formula weight 624.64 
Temperature/K 99.99(10) 
Crystal system orthorhombic 




















 0.2411 × 0.0477 × 0.0362 
Radiation CuKα (λ = 1.54184) 
2Θ range for data collection/° 7.418 to 147.384 
Index ranges -9 ≤ h ≤ 8, -29 ≤ k ≤ 27, -20 ≤ l ≤ 30 
Reflections collected 14339 





Final R indexes [I>=2σ (I)] R1 = 0.0538, wR2 = 0.1326 
Final R indexes [all data] R1 = 0.0559, wR2 = 0.1340 
Largest diff. peak/hole / e Å
-3
 1.90/-1.82 





9.2.2 2nd series 
Table 9.6: Crystal data and structure refinement for [Ir(dMeOppy)2(acac)] (11). 
  
Empirical formula C31H31IrN2O6 
Formula weight 719.78 
Temperature/K 100.00(10) 
Crystal system monoclinic 




















 0.2591 × 0.1087 × 0.0996 
Radiation MoKα (λ = 0.71073) 
2Θ range for data collection/° 6.014 to 52.74 
Index ranges -24 ≤ h ≤ 19, -12 ≤ k ≤ 12, -17 ≤ l ≤ 15 
Reflections collected 7728 





Final R indexes [I>=2σ (I)] R1 = 0.0222, wR2 = 0.0407 
Final R indexes [all data] R1 = 0.0263, wR2 = 0.0425 







Table 9.7: Crystal data and structure refinement for [Ir(dMeOMeppy)2(acac)] (12). 
  
Empirical formula C33H35IrN2O6 
Formula weight 747.83 
Temperature/K 100.00(10) 
Crystal system monoclinic 


















Crystal size/mm3 0.2759 × 0.0459 × 0.0229 
Radiation MoKα (λ = 0.71073) 
2Θ range for data collection/° 4.842 to 52.74 
Index ranges -9 ≤ h ≤ 10, -39 ≤ k ≤ 42, -11 ≤ l ≤ 13 
Reflections collected 16260 





Final R indexes [I>=2σ (I)] R1 = 0.0293, wR2 = 0.0470 
Final R indexes [all data] R1 = 0.0412, wR2 = 0.0487 







Table 9.8: Crystal data and structure refinement for [Ir(dMeOMeOppy)2(acac)] (13). 
  
Empirical formula C34H37Cl2IrN2O8 
Formula weight 864.75 
Temperature/K 100.01(10) 
Crystal system monoclinic 


















Crystal size/mm3 0.2969 × 0.1458 × 0.0785 
Radiation MoKα (λ = 0.71073) 
2Θ range for data collection/° 4.508 to 51.358 
Index ranges -17 ≤ h ≤ 14, -15 ≤ k ≤ 14, -18 ≤ l ≤ 22 
Reflections collected 13657 





Final R indexes [I>=2σ (I)] R1 = 0.0234, wR2 = 0.0525 
Final R indexes [all data] R1 = 0.0274, wR2 = 0.0548 







Table 9.9: Crystal data and structure refinement for [Ir(dMeOppy)(diFppy)(acac)] (14). 
  
Empirical formula C29H25F2IrN2O4 
Formula weight 695.71 
Temperature/K 99.98(12) 
Crystal system triclinic 




















 0.1736 × 0.1286 × 0.0272 
Radiation CuKα (λ = 1.54184) 
2Θ range for data collection/° 13.01 to 140.146 
Index ranges -14 ≤ h ≤ 14, -17 ≤ k ≤ 15, -18 ≤ l ≤ 19 
Reflections collected 17965 





Final R indexes [I>=2σ (I)] R1 = 0.0508, wR2 = 0.1289 
Final R indexes [all data] R1 = 0.0573, wR2 = 0.1352 







Table 9.10: Crystal data and structure refinement for [Ir(dMeOppy)(diFppz)(acac)] (15). 
  
Empirical formula  C27H24F2IrN3O4  
Formula weight  684.69  
Temperature/K  100.00(10)  
Crystal system  triclinic  
Space group  P-1  
a/Å  9.4448(3)  
b/Å  10.1096(4)  
c/Å  13.2912(5)  
α/°  99.958(3)  
β/°  90.087(3)  
γ/°  99.701(3)  
Volume/Å
3
  1231.46(8)  
Z  2  
ρcalcg/cm
3
  1.847  
μ/mm
-1
  5.476  
F(000)  668.0  
Crystal size/mm
3
  0.3229 × 0.2029 × 0.1067  
Radiation  MoKα (λ = 0.71073)  
2Θ range for data collection/°  5.292 to 50.688  
Index ranges  -10 ≤ h ≤ 11, -12 ≤ k ≤ 12, -16 ≤ l ≤ 14  
Reflections collected  9281  
Independent reflections  4500 [Rint = 0.0294, Rsigma = 0.0461]  
Data/restraints/parameters  4500/12/338  
Goodness-of-fit on F
2
  1.062  
Final R indexes [I>=2σ (I)]  R1 = 0.0272, wR2 = 0.0600  
Final R indexes [all data]  R1 = 0.0336, wR2 = 0.0631  
Largest diff. peak/hole / e Å
-3





Table 9.11: Crystal data and structure refinement for [Ir(dMeOMeppy)(diFppy)(acac)] (16). 
  
Empirical formula C30H27F2IrN2O4 
Formula weight 709.73 
Temperature/K 100.00(10) 
Crystal system orthorhombic 




















 0.3316 × 0.0805 × 0.0406 
Radiation MoKα (λ = 0.71073) 
2Θ range for data collection/° 4.808 to 52.742 
Index ranges -23 ≤ h ≤ 20, -10 ≤ k ≤ 10, -41 ≤ l ≤ 42 
Reflections collected 29221 





Final R indexes [I>=2σ (I)] R1 = 0.0225, wR2 = 0.0432 
Final R indexes [all data] R1 = 0.0249, wR2 = 0.0443 
Largest diff. peak/hole / e Å
-3
 0.97/-0.56 





Table 9.12: Crystal data and structure refinement for [Ir(dMeOMeppy)(diFppz)(acac)] (17). 
  
Empirical formula C28H26F2IrN3O4 
Formula weight 698.72 
Temperature/K 100.00(10) 
Crystal system triclinic 




















 0.1804 × 0.1347 × 0.0665 
Radiation MoKα (λ = 0.71073) 
2Θ range for data collection/° 4.19 to 50.7 
Index ranges -11 ≤ h ≤ 11, -12 ≤ k ≤ 12, -16 ≤ l ≤ 16 
Reflections collected 18611 





Final R indexes [I>=2σ (I)] R1 = 0.0198, wR2 = 0.0403 
Final R indexes [all data] R1 = 0.0240, wR2 = 0.0421 







Table 9.13: Crystal data and structure refinement for [Ir(dMeOMeOppy)(diFppy)(acac)] (18). 
  
Empirical formula C30H27N2O5F2Ir 
Formula weight 725.73 
Temperature/K 100.01(10) 
Crystal system monoclinic 




















 0.2671 × 0.0786 × 0.0554 
Radiation MoKα (λ = 0.71073) 
2Θ range for data collection/° 5.834 to 52.744 
Index ranges -20 ≤ h ≤ 20, -10 ≤ k ≤ 10, -23 ≤ l ≤ 23 
Reflections collected 52018 





Final R indexes [I>=2σ (I)] R1 = 0.0170, wR2 = 0.0368 
Final R indexes [all data] R1 = 0.0205, wR2 = 0.0384 







Table 9.14: Crystal data and structure refinement for [Ir(dMeOMeOppy)(diFppz)(acac)] (19). 
  
Empirical formula C28H26F2IrN3O5 
Formula weight 714.72 
Temperature/K 99.9(7) 
Crystal system triclinic 




















 0.2416 × 0.1891 × 0.1057 
Radiation MoKα (λ = 0.71073) 
2Θ range for data collection/° 4.652 to 51.362 
Index ranges -11 ≤ h ≤ 11, -20 ≤ k ≤ 20, -20 ≤ l ≤ 20 
Reflections collected 101892 





Final R indexes [I>=2σ (I)] R1 = 0.0204, wR2 = 0.0501 
Final R indexes [all data] R1 = 0.0227, wR2 = 0.0515 







9.2.3 3rd series 
Table 9.15: Crystal data and structure refinement for [Ir(mespim)2(acac)] (20). 
  
Empirical formula C41H42.4IrN4O2.7 
Formula weight 826.59 
Temperature/K 99.98(10) 
Crystal system monoclinic 




















 0.3506 × 0.1365 × 0.1007 
Radiation MoKα (λ = 0.71073) 
2Θ range for data collection/° 5.896 to 52.744 
Index ranges -18 ≤ h ≤ 14, -34 ≤ k ≤ 34, -23 ≤ l ≤ 23 
Reflections collected 18652 





Final R indexes [I>=2σ (I)] R1 = 0.0220, wR2 = 0.0421 
Final R indexes [all data] R1 = 0.0291, wR2 = 0.0456 







Table 9.16: Crystal data and structure refinement for [Ir(mespim)(dFppy)(acac)] (21). 
  
Empirical formula  C34H28.5F2IrN3O2  
Formula weight  741.30  
Temperature/K  100.0(3)  
Crystal system  monoclinic  
Space group  P21/n  
a/Å  15.5700(18)  
b/Å  18.6452(9)  
c/Å  25.550(3)  
α/°  90  
β/°  128.108(19)  
γ/°  90  
Volume/Å
3
  5836.3(16)  
Z  8  
ρcalcg/cm
3
  1.687  
μ/mm
-1
  9.266  
F(000)  2916.0  
Crystal size/mm
3
  0.2098 × 0.133 × 0.024  
Radiation  CuKα (λ = 1.54184)  
2Θ range for data collection/°  5.676 to 140.148  
Index ranges  -13 ≤ h ≤ 18, -12 ≤ k ≤ 22, -31 ≤ l ≤ 30  
Reflections collected  22663  
Independent reflections  11032 [Rint = 0.0524, Rsigma = 0.0526]  
Data/restraints/parameters  11032/0/347  
Goodness-of-fit on F
2
  2.067  
Final R indexes [I>=2σ (I)]  R1 = 0.1693, wR2 = 0.4282  
Final R indexes [all data]  R1 = 0.1945, wR2 = 0.4777  
Largest diff. peak/hole / e Å
-3





Table 9.17: Crystal data and structure refinement for [Ir(CF3ppz)2(acac)] (23). 
  
Empirical formula  C26H21Cl2F6IrN4O2  
Formula weight  798.57  
Temperature/K  100.00(10)  
Crystal system  triclinic  
Space group  P-1  
a/Å  9.4497(3)  
b/Å  10.9150(4)  
c/Å  14.0977(5)  
α/°  72.244(3)  
β/°  80.576(3)  
γ/°  84.238(3)  
Volume/Å
3
  1364.16(9)  
Z  2  
ρcalcg/cm
3
  1.944  
μ/mm
-1
  5.164  
F(000)  772.0  
Crystal size/mm
3
  0.3886 × 0.2456 × 0.1177  
Radiation  MoKα (λ = 0.71073)  
2Θ range for data collection/°  4.978 to 50.696  
Index ranges  -11 ≤ h ≤ 11, -13 ≤ k ≤ 13, -14 ≤ l ≤ 16  
Reflections collected  11852  
Independent reflections  4985 [Rint = 0.0375, Rsigma = 0.0487]  
Data/restraints/parameters  4985/1/382  
Goodness-of-fit on F
2
  1.036  
Final R indexes [I>=2σ (I)]  R1 = 0.0241, wR2 = 0.0498  
Final R indexes [all data]  R1 = 0.0269, wR2 = 0.0516  
Largest diff. peak/hole / e Å
-3





9.2.4 Pic complexes 
Table 9.18: Crystal data and structure refinement for [Ir(dFppy)(ppy)(pic)] (3a) 
  
Empirical formula C28H18F2IrN3O2 
Formula weight 658.65 
Temperature/K 100.01(10) 
Crystal system orthorhombic 




















 0.1932 × 0.1488 × 0.1233 
Radiation MoKα (λ = 0.71073) 
2Θ range for data collection/° 4.968 to 54.958 
Index ranges -19 ≤ h ≤ 18, -21 ≤ k ≤ 21, -11 ≤ l ≤ 12 
Reflections collected 24233 





Final R indexes [I>=2σ (I)] R1 = 0.0178, wR2 = 0.0348 
Final R indexes [all data] R1 = 0.0214, wR2 = 0.0364 
Largest diff. peak/hole / e Å
-3
 0.79/-0.93 





Table 9.19: Crystal data and structure refinement for [Ir(dFppy)(ppy)(pic)] (3b) 
 
  
Empirical formula C29.5H22Cl3F2IrN3O2.5 
Formula weight 795.05 
Temperature/K 100.01(10) 
Crystal system monoclinic 




















 0.2164 × 0.1215 × 0.0362 
Radiation MoKα (λ = 0.71073) 
2Θ range for data collection/° 5.892 to 50.688 
Index ranges -20 ≤ h ≤ 17, -13 ≤ k ≤ 14, -18 ≤ l ≤ 18 
Reflections collected 14404 





Final R indexes [I>=2σ (I)] R1 = 0.0258, wR2 = 0.0606 
Final R indexes [all data] R1 = 0.0314, wR2 = 0.0637 







Table 9.20: Crystal data and structure refinement for [Ir(dFppy)(ppz)(pic)] (9a) 
  
Empirical formula C26H17F2IrN4O2 
Formula weight 647.63 
Temperature/K 99.97(10) 
Crystal system monoclinic 




















 0.2106 × 0.0601 × 0.0459 
Radiation CuKα (λ = 1.54184) 
2Θ range for data collection/° 8.056 to 136.498 
Index ranges -8 ≤ h ≤ 11, -17 ≤ k ≤ 17, -19 ≤ l ≤ 19 
Reflections collected 12463 





Final R indexes [I>=2σ (I)] R1 = 0.0314, wR2 = 0.0803 
Final R indexes [all data] R1 = 0.0361, wR2 = 0.0840 







Table 9.21: Crystal data and structure refinement for [Ir(dFppy)(ppz)(pic)] (9b) 
 
  
Empirical formula C27.5H20Cl3F2IrN4O2 
Formula weight 775.02 
Temperature/K 100.01(10) 
Crystal system monoclinic 




















 0.4159 × 0.1754 × 0.0943 
Radiation CuKα (λ = 1.54184) 
2Θ range for data collection/° 6.144 to 144.228 
Index ranges -20 ≤ h ≤ 14, -14 ≤ k ≤ 13, -19 ≤ l ≤ 19 
Reflections collected 16925 





Final R indexes [I>=2σ (I)] R1 = 0.0350, wR2 = 0.0841 
Final R indexes [all data] R1 = 0.0356, wR2 = 0.0845 







9.3 UV-VIS AND EMISSION SPECTRA 
9.4 1st series 
 
Figure 9.2: Emission (left) and UV-visible (right) spectra of [Ir(ppy)2(acac)] (1). DCM: solid line, 






Figure 9.3: Emission (left) and UV-visible (right) spectra of [Ir(dFppy)2(acac)] (2). DCM: solid line, 
CCl4: dashed line, PMMA film: dotted line. 
 
Figure 9.4: Emission (left) and UV-visible (right) spectra of [Ir(dFppy)(ppy)(acac)] (3). DCM: solid 






Figure 9.5: Emission (left) and UV-visible (right) spectra of [Ir(ppy)(ppz)(acac)] (7). DCM: solid line, 
CCl4: dashed line, PMMA film: dotted line. 
 
Figure 9.6: Emission (left) and UV-visible (right) spectra of [Ir(dFppy)(dFppz)(acac)] (8). DCM: 






Figure 9.7: Emission (left) and UV-visible (right) spectra of [Ir(dFppy)(ppz)(acac)] (9). DCM: solid 
line, CCl4: dashed line, PMMA film: dotted line. 
 
Figure 9.8: Emission (left) and UV-visible (right) spectra of [Ir(dFppz)(ppy)(acac)] (10). DCM: solid 






9.4.1 2nd series 
 
Figure 9.9: Emission (left) and UV-visible (right) spectra of [Ir(dMeOppy)2(acac)] (11). DCM: solid 
line, CCl4: dashed line, PMMA film: dotted line. 
 
Figure 9.10: Emission (left) and UV-visible (right) spectra of [Ir(dMeOMeppy)2(acac)] (12). DCM: 






Figure 9.11: Emission (left) and UV-visible (right) spectra of [Ir(dMeOMeOppy)2(acac)] (13). DCM: 
solid line, CCl4: dashed line, PMMA film: dotted line.NMR analyses 
 
Figure 9.12: Emission (left) and UV-visible (right) spectra of [Ir(dMeOppy)(dFppy)(acac)] (14). 






Figure 9.13: Emission (left) and UV-visible (right) spectra of [Ir(dMeOppy)(dFppz)(acac)] (15). 
DCM: solid line, CCl4: dashed line, PMMA film: dotted line. 
 
Figure 9.14: Emission (left) and UV-visible (right) spectra of [Ir(dMeOMeppy)(dFppy)(acac)] (16). 






Figure 9.15: Emission (left) and UV-visible (right) spectra of [Ir(dMeOMeppy)(dFppz)(acac)] (17). 
DCM: solid line, CCl4: dashed line, PMMA film: dotted line. 
 
Figure 9.16: Emission (left) and UV-visible (right) spectra of [Ir(dMeOMeOppy)(dFppy) (acac)] (18). 






Figure 9.17: Emission (left) and UV-visible (right) spectra of [Ir(dMeOMeOppy)(dFppz) (acac)] (19). 






9.4.2 3rd series 
 
Figure 9.18: Emission (left) and UV-visible (right) spectra of [Ir(mespim)2(acac)] (20). 
 
Figure 9.19: Emission (left) and UV-visible (right) spectra of [Ir(mespim)(dFppy)(acac)] (21). DCM: 






Figure 9.20: Emission (left) and UV-visible (right) spectra of [Ir(mespim)(dFppz)(acac)] (22). 
 
Figure 9.21: Emission (left) and UV-visible (right) spectra of [Ir(mespim)(CF3ppz)(acac)] (24). DCM: 





9.4.3 Pic complexes 
 
Figure 9.22: Emission (left) and UV-visible (right) spectra of [Ir(dFppy)(ppy)(pic)] (3a). DCM: solid 
line, CCl4: dashed line, PMMA film: dotted line. 
 
Figure 9.23: Emission (left) and UV-visible (right) spectra of [Ir(dFppy)(ppy)(pic)] (3b). DCM: solid 






Figure 9.24: Emission (left) and UV-visible (right) spectra of [Ir(dFppy)(ppz)(pic)] (9a). DCM: solid 
line, CCl4: dashed line, PMMA film: dotted line. 
 
Figure 9.25: Emission (left) and UV-visible (right) spectra of [Ir(dFppy)(ppz)(pic)] (9b). DCM: solid 






9.4.4 Emission spectra with Gaussian fittings 
 
Figure 9.26: Fit of the emission spectrum of [Ir(dMeOMeOppy)2(acac)] (13) with Gaussians. Solid 
line: normalised emission, dashed line sum of Gaussians, dotted line Gaussian curves.  
 
Figure 9.27: Fit of the emission spectrum of [Ir(dMeOMeOppy)(dFppz)(acac)] (19) with Gaussians. 






Figure 9.28: Fit of the emission spectrum of [Ir(mespim)2(acac)] (20) with Gaussians. Solid line: 
normalised emission, dashed line sum of Gaussians, dotted line Gaussian curves. 
 
Figure 9.29: Fit of the emission spectrum of [Ir(mespim)(dFppz)(acac)] (22) with Gaussians. Solid 





9.5 NMR ANALYSES 
All NMR spectra were measured in CDCl3 unless stated otherwise. 






























































































































































































































































































































































































































































Figure 9.83: Comparison of the 
1








































Figure 9.88: Comparison of the 
13
C-NMR spectra of 9a, 9 and 9b. 
